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Abstract 
PDZ (PSD95/Disc Large/Zona Occludens) domain-containing proteins are scaffolding 
proteins that play important roles in regulating the activity of G protein-coupled receptors. 
Corticotropin Releasing Factor Receptor 1 (CRFR1) and Serotonin 2A Receptor (5-HT2AR) 
are two GPCRs that are commonly associated with mental disorders. Both receptors also 
contain a class I PDZ-binding motif at the carboxyl terminal tail. In the first chapter, we 
investigate the effects of CAL (CFTR-associated ligand) on regulating the trafficking and 
signaling of CRFR1. We demonstrate a role for CAL in inhibiting CRFR1 endocytosis, cell 
surface expression, and CRF-mediated ERK1/2 signaling via the CRFR1 PDZ-binding motif. 
Additionally, CAL can elicit its effects on CRFR1 by mediating the post-translational 
glycosylation of the nascent receptor at the Golgi apparatus. The second and third chapters 
focus on the MAGI (MAGUK with inverted orientation PDZ) proteins; MAGI-1, MAGI-2 and 
MAGI-3. We observe distinct functions for the MAGI proteins in regulating the trafficking 
and signaling of CRFR1 compared to that of 5-HT2AR. MAGI proteins can mediate CRFR1 
endocytosis via regulating β-arrestin recruitment to the receptor. No effect is observed on the 
basal plasma membrane expression of CRFR1 or CRF-stimulated cAMP formation in response 
to overexpression or knockdown of MAGI proteins. On the other hand, MAGI proteins 
regulate 5-HT2AR-stimulated inositol phosphate accumulation as well as surface expression 
levels but do not have an effect on the internalization of the receptor. MAGI proteins can also 
mediate ERK1/2 signaling activated by both CRFR1 and 5-HT2AR. We propose a 
compensatory mechanism of regulation between MAGI-1, MAGI-2 and MAGI-3 based on 
their similar functional roles. Our work characterizes the interactions between two different 
GPCRs and four PDZ proteins, further confirming the importance of this diverse family of 
scaffolding proteins and providing possible targets for specific drug design. 
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Chapter 1  
1 Introduction 
1.1 G Protein-Coupled Receptors 
G Protein-coupled Receptors (GPCRs) represent the largest receptor superfamily 
and regulate numerous physiological responses. These include neurotransmission, immune 
function, reproduction, cardiac function, metabolism, and homeostasis (Gurevich and 
Gurevich, 2008). The number of GPCRs in the human genome is estimated to be 800 to 
1000 and more than 40% of the currently prescribed drugs target GPCRs (Marchese et al., 
1999; Urs et al., 2014). GPCRs share a similar structure that consists of seven 
transmembrane α helical domains connected by three extracellular loops (ECLs) and three 
intracellular loops (ICLs), an extracellular N-terminal domain and an intracellular C-
terminal domain and they are also known as seven Transmembrane Domain Receptors 
(7TMRs). The extracellular and transmembrane regions of the receptor are involved in 
ligand binding while the intracellular domains are important for signal transduction and for 
feedback modulation of receptor function (Marchese et al., 1999). GPCRs can be bound 
and activated by a wide number of ligands such as photons of light, odorants, hormones, 
neurotransmitters, peptides, chemokines, amino acids and Ca2+ ions to name a few 
(Gurevich and Gurevich, 2008). GPCRs mediate their effects by coupling to a variety of 
heterotrimeric guanine nucleotide-binding proteins (G proteins). G proteins have two 
states; the inactive (GDP bound) and the active (GTP bound). Ligand binding to a receptor 
results in the exchange between GDP and GTP. This active G protein (GTP bound) 
dissociates into Gα subunit and Gβγ subunit. These dissociated subunits can mediate 
several downstream effectors such as adenylyl cyclases (AC), GPCR kinases (GRKs) and 
phospholipases and that ultimately leads to the activation of different signaling pathways. 
The compounds that bind GPCRs can be classified into four classes based on their 
effects. 1) Full agonists which by binding the receptor stabilize the active conformation 
and result in maximal receptor activity, 2) partial agonists which bind the receptor without 
causing maximal activity 3) inverse agonists which decrease the constitutive or 
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spontaneous activity of the receptor by stabilizing the inactive conformation of the receptor 
and 4) full antagonists block agonists and inverse agonists activity either by binding to the 
same binding site as the endogenous ligand (competitive) or binding to an allosteric site 
(non-competitive) (Luttrell, 2008; Prazeres and Martins, 2015). 
GPCRs are commonly classified into five major phylogenetic families. Those are 
rhodopsin (Class A), secretin (Class B), glutamate (Class C), adhesion and frizzled 
(Krishnan and Schioth, 2015; Prazeres and Martins, 2015). 
1.2 G Protein-Coupled Receptor Trafficking 
1.2.1 Anterograde Pathway (GPCR Biosynthesis) 
Anterograde trafficking (forward trafficking) of GPCRs can be defined as the 
synthesis of GPCRs at the endoplasmic reticulum (ER) followed by their transport from 
the ER to the plasma membrane (Fig. 1.1). Therefore, it is an essential checkpoint in 
determining the level of expression of the functional receptors at the surface and this in 
turn dictates the strength of the signal initiated by the receptor. This process is mediated by 
multiple factors including ER chaperones, Rab GTPases, receptor activity modifying 
proteins (RAMPs), exit motifs encoded by the receptor sequence and post-translational 
modifications (Wu, 2012). 
1.2.1.1 GPCR Synthesis at the Endoplasmic Reticulum 
GPCRs are plasma membrane proteins and like many other membrane proteins, 
they are synthesized via ribosomes at the membranes of the rough endoplasmic reticulum 
(ER). They undergo the first set of post-translational modifications at the ER and this 
facilitates their proper folding and maturation (Achour et al., 2008). Key factors are 
involved in regulating this process including molecular chaperones such as Bip, calnexin, 
calreticulin, ERp57, HSP70, PDI and GRP94. The interactions that occur between the 
newly synthesized polypeptides and those ER-proteins slow the folding process, prevent 
aggregation and stabilize the intermediate forms of proteins (Dupré et al., 2012).  
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Figure 1.1: Schematic representation of the Anterograde (Forward) Trafficking of a 
GPCR: The receptor is synthesized at the Endoplasmic Reticulum (ER) then transported 
via COPII vesicles to the Golgi apparatus. The receptor undergoes post-translational 
modifications to achieve proper folding before trafficking to the plasma membrane. 
Immature forms of the receptor are transported back from the Golgi apparatus to ER via 
COPI vesicles. Different Rab GTPases are involved in regulating the steps in the pathway. 
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In addition, in order for the receptor to form its native conformation, enzymatic 
processes are required to catalyze disulfide-bond formation or peptidyl-prolyl cis–trans 
isomerization. These ER processes represent a crucial quality control system to ensure 
proper folding of proteins and any misfolded polypeptides are sent for the proteasome for 
degradation (ER-associated degradation) (Achour et al., 2008; Jean-Alphonse and 
Hanyaloglu, 2011). 
1.2.1.2 GPCR Trafficking from ER to Golgi Apparatus 
Once the receptor is mature and properly folded, it traffics from the ER exit sites to 
the Golgi complex via COPII-coated vesicles. The interaction of GPCRs with the 
components of the COPII vesicles is mediated by ER export motifs expressed at their 
carboxyl-terminal tails. These motifs consist of either di-acidic residues (Asp-x-Glu, where 
x = any amino acid), pairs of aromatic residues (Phe-Phe, Tyr-Tyr or Phe-Tyr) or bulky 
hydrophobic residues (Leu-Leu or Ile-Leu) (Achour et al., 2008). This transport of the 
receptor through the ER-Golgi Intermediate Compartment (ERGIC) is facilitated by many 
different regulator proteins including COPI, Rab GTPases and ARF GTPases. Studies on 
GPCRs transport suggest that Rab1 plays a role in anterograde trafficking from ER to 
Golgi, while Rab2 regulate the retrograde trafficking from the Golgi apparatus back to the 
ER and Rab6 is important for GPCRs transport through the Golgi cisternae (Appenzeller-
Herzog and Hauri, 2006; Achour et al., 2008; Wu, 2012). Similar to Rab GTPases, ARF 
GTPases are also important and different members play different roles at distinct cellular 
compartments. ARF1 plays a role in both anterograde and retrograde trafficking by 
recruitment of the COPII complex proteins (Appenzeller-Herzog and Hauri, 2006; Wu, 
2012). 
1.2.1.3 GPCR Trafficking from Golgi to the Plasma Membrane 
The trans-Golgi network (TGN) is known to function as the sorting center for newly 
synthesized proteins where their final destination is determined between the plasma 
membrane, lysosomes or endosomes. The vesicles that regulate post-Golgi transport are 
believed to be clathrin-coated vesicles. The vesicles that are involved in protein transport 
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from the Golgi apparatus to lysosomes are composed of clathrin and the adaptor proteins 
GGAs (Golgi-associated, γ-adaptin homologous, ARF-interacting proteins). GGAs have 
four main domains to facilitate their function. An N-terminal VHS domain that recognizes 
the sorting signals on the carboxyl-terminal tail of the protein being transported, a GAT 
domain that interacts with ARF1, a hinge domain that recruits clathrin and the C-terminal 
GAE domain that binds to accessory proteins (Wu, 2012). On the other hand, the vesicles 
regulating cargo transport from the Golgi apparatus to the plasma membrane are unknown 
and it has been suggested that they could be large pleiomorphic carriers. However, studies 
show that post-Golgi trafficking to the plasma membrane is also highly regulated by Rab 
GTPases and conserved sorting motifs. Rab8 is important for the transport of 
transmembrane proteins and GPCRs specifically from the Golgi apparatus to the plasma 
membrane. It has been previously shown that using Rab8 mutants or knocking down Rab8 
expression results in reduced surface expression of the adrenergic receptors α2B-AR and 
β2-AR and retention of the receptors in the intracellular compartments (Dong et al., 2010; 
Wang and Wu, 2012). As for motifs, studies show an importance for the di-leucine (LL) 
residues at the carboxyl-terminal tail of certain family A GPCRs in plasma membrane 
expression (Schulein et al., 1998; Duvernay et al., 2004; Carrel et al., 2006; Sawyer et al., 
2010). It has been shown that this motif is highly conserved in α2B-AR, α1B-AR, β2-AR, 
angiotensin II type 1 receptor (AT1R), serotonin 5-HT1A and 5-HT1B receptors, vasopressin 
V2 receptor, and M1-muscarinc receptor and mutations lead to the retention of these 
receptors intracellularly and therefore reduced cell surface levels. In addition to the 
conserved motifs at the carboxyl-terminal end of GPCRs, studies illustrate an important 
role for the N-terminal end in GPCRs trafficking. Reports show that mutations of the N-
terminal YS motif in some adrenergic receptors results in their retention in the Golgi (Wu, 
2012). 
1.2.2 The Life Cycle of G Protein-Coupled Receptors 
1.2.2.1 GPCR Desensitization 
GPCR desensitization is defined as the reduced strength of receptor activity or 
responsiveness. The process is mainly initiated after a ligand binds to a receptor to activate 
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it. The mechanisms underlying GPCR signal attenuation include G-protein uncoupling 
from the phosphorylated receptor, receptor internalization to the intercellular 
compartments and receptor degradation. Depending on the receptor structure as well as the 
cellular environment, desensitization can vary from reduced activity to complete loss of 
signaling. G protein uncoupling occurs once the receptor is phosphorylated either by 
second messenger-dependent kinases (PKA and PKC) or by G protein-coupled receptor 
kinases (GRKs). These enzymes commonly phosphorylate threonine and serine residues 
on the intracellular loop or the carboxyl-terminal tail of the receptor (Ferguson, 2001). In 
addition, different GRKs can phosphorylate different sites on the receptor resulting in a bar 
code that dictates the fate of the receptor (Lefkowitz and Shenoy, 2005). 
1.2.2.2 GPCR Endocytosis 
GPCR endocytosis is an important process for the regulation of receptor levels at 
the plasma membrane and hence receptor activity. Different GPCR subtypes undergo 
internalization via various mechanisms. The classical common pathway for internalization 
requires the binding of an agonist to the receptor resulting in a conformational change that 
leads to receptor phosphorylation by GRKs and β-arrestin recruitment (Ferguson and 
Caron, 1998) (Fig. 1.2). When β-arrestin binds the receptor, it uncouples G proteins and 
dissociates the heterotrimeric G protein complex from the receptor. β-arrestin binding also 
results in the recruitment of adaptor proteins AP-2 and clathrin. Studies showed that the 
carboxyl-terminal end of β-arrestin binds the amino-terminal globular region of the clathrin 
heavy chain and the β2-adaptin subunit of the AP-2 heterotetromeric complex (Ferguson 
and Caron, 1998; Ferguson, 2001; Sorkin and von Zastrow, 2009). The β2-adaptin subunit 
is important for the formation of the clathrin coat and the targeting of the receptor to the 
coated pits. These clathrin-coated pits are vesicular structures that are covered on the inner 
cytoplasmic surface by clathrin triskelions, which consist of three clathrin heavy chains 
and three clathrin light chains assembled into the clathrin lattice. The pits contain the 
receptor and the ligand and pinch off from the plasma membrane by a process that is 
mediated by the GTPase dynamin (Ferguson and Caron, 1998; Ferguson, 2001; Sorkin and 
von Zastrow, 2009). These vesicles are targeted to the endosomal compartment where they 
either recycle back to the plasma membrane or traffic to the lysosomes for degradation  
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Figure 1.2: Schematic representation of the life cycle of a GPCR: Upon activation of 
the receptor with a ligand, it is phosphorylated by GRK. This phosphorylation results in 
the recruitment of β-arrestin and the initiation of endocytosis via clathrin-coated pits. The 
receptor is then internalized to the early endosomes and its fate is determined between 
either recycling back to the plasma membrane or getting transported to lysosomes for 
degradation. Rab GTPases as well as PDZ proteins are key modulators of the steps in this 
pathway. Modified from (Ferguson and Caron, 1998). 
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depending on certain motifs usually at the cytoplasmic tail of a GPCR (Sorkin and von 
Zastrow, 2009). 
Although there is data supporting this mechanism for many receptors, there is also 
evidence for alternate steps and mechanisms for endocytosis. Despite the importance of 
GRKs and specially GRK2 for initiating the internalization process, some reports showed 
that phosphorylation by second messenger kinases such as PKA and PKC can also result 
in β-arrestin recruitment and G protein uncoupling. Furthermore, some studies illustrate 
that having sufficient levels of β-arrestin 1 and β-arrestin 2 could eliminate the requirement 
for receptor phosphorylation (Ferguson and Caron, 1998; Ferguson, 2001). 
1.2.2.3 GPCR Recycling 
One of the pathways that the receptor can go through after endocytosis is to recycle 
from the endosomes to the plasma membrane. Studies show that Rab GTPases play an 
important role in regulating this process. While Rab1 and Rab2 are the Rab proteins that 
control the anterograde and retrograde trafficking of GPCRs, Rab4 and Rab11 are involved 
in receptors recycling (Zerial and McBride, 2001). This reflects the specificity of the 
members of the small Rab GTPases family and their distinct distribution among the 
intracellular compartments. Rab4, Rab5 and Rab11 are expressed in the endosomal 
compartment. Furthermore, studies show that Rab5 regulates the transport of clathrin-
coated vesicles from the plasma membrane to the endosomes and facilitates tethering and 
fusion of the vesicles to the early endosomes (Zerial and McBride, 2001). Rab4 and Rab11 
on the other hand have a role in sorting and recycling either through the early endosomes 
(Rab4) or the perinuclear recycling endosomes (Rab11). In addition, recycling via Rab4-
containing endosomes is rapid while Rab11-containing endosomes facilitate the slower 
recycling mechanism (Zerial and McBride, 2001). 
1.2.2.4 GPCR Degradation 
The other common fate for GPCRs following endocytosis is degradation in the 
lysosomes. When the early endosomes mature to multivesicular bodies (MVBs) and late 
endosomes, their cargo of internalized receptors is contained in the intraluminal vesicles 
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(ILVs) which are formed by ESCRT (endosomal sorting complex required for transport) 
complexes (Soldati and Schliwa, 2006; von Zastrow and Williams, 2012). Late endosomes 
and MVBs are then fused to the lysosomes that contain proteolytic enzymes to breakdown 
receptors. Similar to the anterograde pathway, certain motifs and post-translational 
modifications are important for initiating degradation (Sorkin and von Zastrow, 2009). 
However, the most common process that marks receptors for degradation is ubiquitination. 
The process consists of three key steps; First E1 (ubiquitin-activating enzyme) activates a 
ubiquitin molecule in an ATP-dependent step, then E2 (ubiquitin-conjugating enzyme) 
receives the active ubiquitin and transfers it to E3 (ubiquitin ligase) which would recognize 
the protein and label it with the ubiquitin molecule (Sorkin and von Zastrow, 2009; Alonso 
and Friedman, 2013). 
1.3 G Protein-Coupled Receptor Signaling 
1.3.1 G Protein-Dependent Signaling Pathways 
The classical view of GPCRs signaling involves coupling to G proteins as their 
name suggests. Upon agonist binding, the GDP on the Gα subunit is displaced by a GTP 
and this results in the functional disassociation of the heterotrimeric G protein (Gα and 
Gβγ). This would then allow each of the subunits to activate different effectors including 
ion channels and enzymes and eventually multiple signaling pathways. GTPase-activating 
proteins (GAPs) then bind Gα resulting in the hydrolysis of GTP to GDP, which deactivates 
Gα and causes disengagement of the effector (Gilman, 1987; Hepler and Gilman, 1992). 
Finally, Gα reassociates with Gβγ. Therefore, upon activation, the receptor acts as a 
guanine nucleotide exchange factor (GEF) for the heterotrimeric G protein. G proteins 
signaling can be classified into 4 major categories based on the G protein subtype that the 
receptor couples to; Gαs, Gαi, Gαq/11 and G12/13. 
1.3.1.1 cAMP Signaling Pathway 
The cAMP (cyclic adenosine monophosphate) signaling pathway is a downstream 
pathway that is mediated when a GPCR couples to either the stimulatory- or inhibitory- 
regulatory G proteins (Gαs and Gαi) (Kristiansen, 2004). The effector that the G proteins 
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bind to in this case is adenylyl cyclase (AC), an enzyme that synthesizes cAMP from ATP. 
cAMP would in turn activates PKA as well as certain cAMP-regulated guanine nucleotide 
exchange factors, such as EPAC1 and EPAC2. There are 10 isoforms of AC and all of 
which can be stimulated by Gαs. However only some of them can be stimulated by Gβγ or 
inhibited by Gαi. The activity of AC can be also modulated through phosphorylation by 
PKA and PKC (Luttrell, 2008). 
1.3.1.2 IP3 Signaling Pathway 
The inositol 1,4,5-trisphosphate (IP3) signaling pathway is the downstream 
pathway that is mediated when a GPCR couples to Gαq/11 subunit (Kristiansen, 2004). The 
main effector for Gαq is phospholipase Cβ (PLCβ), a membrane-bound enzyme that 
converts phosphatidylinositol-4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and IP3. 
IP3 binds to IP3 receptor in the ER and this results in the release of Ca2+ from intracellular 
stores, while DAG activates PKC. There are four known isoforms for PLCβ, PLCβ1-4 and 
they are known to be regulated by the Gα subunits as well as the Gβγ subunits of Gαq/11. In 
fact, it has been suggested that certain isoforms (PLCβ2 and PLCβ3) are more sensitive to 
Gβγ regulation than others (PLCβ1) (Luttrell, 2008). 
1.3.1.3 Rho Activation Signaling Pathway 
The Rho activation signaling pathway is a less common pathway and it is mediated 
when the GPCR couples to G12/13 subunit. G12/13 is implicated in the regulation of Ras 
homology (Rho) guanine nucleotide exchange factors (RhoGEFs) which is considered to 
function as a link between the heterotrimeric G protein and small GTPase pathways. G12/13 
can control cytoskeletal rearrangement and affect cellular growth (Luttrell, 2008). 
1.3.2 G Protein-Independent Signaling Pathways 
GPCRs can signal via G-protein independent mechanisms and the best 
characterized example is β-arrestin-mediated signaling via Src and mitogen-activated 
kinase pathways (Naor et al., 2000; Kristiansen, 2004; Lefkowitz and Shenoy, 2005). 
Stimulation of many GPCRs leads to the activation of mitogen-activated protein (MAP) 
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kinases. There are three classes of MAP kinase, the extracellular signal-regulated kinases 
(ERK), c-Jun N-terminal kinase/Stress-activated protein kinases (JNK/SAPK) and 
p38/HOG1 MAP kinases (Naor et al., 2000; Belcheva and Coscia, 2002; Lefkowitz and 
Shenoy, 2005). MAP kinases are regulated via a series of modular kinase cascades. Each 
cascade is composed of three kinases that successively phosphorylate and activate the 
downstream component. β-arrestin acts as a multifunctional scaffold protein and helps 
assemble the MAP kinase modules with a GPCR to target it to the endosome of the cell 
(Lefkowitz, 1998; Ferguson, 2001; Lefkowitz et al., 2006). It is important to mention that 
this is a divergent pathway that can also be activated by multiple intracellular intermediates 
such as Ca2+, Ras, PLC, proline-rich tyrosine kinase 2, cAMP, c-Src, and PI3K. For 
example, the activation of Gαs and Gαq via PKA and PKC leads to the phosphorylation of 
Ras. Ras would then activate Raf to phosphorylate MEK which subsequently 
phosphorylate ERK (Luttrell et al., 1999; Belcheva and Coscia, 2002; Kristiansen, 2004). 
1.4 Regulation of GPCR Trafficking and Signaling 
The various steps in the trafficking and signaling pathways of GPCRs are very 
efficiently regulated by two main factors; post-translational modifications and modulatory 
proteins. 
1.4.1 GPCR Regulation by Post-Translational Modifications 
Post-translational modifications serve as a method to label or mark the receptor 
particularly for the trafficking between cellular compartments by the addition of specific 
chemical groups or molecules on certain residues of the receptor. The four major types of 
post-translational modifications that have been well-characterized are glycosylation, 
phosphorylation, palmitoylation, and ubiquitination (Alonso and Friedman, 2013). These 
processes have distinct roles in regulating the expression and function of GPCRs. 
1.4.1.1 Glycosylation 
There are two forms of glycosylation; N- linked glycosylation and O-linked 
glycosylation. N-glycosylation is the addition of oligosaccharide to the nitrogen in the side-
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chain amid of asparagine residues and it is the more common way of GPCRs glycosylation. 
Approximately 90% of all GPCRs are glycosylated on their extracellular domains at 
conserved consensus sites Asn-x-Ser/Thr (where x = any amino acid except proline). This 
process usually starts at the ER and is completed during the transport through the Golgi. 
O-Glycosylation on the other hand is the transfer of N-acetyl-galactosamine to a serine or 
threonine residue on the target protein (Qiu and Law, 2011). Studies with the β2-AR and 
opioid receptors demonstrate an importance of glycosylation in receptor expression at the 
cell surface (McLawhon et al., 1983; Stiles et al., 1984; Law et al., 1985; George et al., 
1986). Studies with the protease activated receptors (PARs) point to an effect for 
glycosylation on receptor signaling (Grimsey et al., 2011). It is suggested that inhibiting 
PAR1 glycosylation can enhance its signaling either due to the lack of the bulky sugars 
allowing for more efficient interaction of the newly generated tethered ligand with the 
second extracellular loop or a change in conformation that provide more flexibility of the 
ECL2 domain and more efficient G protein coupling (Grimsey et al., 2011). Receptor 
glycosylation is studied using different methods including monitoring the mobility of 
receptors on SDS-PAGE, enzymatic deglycosylation and site-directed mutagenesis. 
Multiple glycosidases have been characterized and shown to cleave the glycan chain 
differently (Spiro, 2002). Those include neuraminidases that cleave terminal N-
aceylneuraminic acid, α-mannosidases that cleave mannose, endoglycosidases H that 
cleave asparagine-linked mannose rich oligosaccharides, Peptide N-Glycosidases F 
(PNGase F) which remove all types of N-linked glycosylation and O-glycosidase that 
cleaves O-linked glycan chains (Qiu and Law, 2011). 
1.4.1.2 Phosphorylation 
As explained earlier, GPCRs are phosphorylated by GRKs upon agonist activation. 
GPCRs can also be phosphorylated by protein kinase C (PKC), protein kinase A (PKA), 
casein kinases and receptor tyrosine kinases (Ferguson, 2001). Receptor phosphorylation 
occurs mainly on serine or threonine residues within the carboxyl-terminal tail or third 
intracellular loop. Studies with β2-AR demonstrate the importance of GPCRs 
phosphorylation in regulating desensitization and internalization. Receptor 
phosphorylation promotes the association of arrestins to the activated receptor. This not 
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only uncouples the receptor from G protein to stop signaling (desensitization) but also 
recruits the receptor to the endocytic machinery (internalization) (Ferguson, 2001). 
Therefore, phosphorylation is an important factor in determining the fate of the receptor. 
In addition, studies on phosphorylation of the opioid receptors show an effect for this 
modification on the activity of adenylyl cyclase (Zhang et al., 2009). This suggests that 
post-translational modifications can play important roles in regulating receptor signaling 
in addition to the role they play in regulating trafficking. Studies on PAR1 illustrate that 
phosphorylation sites can be very specific in terms of regulating different functions 
meaning that different residues can differentially regulate association with clathrin 
adaptors that facilitate receptor internalization versus uncoupling from G protein signaling 
(Grimsey et al., 2011). Receptor phosphorylation is commonly studied by [32P] 
orthophosphate labeling, mass spectrometry and phospho-specific antibodies. 
1.4.1.3 Palmitoylation 
Palmitoylation involves the attachment of palmitate to cysteine residues on the 
carboxyl-terminal tail or intracellular loop of the receptor through a thioester linkage. It is 
a covalent lipid modification that is observed with many GPCRs including rhodopsin, β2-
AR and the opioid receptors MOR and DOR (Qiu and Law, 2011). It usually occurs very 
early during protein synthesis. Therefore, it is important for receptor maturation and hence 
for receptor expression on the cell surface. However, there is evidence indicating that the 
receptor can undergo palmitoylation and depalmitoylation cycles in an agonist-dependent 
manner but the role of these processes is still unknown (Qanbar and Bouvier, 2003). There 
are multiple methods used to assess receptor palmitoylation such as metabolic labeling with 
[3H] palmitate followed by immunoprecipitation, fatty acyl exchange labeling, SDS-PAGE 
and fluorography. 
1.4.1.4 Ubiquitination 
As described in the GPCR degradation section, ubiquitination is an important label 
that drives the receptor towards the degradation pathway. Furthermore, ubiquitination is 
important during the biosynthetic pathway to identify misfolded proteins and send them 
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for proteasomal degradation (ER-associated degradation) (Achour et al., 2008; Jean-
Alphonse and Hanyaloglu, 2011). Ubiquitination involves the covalent addition of 
ubiquitin to the lysine side chains of the receptor which is facilitated by three enzymes; E1, 
ubiquitin-activating enzyme, E2, ubiquitin-carrying enzyme and E3, ubiquitin ligase 
(Sorkin and von Zastrow, 2009; Alonso and Friedman, 2013; Marchese and Trejo, 2013). 
First, ubiquitin is activated by E1 and transferred to the active site of the enzyme in an 
ATP-dependent process. Then, the ubiquitin molecule is passed on to E2 by a 
transthiolation reaction. Finally, E3 recognizes the target protein and label it with ubiquitin 
(Alonso and Friedman, 2013; Marchese and Trejo, 2013). Ubiquitination of GPCRs mainly 
occurs on the lysine residues of the carboxyl-terminal tail but studies show ubiquitin sites 
on the first cytoplasmic loop for µ-opioid receptor and on the third intracellular loop for 
the vasopressin V2 receptor (V2R) and β2-AR receptor. Ubiquitin is a highly conserved 
76-amino acid polypeptide and since it contains lysine residues, the peptide itself can be 
ubiquitinated forming polyubiquitin chains. In addition to its role in targeting the receptor 
to the late endosomes for degradation in the lysosomes, ubiquitination can serve as a quality 
control step for newly synthesized receptors resulting in this case in their proteosomal 
degradation. Studies with the DOR, MOR and thyrotropin-releasing hormone receptor 
show that when the receptor is misfolded, it gets retranslocated to the ER where it is labeled 
with ubiquitin to be degraded by the proteasome (Chaturvedi et al., 2001; Petaja-Repo et 
al., 2001; Shenoy, 2007). GPCRs can also be deubiquitinated by deubiquitination enzymes 
130 and this leads to their rescue from degradation and an increase in their cell surface 
expression levels (Sorkin and von Zastrow, 2009). Furthermore, studies on PAR1 illustrate 
the importance for ubiquitination in the constitutive internalization of the receptor (Alonso 
and Friedman, 2013). In addition to regulating GPCRs trafficking, ubiquitination can 
indirectly regulate GPCRs signaling by regulating GRKs, MAPKs and β-arrestins (Alonso 
and Friedman, 2013; Marchese and Trejo, 2013). Ubiquitination is commonly studied by 
protease inhibitors and ubiquitin antibodies. 
 
In addition to the previous main post-translational modifications that GPCRs 
undergo, recent studies are exploring two more processes; isoprenylation and sumoylation 
(Qiu and Law, 2011). Isoprenylation is a lipid modification of proteins characterized by 
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the addition of an isoprenoid moiety to the sulfhydryl group of a cysteine residue via a 
thioether bond. It has been suggested that isoprenylation and palmitoylation may 
collectively regulate GPCRs function (Miggin et al., 2003). Isoprenylation of prostacyclin 
receptors is suggested to be important for G-protein coupling, as well as receptor 
internalization (Miggin et al., 2002). Sumoylation is the covalent attachment of SUMO (an 
ubiquitin-like peptide) to lysine on the target receptor but unlike ubiquitin, it is not used to 
label the proteins for degradation. It appears to be important for transcriptional regulation, 
protein stability and receptor trafficking. Studies suggest that metabotropic glutamate 
receptors contains a sumoylation motif and can undergo this modification (Qiu and Law, 
2011; Tang et al., 2005). However, further characterization of both isoprenylation and 
sumoylation is still required to understand their effects on regulating GPCRs activity. 
1.4.2 GPCR Regulation by Modulator Proteins 
Many intracellular and transmembrane proteins associate with GPCRs to regulate 
their processing in the endoplasmic reticulum, trafficking to the cell surface, 
compartmentalization to the plasma membrane microdomains, endocytosis and trafficking 
between intracellular membrane compartments. Examples include β-arrestins, receptor 
activity-modifying proteins (RAMPs), PSD95/Disc Large/Zona Occludens (PDZ) domain-
containing proteins, small GTPases, regulators of G-protein signaling (RGS), GPCR-
associated sorting proteins (GASPs), molecular chaperones, Homer, GRKs and protein 
phosphatases (Magalhaes et al., 2012). 
1.5 PDZ Domain-Containing Proteins 
PDZ domains comprise ~90 residues and PDZ domain-containing proteins are 
mainly known to be scaffolding proteins. They modulate protein interactions by 
recognizing short amino acid motifs usually at the carboxyl-terminal end of their target 
proteins (Lee and Zheng, 2010; Romero et al., 2011). They are found on more than 100 
proteins in the human genome and there is usually more than one domain on the same 
protein to enable them to bind multiple proteins simultaneously and form functional 
molecular complexes. These complexes can regulate multiple biological processes such as 
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transport, ion channel signaling, protein trafficking and other signal transduction systems 
(Dunn and Ferguson, 2015). PDZ domains contain a conserved sequence that consists of 
glycine-leucine-glycine-phenylalanine and forms the globular structure of the domain that 
recognizes the PDZ-binding motif. PDZ motifs are usually classified into three classes. 
Class I is identified by their final three–amino acid sequence which consists of S/T-x-φ, 
where x symbolizes any amino acid and φ symbolizes any hydrophobic amino acid. The 
most common hydrophobic amino acids are found to be valine, isoleucine, or leucine 
(Songyang et al., 1997; Bezprozvanny and Maximov, 2001; Sheng and Sala, 2001; Vaccaro 
and Dente, 2002). Class II is characterized by having φ-x-φ as the final three amino acids. 
Class III is characterized by having Ѱ-x-Ѱ as the final three amino acids, where Ѱ 
symbolizes any acidic amino acid residue (Sheng and Sala, 2001). 
PDZ domain-containing proteins also contain multiple other modular protein 
interaction domains such as: Src-homology 2 (SH2), SH3, phosphotyrosine binding (PTB), 
WW motifs, guanylate kinase-like (GK), calmodulin kinase-like (CaMK) and Ras-
associated (RA) domains (Harris and Lim, 2001; Magalhaes et al., 2012) (Fig. 1.3). Some 
of the recent studies show that PDZ proteins have distinct functions depending on the 
receptor being investigated (Table 1). A good example for that is MUPP1, which can 
enhance GABAB receptor signaling (Balasubramanian et al., 2007), uncouple the 
melatonin-1 receptor from Gαi and facilitate the dephosphorylation (Guillaume et al., 2008) 
and resensitization of the 5-HT2CR (Parker et al., 2003). Other studies show that unique 
PDZ proteins can regulate different pathways of the same receptor. For example, MAGI-2 
has been shown to promote β1-AR internalization while MAGI-3 seems to selectively 
attenuate β1-AR signaling via ERK1/2 (He et al., 2006). 
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Figure 1.3: PDZ proteins that regulate Golgi sorting and MAGUKs: PDZ domain-
containing proteins possess multiple domains that facilitate their function, binding to their 
target and subcellular localization. (Dunn and Ferguson, 2015). 
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Table 1: PDZ proteins and their role in GPCRs regulation (The table is part of tables 
published in Dunn and Ferguson, 2015) 
PDZ protein Effect on GPCR Receptor 
CAL/GOPC ↓ Membrane localization  β1-AR, SSTR5 
↓ Recycling β1-AR 
↑ Golgi localization SSTR5 
↓ ERK mGluR1, β1-AR 
GIPC ↓ Gi coupling Dopamine 3 receptor 
↑ Protein kinase B, ↑ Trafficking to 
early endosome 
LPA1R 
↓ ERK β1-AR 
↑ Endosome/Golgi localization D2R, dopamine 3 receptor 
↑ Membrane stability Human LH receptor 
SNX27 ↑ Recycling  β2-AR, β1-AR, SSTR5 
MAGI-2 ↓ endocytosis VPAC1 
↑ endocytosis β1-AR 
↑ Golgi localization mGluR1a 
↓ cAMP VPAC1 
MAGI-3 ↑ ERK BAI-1, LPA2R 
↑ Rho LPA2R 
↓ ERK β1-AR, β2-AR 
SAP97 ↑ Inositol 1,4,5-trisphosphate, ↑ ERK 5-HT2AR 
↑ ERK CRFR1, CRFR2 
↓ Endocytosis CRFR1, 5-HT2AR 
PSD-95 ↑ Inositol 1,4,5-trisphosphate  5-HT2AR 
↑ cfos, ↑ Desensitization of Ca2+, 
↑ Endocytosis 
5-HT2CR 
↑ Membrane localization  GPR30 
↓ or = cAMP, ↑ Recycling, 
↑ Endocytosis 
D1R 
↓ Endocytosis 
↓ Endocytosis, ↓ β-arrestin recruitment 
β1-AR, 5-HT2AR 
CRFR1 
SAP102 ↑ ERK, ↓ Mobility A2AR 
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1.5.1 Golgi- Associated PDZ Proteins (PDZ Proteins that Regulate 
Golgi Trafficking and Sorting) 
1.5.1.1 CFTR-Associated Ligand (CAL) 
The Golgi-localized cystic fibrosis transmembrane conductance regulator-
associated ligand (CAL) is a single PDZ domain-containing protein with two coiled-coil 
motifs and two evolutionally conserved regions which are required for its Golgi 
localization (Charest et al., 2001; Yao et al., 2001; Cheng et al., 2002). CAL is also known 
as GOPC (Golgi-associated PDZ and coiled-coil motif-containing protein), PIST (PDZ 
domain protein interacting specifically with TC10) and FIG (fused in glioblastoma). CAL 
overexpression reduces cell surface expression of the β1-AR and mGluR1a by retaining the 
receptor inside the cell via a direct interaction (He et al., 2004; Zhang et al., 2008). CAL 
also interacts with mGluR5a and stabilizes receptor expression by a mechanism that is 
proposed to involve the inhibition of ubiquitination-dependent degradation (Cheng et al., 
2010). CAL also contributes to the regulation of somatostatin receptor recycling and 
degradation (Wente et al., 2005; Bauch et al., 2014). 
1.5.1.2 GAIP-Interacting Protein (GIPC) 
Another PDZ-binding protein involved in regulating the trafficking and sorting 
from Golgi is the Gα-Binding Protein Interacting Protein Carboxyl-Terminus (GIPC) (Liu 
et al., 2001). Similar to CAL/GOPC, GIPC contains one PDZ domain. GIPC is also known 
as Tax interaction protein 2 (TIP-2) and Synectin (Dunn and Ferguson, 2015). GIPC 
facilitates the trafficking of D2R to the endosomes and Golgi (Jeanneteau et al., 2004). 
Similarly it has been found to enhance the trafficking of LPA1R to the early endosomes 
and promote the receptor activation of the protein kinase B signaling pathway (Varsano et 
al., 2012). GIPC is also shown to regulate the trafficking of the human luteinizing hormone 
receptor and stabilize its expression at the plasma membrane (Hirakawa et al., 2003). In 
addition, GIPC plays a role in regulating the signaling of β1-AR via the MAPK pathway 
but has no effect on the Gαs pathway since GIPC can reduce β1-AR-stimulated ERK1/2 
phosphorylation but does not interfere with cAMP formation (Hu et al., 2003). However, 
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GIPC prevents the coupling of Dopamine 3 receptor to Gαi to reduce signaling through the 
G protein-dependent pathway. (Jeanneteau et al., 2004; Dunn and Ferguson, 2015). 
1.5.1.3 Sorting Nexin 27 (SNX27) 
Sorting Nexin 27 (SNX27) contains one amino terminal PDZ domain, a Phox 
homology domain and a Ras-associating domain (Joubert et al., 2004). SNX27 can drive 
multiple GPCRs to the recycling pathway and therefore prevent their degradation. These 
include β2-AR, β1-AR and SSTR5 (Lauffer et al., 2010; Temkin et al., 2011; Nakagawa 
and Asahi, 2013; Bauch et al., 2014; Dunn and Ferguson, 2015). One of the mechanisms 
suggested for this role in recycling is that SNX27 can target the receptor to the retromer 
tubule by interacting with the endosomal WASH complex (Temkin et al., 2011). 
1.5.2 Membrane-Associated Guanylate-like kinases (MAGUKs) 
Membrane Associated Guanylate Kinase (MAGUK) family proteins are synaptic 
scaffolding proteins within a structured protein network responsible for the spatial 
organization of the presynaptic and postsynaptic compartments. They play a crucial role in 
the formation and function of synapses in the Central Nervous System (CNS) by regulating 
multiple aspects of synapse physiology such as synaptogenesis, receptor trafficking, 
synaptic function, and plasticity (Funke et al., 2005; Feng and Zhang, 2009; Yamagata and 
Sanes, 2010). MAGUKs are well-conserved throughout evolution and are widely-
expressed in the brain and periphery. They include multiple subfamilies including 
membrane palmitoylated proteins (MPPs), zona occludens (ZO), caspase recruitment 
domain-containing MAGUK protein (CARMA), discs larges (DLGs) and MAGUK with 
inverted orientation PDZ proteins (MAGIs) (Oliva et al., 2012). Generally, these proteins 
contain multiple domains that control their function and facilitate their interactions with 
their targets. The two common domains among all members are PDZ domains and 
guanylate kinase (GK) domains (Oliva et al., 2012). An important target for the MAGUKs 
scaffolding proteins is the G protein-coupled receptors (GPCRs) family (Dunn and 
Ferguson, 2015). This protein-protein interaction between the receptor and MAGUKs 
results in the regulation of GPCRs function. MAGUK proteins play a key role in mediating 
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the subcellular localization, trafficking, cell surface expression and signal transduction of 
multiple GPCRs and different proteins have both overlapping and distinct roles in the 
regulation of GPCR activity (Harris and Lim, 2001; Lee and Zheng, 2010; Romero et al., 
2011; Magalhaes et al., 2012). One of the important subfamilies of MAGUKs is MAGIs. 
It consists of three members; MAGI-1, MAGI-2 and MAGI-3. All three proteins share a 
similar structure containing one GK domain, two tryptophan tryptophan (WW) domains 
and six PDZ domains (te Velthuis et al., 2007; Oliva et al., 2012; Dunn and Ferguson, 
2015). 
1.5.2.1 MAGUK with Inverted orientation PDZ (MAGIs) 
MAGI-1, also known as BAP-1 (BAI-1-associated protein 1), has 7 isoforms that 
are widely expressed in different tissues. Isoform 1, isoform 2 and isoform 6 are highly 
expressed in colon, kidney, lung, liver, and pancreas. Isoform 5 is predominantly expressed 
in brain and heart. Isoform 3 and isoform 4 are highly expressed in pancreas and brain 
(Dobrosotskaya et al., 1997; Laura et al., 2002). MAGI-1 interacts with BAI-1 (brain-
specific angiogenesis inhibitor-1), a family B GPCR that functions as an adhesion molecule 
(Shiratsuchi et al., 1998). Therefore, it is suggested that MAGI-1 might play an important 
role in the organization of membrane proteins and cytoskeleton by transmitting signals 
related to cell- cell or cell- matrix interactions through BAI-1 (Shiratsuchi et al., 1998; 
Stetak et al., 2009; Stephenson et al., 2013). MAGI-1 also regulates AMPA receptor 
activity and modulate behavioral plasticity (Emtage et al., 2009). 
MAGI-2, also known as S-SCAM (synaptic scaffolding molecule), is specifically 
expressed in the brain and has 2 isoforms (Wood et al., 1998). Previous studies illustrate 
an association between MAGI-2 and β1-AR that is enhanced upon agonist stimulation (Xu 
et al., 2001). The study also demonstrate an increase in agonist-induced internalization of 
β1-AR when MAGI-2 is co-expressed but no effect on cAMP generation induced by 
isoproterenol stimulation. Alternatively, a study of the effects of MAGI-2 on vasoactive 
intestinal polypeptide type1 (VPAC1) receptor demonstrate an opposite function, where 
MAGI-2 overexpression results in the inhibition of VPAC1-mediated cAMP production 
and agonist-induced VPAC1 internalization (Gee et al., 2009). 
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MAGI-3 is widely expressed in different tissues. It has been shown to interact with 
β2-AR and reduce signaling via the extracellular signal-regulated kinase 1 and 2 (ERK1/2) 
pathway (Yang et al., 2010). MAGI-3 can also associate with lysophosphatidic acid-
activated receptor subtype-2 (LPA2R) and contrary to the effect observed with β2-AR, 
knockdown of MAGI-3 results in a decrease of receptor-mediated ERK1/2 signaling 
(Zhang et al., 2007). The study also reports a significant reduction in Rho activation upon 
knockdown of MAGI-3. 
1.5.2.2 Discs Large (DLGs) 
This subfamily of MAGUKs contain five proteins (DLGs 1-4) also known as 
SAP97 (DLG1), PSD-93 (DLG2), SAP102 (DLG3) and PSD-95 (DLG4) as well as a Discs 
Large Homolog 5 (DLG5). All members contain an SH3 domain, a GK domain and three 
PDZ domains (with the exception of DLG5 which has 4 PDZ domains). All PDZ domains 
are type I domains (they bind class I PDZ binding motif consisting of T/S-x-φ) (Oliva et 
al., 2012). Similar to MAGIs, DLGs are widely expressed in the central nervous system 
and have been shown to regulate synaptic function (Dunn and Ferguson, 2015). 
SAP97 (DLG1) regulates the trafficking and signaling of different members of the 
GPCRs family. It can antagonize the agonist-induced internalization of both CRFR1 and 
5-HT2AR when overexpressed. Furthermore, it plays an essential role in regulating the 
MAPK pathway for multiple GPCRs including CRFR1, CRFR2 and 5-HT2AR. The fact 
that CRFR2 does not possess a PDZ-binding motif suggests that this role for SAP97 in 
regulating ERK1/2 activation does not require an interaction with the receptor and could 
be a global role for the regulation of MAPK pathway (Dunn et al., 2013). SAP97 can also 
enhance 5-HT-induced IP3 formation which illustrates how one PDZ-binding protein can 
regulate G protein-dependent as well as G protein-independent signaling pathways 
activated by the same receptor. In addition, SAP97 facilitates the recycling of β1-AR and 
this emphasizes the involvement of PDZ proteins at different steps of the GPCRs life cycle. 
PSD-95 (DLG4) has been shown to regulate a number of GPCRs. It has been shown 
to antagonize the internalization of both β1-AR and 5-HT2AR (Hu et al., 2000; Xia et al., 
2003). It also has an enhancement effect on Gαq signaling mediated by 5-HT2AR. 
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Interestingly, PSD-95 has been shown to have an opposite effect on 5-HT2CR since it can 
enhance the internalization of the receptor and decrease its cell surface expression 
(Gavarini et al., 2006). There are reports of an association between PSD-95 and D1R 
resulting in an increase in internalization and reduction in cAMP formation by the receptor 
(Zhang et al., 2007). Other studies suggest that PSD-95 can enhance the recycling of D1R 
without affecting its signaling via Gαs (Sun et al., 2009). A recent study has illustrated the 
effects of PSD-95 in regulating CRFR1 function. Similar to the effects observed with β1-
AR and 5-HT2AR, PSD-95 can reduce the endocytosis of CRFR1 (Dunn et al., 2016). The 
study also provide a mechanism for this regulation presented by a negative effect of PSD-
95 on β-arrestin recruitment. The role of PSD-93 (DLG2) is not fully characterized yet. 
Reports indicate that PSD-93 and PSD-95 can compensate for one another and hence it is 
suggested they have similar functions (Sun and Turrigiano, 2011). 
SAP102 (DLG3) is another understudied member of the DLGs subfamily. It has an 
effect on the adenosine A2A receptor since it can regulate the mobility of the receptor and 
enhance ERK1/2 activation by the receptor (Thurner et al., 2014). Further studies are 
required to fully assess and understand the function of SAP102 in regulating GPCRs. 
DLG5 has some differences in topology compared to the other four members of the 
subfamily. It contains four PDZ domains as opposed to three domains in the other proteins. 
It also contains a caspase activation and recruitment domain (CARD) at the amino terminal 
that is not present in any of the other DLGs (de Mendoza et al., 2010). There are no reports 
that suggest a direct role for DLG5 in regulating GPCRs function. However, it can scaffold 
PKC isoforms which might be a mechanism for mediating GPCRs signaling. 
1.5.3 PDZ Proteins Network 
 The previous section highlighted the role that PDZ domain-containing proteins 
have in regulating different functions of GPCRs including their internalization, recycling, 
degradation and signaling. However, another important aspect that should always be 
considered when studying PDZ proteins is the interplay between the different proteins 
themselves. Bearing in mind the similar domains that PDZ proteins possess and their 
overlapping functions, there is a possibility for these proteins to either have 
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“complementary” effects or “competitive” effects. This also provides a possible 
explanation for the observation that one receptor can be mediated by multiple PDZ 
proteins. 
 A recent example that illustrates a complementary effect is the regulation of the 
somatostatin receptor subtype 5 (SSTR5) by PDZ proteins (Bauch et al., 2014). The 
trafficking of the receptor was studied and it appears that CAL, SNX27 and NHERF1 are 
involved in mediating the different steps to determine the subcellular distribution and 
membrane availability of the receptor. The data demonstrate that the receptor’s interaction 
with SNX27 can drive the trafficking pathway away from lysosomal targeting and towards 
the recycling pathway (Bauch et al., 2014). It also shows that while CAL overexpression 
leads to the retention of SSTR5 in the Golgi, NHERF1 can reverse this effect and is able 
to release the receptor and enhance its trafficking to the cell surface. The study also 
suggests that the protein interacting with C kinase 1 (PICK1), a fourth PDZ protein, and 
SNX27 act antagonistically to mediate receptor recycling. This is an example showing that 
PDZ proteins can perhaps sequentially perform their function depending on the stage of 
receptor trafficking. Another study on β1-AR demonstrated that PSD-95 can antagonize the 
intracellular retention of β1-AR upon CAL overexpression and restore plasma membrane 
expression (Koliwer et al., 2015). 
 A similar observation is reported between CAL and two other PDZ proteins when 
the transmembrane protein Cadherin 23 is investigated (Xu et al., 2010). Overexpression 
of CAL can lead to the retention of Cadherin 23 in the transgolgi network and hence to a 
reduction in plasma membrane expression. This effect is reversed by MAGI-1 as well as 
harmonin. 
 In addition to the regulation of trafficking, the interplay between PDZ proteins can 
be important for regulation of GPCR signaling. It has been shown that NHERF2 and 
MAGI-3 can compete for binding to LPA2R and this can bias the signaling of the receptor 
(Lee et al., 2011). The study shows that MAGI-3 can increase the coupling of Gα12/13 to 
LPA2R and hence decrease PLC activation while NHERF2 promotes the coupling of Gαq 
to the receptor resulting in an enhancement in PLC activity. Therefore, MAGI-3 and 
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NHERF2 exhibit opposite effects on LPA-induced PLC activity by differentially regulating 
G protein coupling. 
 A similar role of PDZ proteins in regulating GPCRs signaling resulting in bias from 
one pathway to another was reported with the Parathairoid Hormone receptor 1 (PTH1R). 
The study showed that NHERF1 can bias signaling from activating adenylyl cyclase to 
activating PLCβ. In addition, NHERF1 was shown to interfere with β-arrestin recruitment 
to PTH1R and hence reduce receptor internalization (Mahon et al., 2002). 
 An example for a compensation effect between PDZ proteins is between PSD-93 
and PSD-95 (Sun and Turrigiano, 2011). Double knockout studies show a functional 
compensation between PSD-95 and PSD-93 during scaling up in young cortical neurons. 
1.6 G Protein-Coupled Receptors and Disease 
In addition to being involved in regulating all physiological processes from 
neurotransmission and cardiovascular function to inflammation, metabolism and endocrine 
function, dysregulation or dysfunction of GPCRs has been associated with a broad range 
of pathological conditions. This is not surprising given their regulation of all physiological 
processes as well as their wide distribution in the different organs of the body. These 
conditions include neurological and cardiovascular disorders, renal and pulmonary 
diseases, immunological diseases, pain and cancer. 
One important example that has been well studied would be heart diseases. There 
are approximately 200 members of the GPCR superfamily that have been shown to regulate 
heart function (cardiac GPCRs) (Salazar et al., 2007). However, most of the drugs used to 
treat heart problems act on the angiotensin and adrenergic receptors. These available drugs, 
although improving the quality of life for patients, still have their limitations since they 
show major side effects in some cases due to off target effects or the ubiquitous distribution 
of the receptors in organs other than the heart. To produce better drugs with fewer side 
effects, further characterization of GPCRs, their assembly into signaling complexes, their 
interacting partners as well as their trafficking from the endoplasmic reticulum to the cell 
surface is required to establish a complete understanding of the key factors in the processes. 
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The example that is going to be the focus for this project is psychiatric disorders. 
The role of GPCRs in regulating neurotransmission and the function of the central nervous 
system has been well documented. The two families that demonstrate crucial effects on 
synaptic transmission, synapse formation, axon guidance and development of neuronal 
circuits are Rhodopsin and Glutamate. Rhodopsin family GPCRs have this role because 
they are the main molecular targets for various neurotransmitters such as serotonin, 
dopamine, acetylcholine, histamine, adrenaline and norepinephrine and neuropeptides such 
as somatostatin, melanocortins, neuropeptide Y and neuropeptide FF. The same reason 
applies for Glutamate receptors being the target for glutamate which represent the principal 
excitatory neurotransmitter of the CNS. 
A common disorder that has been associated with mGluR activation is Fragile X 
mental retardation (FMR) where it has been suggested that FMR results from unbalanced 
activation of Group I mGluRs and impaired synaptic maturation. mGluRs have also been 
associated with dementia and Alzhiemer’s disease (Bear, 2005; Yan et al., 2005). 
As for the rhodopsin family, the 5-HT2C receptor has been shown to play an 
essential role in the regulation of mood and alteration of its functional activity has been 
implicated in the etiology of anxio-depressive states (Millan et al., 2005). Therefore, it has 
been targeted by antidepressants as a therapeutic approach. 5-HT2CR is not the only 5-HT-
activated receptor to be implicated in mood disorders and have antidepressants actions. 
Dopamine signaling via D1 and D2 receptors plays a key role in schizophrenia and 
blocking dopamine D2 receptors with any antipsychotic drug is thought to alleviate 
positive symptoms, but not sufficiently address negative symptoms and cognitive deficits 
(Meltzer et al., 1989). The A2a receptor plays an important role in modulation of 
dopaminergic and glutamatergic neurotransmission and has been used as a target for the 
treatment of drug addiction, anxiety and depression (Komatsu, 2015). 
Recently, some attention is being directed toward the role of adhesion GPCRs in 
regulating neurotransmission (Stephenson et al., 2014). For example, studies show effects 
of GPR56 on regulating brain development and brain-specific angiogenesis inhibitor (BAI) 
subfamily in mediating synaptogenesis. Another examples is GPR88 since the knockout 
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mouse model for this receptor shows abnormal behaviors associated with schizophrenia 
such as disrupted sensorimotor gating and impaired learning and bipolar disorder (Logue 
et al., 2009; Quintana et al., 2012; Komatsu, 2015). 
1.6.1 Mental Disorders 
Depression and Anxiety are co-morbid disorders that associate with stressful events 
(Anisman et al., 2008). According to Health Canada and Statistics Canada, 10-15% of 
Canadians are affected by depression and anxiety, and females are at higher risk since the 
number of women affected is doubled compared to men. Also, anxiety and depression are 
the leading causes of disability in females and the second cause generally just after 
ischemic heart disease (Nemeroff and Owens, 2004). The causes of depression and anxiety 
vary to include genetic determinants and environmental factors, but early life experiences 
and the effect of the environment seem to be more crucial, especially in the progression of 
the disease. There are some drugs available for the relief of symptoms associated with 
depression and anxiety. Despite being regularly prescribed to patients, these drugs still 
have limitations with the onset of action, response, remission rates, and side-effect profiles, 
especially that they are only effective in 50% of patients. These medications include 
serotonin 2A receptor (5-HT2AR) antagonists, CRF receptor 1 (CRFR1) antagonists, 
selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants and monoamine 
oxidase inhibitors (Marek et al., 2003; Holtzheimer and Nemeroff, 2006). 
Two of the major molecules implicated in these disorders are the corticotropin-
releasing factor (CRF) and serotonin (5-HT). CRF is known to regulate physiological 
responses in anxiety states and behavioral mechanisms of defense and it can trigger some 
changes in the other neurotransmitter systems such as serotonergic signaling (Macri et al., 
2007). Serotonin is also important in the central nervous system (CNS) and it modulates 
the etiology of anxiety and the response to anxiolytic drugs via its different receptors 
(Holmes et al., 2003; Holsboer, 2003). Different members of the serotonin receptors family 
are used as targets for the treatment of brain-related disorders such as schizophrenia, 
depression, anxiety, eating disorders and obesity (Roth et al., 2004). These two 
neurotransmitters elicit their effects via acting on their corresponding G protein-coupled 
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receptors. CRF activates two receptors, CRFR1 and CRFR2 while serotonin receptors form 
a bigger family with 15 members. Among these GPCRs, 5-HT2AR and CRFR1 have been 
directly associated with anxiety behaviours (Magalhaes et al., 2010).  Also, the role of 5-
HT2AR and CRFR1 in modulating anxiety and depression is clear given that the currently 
available drugs act directly or indirectly on these receptors. 
1.6.2 Targeting Protein- Protein Interactions as a Pharmacological 
Tool 
An increasing number of neurological and psychiatric disorders have been found to 
result from an alteration in the interaction between a GPCR and GPCR-interacting protein. 
This can provide new tools for therapeutic intervention. Many studies that investigated the 
association between GPCRs and diseases conclude that sometimes it is these interactions 
between the receptor and a specific protein that could be causing the problem (Bockaert et 
al., 2010). For example, it has been demonstrated that the interaction of Homer protein 
with mGluRs is associated with schizophrenia and anxiety (Norton et al., 2003; Szumlinski 
et al., 2005). Similarly, the interaction of Shank proteins and specifically Shank3 with 
mGluRs and somatostatin SSTR2 receptor is associated with autism (Durand et al., 2007). 
In addition, the interaction between mGluR7 and PICK1 (protein interacting with C kinase 
1) is implicated with neurological disorders like epilepsy and in fact, in vivo studies showed 
that injecting rats and mice with a cell permeable mimetic peptide to specifically disrupt 
this interaction display a phenotype characteristic of absence epilepsy (Bockaert et al., 
2010).  
Serotonin receptors were the focus of many similar studies as well. It is suggested 
that targeting the interaction between 5-HT2C receptor and PTEN (protein phosphatase and 
tensin homolog) might be an effective strategy for the treatment of addiction-related 
behaviors, with perhaps less pronounced side effects than 5-HT2C agonists (Ji et al., 2006). 
Other proteins with important associations with the serotonin receptors are the PDZ 
domain-binding proteins. Proteins like PSD-95 and MAGUK p55 subfamily member 3 
(MPP3) can mediate receptors desensitization and internalization (Gavarini et al., 2006). 
Therefore, targeting 5-HTR-PDZ protein interactions can be an attractive strategy to 
develop new drugs that may improve the therapeutic efficacy of antidepressants. P11 (also 
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called S100A10 or calpactin 1 light chain or annexin 2 light chain) is another important 
interactor with 5-HT receptors (Svenningsson et al., 2006; Warner-Schmidt et al., 2009). 
The interaction between p11 and 5-HT1B receptors is implicated in the response of 
Parkinson’s disease patients to L-DOPA treatment. It is also suggested to be involved in 
the anxiolytic effects of 5-HT1B and 5-HT4 receptors (Bockaert et al., 2010). 
1.7 Corticotropin Releasing Factor Receptors 
This family consists of two Class B GPCRs; CRFR1 and CRFR2. They are both 
activated by CRF and although they share 71% sequence homology, CRFR1 has ten-fold 
higher affinity for CRF than CRFR2 (Dautzenberg and Hauger, 2002). CRF is released in 
response to stress and it regulates the secretion of adrenocorticotropin (ACTH) from the 
anterior pituitary gland. In addition to anxiety and depression, CRF receptors are also 
known to regulate cardiovascular and inflammatory processes since they were shown to 
play a role in cardio-protection against ischemia reperfusion injury (Brar et al., 2004) and 
in the regulation of IL-18 expression. 
The tissue distribution of CRFR1 and CRFR2 is also different. CRFR1 is expressed 
widely in the brain (neocortex and cerebellum) and pituitary, while CRFR2 is usually found 
in the heart and skeletal muscle (Chalmers et al., 1995; Dautzenberg and Hauger, 2002). 
Also, CRFR1 has a PDZ-binding motif on the carboxyl-terminal tail composed of three 
amino acids; threonine, alanine and valine (TAV), while CRFR2 does not (Myers et al., 
1998; Chen et al., 2005). Upon CRF activation, both receptors mainly signal via coupling 
to Gαs to activate adenylyl cyclase resulting in the formation of cAMP.  Interestingly, this 
cAMP pathway plays a central role in amplifying and diversifying the signaling pathways 
activated by CRF receptors. cAMP formation results in the activation of PKA and this leads 
to the activation of diverse downstream signaling molecules including membrane guanylyl 
cyclase, the NF-kB transcription factor, glycogen synthase kinase-3 and the Wnt/β-catenin 
pathway, ERK1/2, tyrosine hydroxylase and ion channels (Haug and Storm, 2000; 
Aggelidou et al., 2002; Kovalovsky et al., 2002; Zhao and Karalis, 2002; Facci et al., 2003; 
Nemoto et al., 2005; Khattak et al., 2010). One of these important signaling pathways is 
the MAPK pathway. Studies show that PKA activation can have opposite effects on 
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ERK1/2 signaling depending on the tissues or type of cells investigated. For example, in 
the hippocampus, neuronal cells or pituitary, PKA activation leads to enhanced ERK1/2 
phosphorylation, while in the myometrium, endometrial adenocarcinoma and breast 
cancer, PKA activation via CRF results in the inhibition of ERK activity (Elliott-Hunt et 
al., 2002; Kovalovsky et al., 2002; Graziani et al., 2007) (Fig. 1.4). 
1.8 Serotonin Receptors 
This family consists of 7 receptor types and 15 subtypes that belong to Class A 
GPCRs (except for 5-HT3Rs which are ligand-gated ion channels). Serotonin receptors are 
involved in the modulation of sleep-wake cycles, appetite, mood, memory, breathing, 
cognition and sexual behavior (McCorvy and Roth, 2015). Serotonin has been the focus of 
many pharmacological studies for the treatment of neuropsychiatric disorders with drugs 
that target either the serotonin receptors or serotonin reuptake. Examples include serotonin-
selective reuptake inhibitors (SSRIs), dual serotonin-norepinephrine reuptake inhibitor 
(SNRI) and partial agonist or antagonist for the serotonin receptors. 
The 5-HT1 subfamily consists of 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F and 
mainly couples to Gαi resulting in the inhibition of the activity of adenylyl cyclase and 
reduction in cAMP formation. 5-HT1AR has been implicated in anxiety and depression 
while the other subtypes have been associated with migraine. 
5-HT2 subfamily consists of three subtypes; 5-HT2A, 5-HT2B and 5-HT2C. The 
family mainly couples to Gαq for the activation of phospholipase C (PLC) which 
hydrolyzes the phosphatidylinositol diphosphate releasing diacylglycerol (DAG), protein 
kinase C (PKC) and inositol triphosphate (IP3). This also leads to the release of Ca2+ from 
intracellular stores (Roth et al., 2004; Gray and Roth, 2001). 5-HT2AR has been suggested 
to be a good target for the treatment of a number of mental illnesses including 
schizophrenia, depression, and Tourette’s syndrome given its high levels in the cortex 
(Meltzer and Roth, 2013). Similarly, 5-HT2CR is ubiquitously distributed in the CNS and 
has been shown to regulate dopamine release upon treatment with antidepressants   
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Figure 1.4: Signaling pathways activated by CRFR1: CRFR1 couples mainly to Gαs to 
stimulate Adenylyl Cyclase (AC) leading to the formation of cAMP. It can also signal via 
the MAPK pathway to activate ERK1/2 phosphorylation. 
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(Mengod et al., 1996; Millan et al., 2005). Little is known about the 5-HT2BR other than 
being unselectively activated by 5-HT2A and 5-HT2C receptor ligands. There is also some 
evidence to support that 5-HT2B activation can result in cardiac hypertrophy. 
5-HT4 receptors couple to Gαs to activate AC leading to cAMP release. They are 
expressed in different tissues and therefore their activation can result in variable effects 
such as long-term potentiation (LTP) in hippocampus and peristalsis in the gut (McCorvy 
and Roth, 2015). It has been suggested that blocking the receptor with selective 5-HT4R 
antagonists can be useful in the treatment of atrial fibrillation, irritable bowel syndrome, 
and urinary incontinence. 
Similar to 5-HT1, 5-HT5 receptors couple to Gαi. The family has two subtypes; 5-
HT5A and 5-HT5B that have been associated with psychiatric disorders but have not been 
used as pharmacological targets (Thomas, 2006). Both 5-HT6 and 5-HT7 receptors, are 
Gαs-coupled and expressed in the CNS (thalamus, hypothalamus and hippocampus) and 
peripheral tissues. Similar to the rest of serotonin receptors, they have been proposed as 
targets for the treatment of depression (McCorvy and Roth, 2015). 
Among these serotonin receptor subtypes, the most ubiquitous and extensively 
studied serotonin receptors in the human brain are the 5-HT1AR and 5-HT2AR. These 
receptors have been shown to have potential roles in different neuropsychiatric diseases 
such as Alzheimer’s disease, Schizophrenia, depression and suicide (Burnet et al., 1995). 
This project particularly focuses on 5-HT2AR which is expressed in the neocortex (mainly 
prefrontal, parietal, and somatosensory cortex). It is involved in the modulation of mood 
and perception (Hall et al., 2000). Similar to the CRFR1, the 5-HT2AR has a PDZ-binding 
motif at the carboxyl-terminal tail formed by three amino acids; serine, cysteine and valine 
(SCV). Furthermore, in addition to coupling to Gαq for the activation of PLC, it can activate 
the MAPK pathway resulting in ERK1/2 phosphorylation (Fig. 1.5). 
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Figure 1.5: Signaling pathways activated by 5-HT2AR: 5-HT2AR couples mainly to Gαq 
to stimulate phospholipase Cβ (PLCβ) leading to the hydrolysis of phosphatidylinositol-
4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (IP3). 
IP3 results in the release of Ca2+ from intracellular stores while DAG activates PKC. It can 
also signal via the MAPK pathway to activate ERK1/2 phosphorylation. 
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1.9 Corticosteroid-Serotonin Interactions 
The studies on stress-related disorders such as depression have revealed that the 
two main systems involved are the Hypothalamo-Pituitary-Adrenal (HPA) Axis and the 
monoaminergic system and in particular the serotonergic (5-hyroxytryptamine) system. 
Studies show cross-regulation of the HPA axis and 5-HT system under normal 
physiological conditions, as well as pathological conditions. 
1.9.1 Hypothalamo-Pituitary-Adrenal (HPA) Axis 
The Hypothalamo-Pituitary-Adrenal (HPA) Axis is a neuroendocrine system that 
is responsible for regulating the stress response to restore homeostasis (Macri et al., 2007; 
Pompili et al., 2010). When the body is exposed to a stressor, the paraventricular nucleus 
(PVN) of the hypothalamus releases corticotrpoin-releasing hormone (CRH) and arginine-
vasopressin (AVP). CRH and AVP activate the anterior pituitary gland to release 
adrenocorticotropin hormone (ACTH). ACTH which is secreted into the circulation 
stimulates the adrenal cortex to produce glucocorticoids. These are represented by the 
secretion of cortisol in human and corticosteroids in rodents. These hormones can control 
the response via a negative feedback mechanism by activating glucocorticoid receptor 
(GR) in the adrenal cortex, anterior pituitary gland, hypothalamus and hippocampus 
(Lanfumey et al., 2008; Pompili et al., 2010). Many reports demonstrate the effect that the 
serotonin system has on the release of corticosteroids. One example is the increase in 
ACTH and cortisol levels upon administration of 5-HT1A agonists. Other studies show that 
5-HT acts via synaptic contacts between the serotonergic terminals and CRH-containing 
cells in the PVN (Liposits et al., 1987). This is demonstrated when the activation of 5-HT1A 
receptors on the PVN results in the secretion of ACTH (Lanfumey et al., 2008). 
1.9.2 Serotonergic System 
The serotonergic network is one of the most important systems in the brain, since 
the serotonergic neurons project to all parts of the CNS (Macri et al., 2007; Lanfumey et 
al., 2008; Pompili et al., 2010). One of these main structures is the hippocampus which 
receives many 5-HT projections from the neurons in the raphe nucleus. Therefore, different 
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5-HT receptor types are expressed in the hippocampus. The serotonin system can regulate 
variable functions such as food intake, learning and memory, thermoregulation, 
locomotion, cardiovascular function, sleep, endocrine regulation and sexual behavior. 
Studies demonstrate that the activation of HPA axis can result in a significant increase in 
the synthesis and production of 5-HT. 
1.10 Hypothesis and Objectives 
The previous section highlighted that there is plenty of evidence to support the 
interaction between the HPA axis and the serotonergic system. Interestingly, a recent study 
from our laboratory illustrates a crosstalk between the two systems at the receptor level. 
The study demonstrates a sensitization effect of 5-HT2AR signaling upon pretreatment with 
CRF (Magalhaes et al., 2010). The study also proposes that this phenomena is dependent 
on the internalization and trafficking pathways of both receptors and suggests the 
involvement of a PDZ protein as a key regulator for this crosstalk. The role of PDZ proteins 
in regulating GPCRs function has been the focus of many studies in the last decade which 
confirms their significance and the important roles they play in that field. However, many 
interactions remain to be characterized to gain better understanding of the role of PDZ 
proteins in regulating GPCRs activity. Achieving complete characterization of PDZ-
GPCRs interactions can provide an interesting pharmacological tool to develop more 
specific drugs. Targeting protein-protein interactions that are involved in pathological 
conditions is a challenging, yet very attractive, concept and focusing on the domains that 
mediate these interactions (such as PDZ domains) should be the priority. Such drugs will 
be very selective compared to agonists/antagonists of receptors and will therefore have 
fewer side effects. In order to be able to assess the effects of different PDZ proteins on the 
crosstalk between CRFR1 and 5-HT2AR, we would have to first study these effects on each 
receptor separately. The PDZ proteins that this project focuses on are CAL, MAGI-1, 
MAGI-2 and MAGI-3. The MAGI proteins have been shown to regulate synaptic function 
and have effects on learning and memory. CAL on the other hand has not been shown to 
be associated with mental disorders, but it is expressed in multiple regions of the brain 
including the cortex, hypothalamus and hippocampus which suggests a role that still needs 
to be explored. 
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Our HYPOTHESIS is that MAGI and CAL PDZ domain-containing proteins can 
differentially regulate the activity of GPCRs. The objectives are to determine the role of 
our PDZ proteins of interest in regulating the trafficking and signaling of CRFR1 and 5-
HT2AR. The three main aims for this project are: 
1. To determine the role of CAL in regulating the trafficking and 
signaling of CRFR1 and the mechanism for this regulation 
 
2. To determine the role of MAGI proteins in regulating the trafficking 
and signaling of CRFR1 and the mechanism for this regulation 
 
3. To determine the role of MAGI proteins in regulating the trafficking 
and signaling of 5-HT2AR and the mechanism for this regulation 
 
We use Human Embryonic Kidney 293 (HEK 293) cells to test the effects of 
overexpressing or knocking down the PDZ proteins of interest. We use co-
immunoprecipitation and immunofluorescent microscopy to assess the interactions 
between the receptors and PDZ proteins. We employ flow cytometry assays to assess the 
trafficking and internalization of receptors. We examine the effects of PDZ proteins on 
GPCR signaling by BRET-based assays for cAMP formation, scintillation proximity 
assays for IP formation and western blotting for ERK1/2 activation. 
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Chapter 2  
2 Role of CAL in regulating CRFR1 activity 
A version of this chapter has been published in the Journal of Cellular Signaling 
Hammad, M.M., Dunn, H.A., Walther, C., and Ferguson, S.S., (2015). Role of cystic 
fibrosis transmembrane conductance regulator-associated ligand (CAL) in regulating the 
trafficking and signaling of corticotropin-releasing factor receptor 1. Cell. Signal. 27 , 
2120-2130. 
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2.1 Introduction 
Corticotropin-releasing factor (CRF) is a 41 amino acid polypeptide that is secreted 
from the paraventricular nucleus of the hypothalamus in response to stress subsequently 
leading to the activation of the hypothalamic-pituitary-adrenal axis (HPA axis) (Vale et al., 
1981; Arzt and Holsboer, 2006). CRF activates two Class B G protein-coupled receptor 
(GPCR) subtypes, CRFR1 and CRFR2, which are widely expressed in the brain (neocortex 
and cerebellum) and pituitary (Chalmers et al., 1995; Palchaudhuri et al., 1998). CRF can 
regulate the endocrine response to stress by triggering the anterior pituitary gland to release 
adrenocorticotropin hormone (ACTH) into circulation. ACTH then stimulates the secretion 
of glucocorticoids from the adrenal cortex. Glucocorticoids regulate various functions both 
in the central nervous system (CNS) and at the periphery (Lanfumey et al., 2008). In 
addition, studies have shown a link between pathophysiological changes in the CRF system 
and various neuropsychiatric disorders such as major depression, panic disorder, anorexia 
nervosa, and Alzheimer's disease (Behan et al., 1996; Lanfumey et al., 2008). CRFRs are 
primarily coupled to Gαs for the activation of adenylyl cyclase leading to the formation of 
cyclic adenosine monophosphate (cAMP) (Chalmers et al., 1996) as well as the mitogen 
activated protein kinase (MAPK) signaling pathway (Kageyama et al., 2007). 
GPCRs can interact with a wide range of different proteins that control the 
trafficking, cell surface expression and signal transduction. Examples of these proteins 
include: β-arrestins, GPCR-associated sorting proteins (GASPs), small GTPases and 
PSD95/Disc Large/Zona Occludens (PDZ) proteins (Magalhaes et al., 2012). Many 
GPCRs, including CRFR1, encode a short class I PDZ domain recognition motif (S/T-x-ϕ, 
where ϕ is any aliphatic amino acid residue) at the end of the carboxyl-terminal tail. PDZ 
proteins are comprised of one or more 90 amino acid residue protein interaction domains 
that are thought to scaffold signaling complexes (Lee and Zheng, 2010; Romero et al., 
2011). PDZ proteins function to regulate the subcellular localization, trafficking and signal 
transduction of multiple GPCRs and different PDZ proteins have both overlapping and 
distinct roles in the regulation of GPCR activity (Harris and Lim, 2001; Lee and Zheng, 
2010; Romero et al., 2011; Magalhaes et al., 2012). 
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It is now recognized that PDZ proteins have distinct functions depending upon the 
particular GPCR with which they are associated. For example, MUPP1 interactions 
enhance GABAB receptor signaling (Balasubramanian et al., 2007), whereas MUPP1 
functions to uncouple the melatonin-1 receptor from Gαi (Guillaume et al., 2008) and 
facilitates resensitization of the 5-HT2CR (Parker et al., 2003). In the case of the β1-
adrenergic receptor (β1-AR), MAGI-2 has been shown to promote β1-AR internalization, 
whereas MAGI-3 selectively attenuates β1-AR-mediated ERK1/2 signaling (Xu et al., 
2001; He et al., 2006). In contrast, PSD-95 inhibits the internalization of β1-AR and 
facilitates the formation of β1-AR heterodimer with N-methyl-D-aspartate receptors (Hu et 
al., 2000). SAP97 functions to antagonize the internalization of both CRFR1 and 5-HT2AR, 
whereas PDZK1 reduces the extent of 5-HT2AR internalization, but has no significant effect 
on the endocytosis of CRFR1 (Dunn et al., 2013; Dunn et al., 2014; Walther et al., 2015). 
Although SAP97 regulates GPCR ERK1/2 signaling in a receptor-interaction independent 
manner, PDZK1 overexpression increases CRFR1- but not 5-HT2AR-mediated ERK1/2 
activity. 
The Golgi-localized cystic fibrosis transmembrane conductance regulator-
associated ligand (CAL) is a single PDZ domain-containing protein with two coiled-coil 
motifs and two evolutionally conserved regions which are required for its Golgi 
localization (Charest et al., 2001; Yao et al., 2001; Cheng et al., 2002). CAL is also known 
as GOPC, PIST and FIG. CAL overexpression reduces the cell surface expression of the 
β1-AR and mGluR1a by retaining the receptor inside the cell via a direct interaction (He et 
al., 2004; Zhang et al., 2008). CAL interacts with mGluR5a and stabilizes receptor 
expression by a mechanism that is proposed to involve the inhibition of ubiquitination-
dependent degradation (Cheng et al., 2010). CAL also contributes to the regulation of 
somatostatin receptor recycling and degradation (Wente et al., 2005; Bauch et al., 2014). 
In the present study, we have identified CAL as a protein that interacts with CRFR1. 
We find that CAL overexpression leads to the retention of CRFR1 in the Golgi apparatus 
and alters the post-translational N-glycosylation status of the receptor, suggesting that CAL 
negatively regulates the anterograde transport of CRFR1 from the ER-Golgi to the plasma 
membrane surface. We also find that CAL knockdown enhances ERK1/2 phosphorylation 
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in response to CRFR1 activation, but that CAL expression does not influence cAMP 
signaling. Taken together, our results indicate that CAL interactions with CRFR1 play an 
important role in regulating the maturation and cell surface expression of CRFR1. 
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2.2 Materials and Methods 
2.2.1 Materials 
Protein G beads were purchased from GE Healthcare (Oakville, ON, Canada). CRF was 
purchased from R&D Systems (Minneapolis, MN, USA). HA peroxidase high affinity 
antibody was purchased from Roche (Mississauga, ON, Canada). Rabbit anti-GFP 
antibody was obtained from Invitrogen/Life Technologies (Burlington, ON, Canada). ECL 
Western blotting detection reagents were purchased from Bio-Rad (Mississauga, ON, 
Canada). Alexa Fluor 647 anti-mouse IgG antibody was purchased from 
Invitrogen/Molecular Probes (Burlington, ON, Canada). Rabbit CAL antibody was 
purchased from Abcam (Toronto, ON, Canada). Rabbit anti-phospho-p44/42 MAP kinase 
(Thr202/Tyr402), and rabbit anti-p44/42 MAP kinase antibodies were obtained from Cell 
Signaling Technology (Pickering, ON, Canada). Mouse anti-HA antibody, 
endoglycosidases F and H and all other biochemical reagents were purchased from Sigma-
Aldrich (Oakville, ON, Canada). 
2.2.2 Plasmids 
HA-CRFR1 and HA-CRFR1-ΔTAV were described previously (Holmes et al., 2006; 
Magalhaes et al., 2010). Human CAL was kindly provided by Dr. Randy Hall (Emory 
University, School of Medicine). The CAL cDNA was subcloned into the expression 
vector pEYFP-N1. CAL siRNA (Hs_GOPC_3) GCUGCAGCUUCAUGCUAAATT was 
purchased from Qiagen (Toronto, ON, Canada). For the negative controls, we used Silencer 
Negative Control #1 AM4635 AGUACUGCUUACGAUACGGTT from Invitrogen 
(Burlington, ON, Canada). The exchange proteins directly activated by cAMP biosensor 
(EPAC) was a gift from Drs. Ali Salahpour (University of Toronto) and Marc Caron (Duke 
University) (Barak et al., 2008). TGN-CFP was kindly provided by Dr. Stephen Pasternak 
(University of Western Ontario). Site-directed mutagenesis was used to introduce N to Q 
in the following constructs: CRFR1 N38Q, CRFR1 N78Q, CRFR1 N90Q and CRFR1 
N98Q and mutations were confirmed by sequencing. 
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2.2.3 Cell culture and transfection 
Human embryonic kidney (HEK 293) cells were grown in Eagle's minimal essential 
medium supplemented with 10% fetal bovine serum. Cells were plated on 10-cm dishes 
24h prior to transfection. All experiments were performed on 75–80% confluent plates. 
Transfections were performed using calcium phosphate protocol except for siRNA 
transfections which were performed using Lipofictamine 2000 following manufacturer's 
instructions. Transfections were performed with 1 μg of each construct. Empty pcDNA3.1 
vector was used to equalize the total amount of plasmid cDNA used to transfect cells. 18h 
post transfection, cells were washed with phosphate-buffered saline (PBS) and 
resuspended with trypsin, 0.25% EDTA. Experiments were performed approximately 48h 
after transfection except for knockdown experiments which were performed 72h post 
transfection since this protocol resulted in the maximum knockdown of CAL. 
2.2.4 Co-immunoprecipitation 
24h after transfection, HEK 293 cells were seeded onto 10-cm dishes. Cells were starved 
with HBSS for 1h at 37 °C then stimulated with 100 nM CRF agonist for 30 min. Cells 
were then lysed in 500 μL lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, and 0.1% 
Triton X-100) containing protease inhibitors (1 mM AEBSF, 10 μg/ml leupeptin, and 2.5 
μg/ml aprotinin) for 20 min on a rocking platform at 4 °C. Samples were collected into 1.5 
ml Eppendorf tubes and centrifuged at 15,000 g for 15 min at 4 °C to pellet insoluble 
material. A Bradford protein assay was performed, and 150 μg of protein was incubated 
for 2–4h at 4 °C with protein G-Sepharose and mouse anti-HA antibody (1:50). Beads were 
washed three times with cold lysis buffer and incubated overnight at room temperature in 
3xSDS loading buffer containing 2-mercaptoethanol. Samples were separated by SDS-
PAGE, transferred to a nitrocellulose membrane, and western blots were then performed 
with the indicated antibodies (rabbit anti-GFP, 1:10000), (HA-POD, 1:1000). 
2.2.5 Confocal microscopy 
HEK 293 cells were co-transfected with HA-CRFR1, CAL-YFP and TGN-CFP in 10-cm 
dishes and 24h after transfection, cells were reseeded onto glass coverslips. 24h later, cells 
were washed with HBSS, fixed with 4% paraformaldehyde in PBS, and permeabilized with 
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0.5% Triton X-100 in PBS for 5 min at room temperature. After rinsing with PBS, cells 
were blocked with 5% donkey serum in PBS for 1h at room temperature then labeled with 
mouse HA antibody (1:1000) for 1h at room temperature. The reaction proceeded by 
incubation with a secondary antibody, donkey anti-mouse Alexa Fluor 647 (1:1000) for 1h 
at room temperature. Coverslips were mounted on slides using Pro- Long Gold Antifade 
Reagent. Confocal microscopy was performed using a Zeiss LSM510 META laser-
scanning confocal microscope equipped with a Zeiss 63X, 1.4 numerical aperture, oil-
immersion lens. 
2.2.6 Receptor endocytosis 
Following transfection, HEK 293 cells were re-seeded into 12- well plates. Cells were 
serum-starved in HBSS for 1h at 37 °C then stimulated for 0, 30 or 60 min with 500 nM 
CRF in HBSS at 37 °C. Cells were washed with cold HBSS and incubated with mouse 
anti- HA antibody (1:1000) for 1h on ice. Cells were washed with cold HBSS then labeled 
with Alexa Fluor 647 donkey anti-mouse IgG (1:1000) for 1h on ice in the dark. Cells were 
washed with cold HBSS and treated with 5 mM EDTA in PBS for 5 min on ice. Cells were 
collected and transferred to flow cytometry tubes containing 4% formaldehyde in PBS. 
Samples were run on a FACS Calibur cytometer using BD Cell Quest Pro software (BD 
Biosciences, Mississauga, ON, Canada) until 10,000 cells were counted. The geometric 
mean of fluorescence was determined using Flow Jo analysis software and was 
representative of the expression levels of the receptor on the plasma membrane (BD 
Biosciences, Mississauga, ON, Canada). 
2.2.7 Bioluminescent Resonance Energy Transfer-based biosensor 
cAMP assay 
HEK 293 cells were co-transfected with HA-CRFR1 (WT or ΔTAV) and either pcDNA3.1, 
CAL, scrambled (SCR) siRNA or CAL siRNA as well as 2 μg of an EPAC (exchange 
proteins directly activated by cAMP) construct in 10-cm dishes. 48h post-transfection, cells 
were re-seeded into 96-well plate (~10,000 cells/well) and left for another 24h. On the 
following day, cells were serum-starved for 1h in induction buffer (200 μM isobutyl-1-
methylxanthine (IBMX) in HBSS). Coelenterazine was then added to the wells at a final 
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concentration of 5 μM. Cells were then stimulated with increasing concentrations of CRF 
peptide for 10 min. The plate was then read by a Victor Plate Reader (Perkin-Elmer) and 
the BRET signal was determined by calculating the ratio of the light emitted at 505 to 555 
nm to the light emitted at 465 to 505 nm. 
2.2.8 ERK phosphorylation 
Following 48h of transfection, HEK 293 cells were re-seeded into 6- well plates. Cells were 
serum starved for 1h at 37 °C in HBSS and then stimulated with 500 nM CRF agonist for 
0, 5 and 15 min. Cells were lysed with lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 
and 1% Triton X-100) containing protease inhibitors (1 mM AEBSF, 10 μg/ml leupeptin, 
and 2.5 μg/ml aprotinin) and phosphatase inhibitors (10 mM NaF and 500 μM Na3VO4) 
for 20 min on a rocking platform at 4 °C. Samples were collected into 1.5 ml Eppendorf 
tubes and centrifuged at 15,000 g for 15 min at 4 °C to pellet insoluble material. A Bradford 
protein assay was performed, and 30–50 μg of protein was incubated overnight at room 
temperature in 3xSDS loading buffer containing 2-mercaptoethanol. Samples were 
separated by SDS-PAGE, transferred to a nitrocellulose membrane, and western blot 
analysis was performed for ERK1/2 (rabbit anti-p44/42MAPK, 1:1000), phospho-ERK1/2 
(rabbit anti-phospho-p44/42 MAPK, 1:1000), CAL-YFP (rabbit CAL, 1:1000), HA-
CRFR1 (HA-POD, 1:1000), and actin. 
2.2.9 Western blot analysis 
75–90 μl of the samples from the different assays which is equivalent to about 30–50 μg 
of protein was diluted in β-mercaptoethanol containing 3x loading buffer and then applied 
to 10% SDS-PAGE (30% acrylamide mix, 1.5 M tris-HCl, 20% SDS, 10% ammonium 
persulfate and TEMED). Separated proteins were then transferred to nitrocellulose 
membranes and membranes were then blocked in 10% milk in TBS for 1h. Membranes 
were then blotted overnight by incubation with the appropriate antibody at 4 °C. 24h later 
membranes were washed at least three times with 1X TBS with 0.05% Tween 20, and then 
incubated with a horseradish peroxidase- conjugated secondary antibody (1:10,000) for 1h. 
Membranes were finally washed again with 1X TBS with 0.05% Tween 20 three times 
before being developed using a BioRad chemiluminescence system. 
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2.2.10 Statistical analysis 
All measurements are represented as mean ± SEM. Comparisons were performed using 
one way analysis of variance test (ANOVA) followed by Bonferroni's or Dunn's Multiple 
comparisons test to determine significance. The symbol * indicates P values less than 0.05 
and is considered to be significant.  
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2.3 Results 
2.3.1 CAL interacts with CRFR1 in a PDZ-binding motif-dependent 
manner 
CAL is a PDZ domain-containing protein that was previously shown to interact with the 
β1-AR and Group I mGluRs (He et al., 2004; Zhang et al., 2008; Cheng et al., 2010). We 
previously identified CAL as one of several PDZ domain-containing proteins that interact 
with a GST fusion of the CRFR1 carboxyl-terminal tail (Dunn et al., 2013). To further 
validate this potential interaction between CAL and CRFR1, we performed co-
immunoprecipitation experiments with CAL-YFP and either wild-type HA-tagged CRFR1 
(HA-CRFR1) or a HA-tagged CRFR1 mutant that lacked a class I PDZ-binding motif (HA-
CRFR1-ΔTAV) in transiently transfected HEK 293 cells. We found that CAL-YFP was 
co-immunoprecipitated with HA-CRFR1, but not CRFR1-ΔTAV and that the interaction 
of CAL-YFP with HA-CRFR1 was not increased following agonist treatment with 100 nM 
CRF (Fig. 2.1A and 2.1B). We also observed that CAL overexpression resulted in a shift 
in the molecular weight of CRFR1 and this will be discussed in section 2.3.6. 
2.3.2 HA-CRFR1 co-localizes with CAL-YFP in the Golgi apparatus 
To further address whether CAL forms a complex with CRFR1, we assessed whether the 
two proteins could be co-localized in HEK 293 cells in a PDZ motif-dependent manner. In 
cells transfected to express HA-CRFR1 and YFP as a control, the HA-CRFR1 labeled with 
Alexa Fluor 647 primary mouse anti-HA antibody in permeabilized cells showed 
predominant localization at the cell surface with some co-localization with Golgi marker 
TGN-CFP (Fig. 2.2A). In HEK 293 cells transfected with HA-CRFR1 and CAL-YFP, 
CAL-YFP fluorescence was extensively co-localized with TGN-CFP consistent with 
previous reports where CAL was localized to the Golgi apparatus and could be used as a 
marker for this organelle (Fig. 2.2B) (Charest et al., 2001; Yao et al., 2001). In 
permeabilized HEK 293 cells, HA-CRFR1 immunofluorescence was co-localized with 
CAL-YFP with extensive co-localization in the Golgi (Fig. 2.2B). Similar to what was 
observed for HA-CRFR1, HA-CRFR1-ΔTAV immunofluorescence was localized at the 
cell surface of HEK 293 cells in YFP transfected cells (Fig. 2.2C), but unlike what was   
60 
 
 
 
 
 
Figure 2.1: CAL-YFP co-immunoprecipitates with HA-CRFR1 in a PDZ-binding 
motif-dependent manner: HEK 293 cells were co-transfected with HA-CRFR1 (WT or 
ΔTAV) and YFP or CAL-YFP. A) Representative immunoblot of CAL-YFP co-
immunoprecipitated (IP) with HA-CRFR1 but not HA-CRFR1-ΔTAV which lacks the 
PDZ-binding motif. SDS-PAGE was used to analyze samples and immunoblots were 
performed with rabbit anti-GFP. B) Effect of CRF treatment was quantified using 
densitometry and had no significant difference on the amount of CAL-YFP co-
immunoprecipitated with HA-CRFR1. Data are representative of 5 independent 
experiments. NT: non-transfected, IB: immunoblot.  
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Figure 2.2: CAL-YFP co-localizes with HA-CRFR1 in the Golgi in a PDZ-binding 
motif-dependent manner: A) Representative confocal microscopy image of fixed HEK 
293 cells transfected with TGN-CFP (blue), YFP (green), and HA-CRFR1 (red). B) 
Representative confocal microscopy image of fixed HEK 293 cells transfected with TGN-
CFP (blue), CAL-YFP (green), and HA-CRFR1 (red). C) Representative confocal 
microscopy image of fixed HEK 293 cells transfected with TGN-CFP (blue), YFP (green), 
and HA-CRFR1-ΔTAV (red). D) Representative confocal microscopy image of fixed HEK 
293 cells transfected with TGN-CFP (blue), CAL-YFP (green), and HA-CRFR1-ΔTAV 
(red). Scale bar=10 μM. Images are representative of 20 cells from five independent 
experiments. 
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observed for HA-CRFR1 it was not extensively localized to the Golgi to co-localize with 
CAL-YFP (Fig. 2.2D). In contrast, HA-CRFR1-ΔTAV immunofluorescence remained 
predominantly localized to the cell surface. Taken together these observations support the 
concept that CAL forms a complex with CRFR1 resulting in the accumulation of the 
receptor in the Golgi. 
2.3.3 Effect of CAL expression on agonist-stimulated CRFR1 
endocytosis 
To determine whether CAL contributed to the regulation of CRFR1 endocytosis, we 
employed flow cytometry to assess the loss of cell surface HA-CRFR1 
immunofluorescence. We found that CAL overexpression attenuated agonist-stimulated 
HA-CRFR1 internalization following treatment with 500 nM CRF for 30 and 60 min (Fig. 
2.3A). The internalization of the mutant HA-CRFR1-ΔTAV was not altered by CAL 
overexpression (Fig. 2.3B). Thus, CAL overexpression attenuated CRFR1 endocytosis in 
a PDZ motif-dependent manner. 
2.3.4 Effect of CAL expression on cAMP signaling 
PDZ domain-containing proteins were previously shown to have the potential to regulate 
cAMP signaling of some GPCRs (Wang et al., 2007; Magalhaes et al., 2012). Therefore, 
we tested whether CAL contributed to the regulation of CRFR1- mediated cAMP 
formation. In HEK 293 cells transfected with either HA-CRFR1 or HA-CRFR1-ΔTAV, 
with or without CAL, and treated with increasing concentrations of CRF for 10 min, there 
was no significant change in the maximum efficacy for CRF-stimulated cAMP signaling 
(Fig. 2.4A and 2.4B). In addition we assessed whether the attenuation of CAL expression 
might alter CRFR1 cAMP signaling. We found that transfection of HEK 293 cells with 
CAL siRNA previously demonstrated to knockdown CAL expression (Cheng et al., 2010) 
had no effect on either HA-CRFR1- or HA-CRFR1-ΔTAV- stimulated cAMP signaling in 
response to the treatment of transfected HEK 293 cells with increasing concentrations of 
CRF (Fig. 2.4C and 2.4D). These results suggest that CAL does not contribute to the 
regulation of CRFR1 activation of the cAMP pathway. 
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Figure 2.3: Effect of CAL expression on agonist-stimulated CRFR1 endocytosis: 
Agonist stimulated internalization of either A) HA-CRFR1 or B) HA-CRFR1-ΔTAV in 
the presence and absence of CAL overexpression following 500 nM CRF treatment for 
either 30 or 60 min. The data represent the mean ± SEM of 4 independent experiments. *P 
< 0.05 versus empty vector control.  
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Figure 2.4: CAL does not regulate CRFR1-mediated cAMP formation: Dose response 
for CRF stimulated cAMP formation assessed using a BRET-based cAMP biosensor assay. 
A) CRFR1- and B) CRFR1-ΔTAV-mediated cAMP formation in either plasmid vector or 
CAL transfected HEK 293 cells. C) CRFR1- and D) CRFR1-ΔTAV-mediated cAMP 
formation in either scrambled or CAL siRNA transfected HEK 293 cells. The data 
represent the mean ± SEM of 3–5 independent experiments. 
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2.3.5 Effect of CAL expression on ERK1/2 signaling 
In addition to being coupled to the Gαs-dependent activation of adenylyl cyclase, agonist 
activation of CRFR1 leads to increased ERK1/2 phosphorylation (Kageyama et al., 2007; 
Dunn et al., 2013; Dunn et al., 2014). Therefore, we assessed whether either CAL-YFP 
overexpression or siRNA-mediated knockdown of endogenous CAL would alter CRFR1-
mediated ERK1/2 phosphorylation in a PDZ interaction- dependent manner in response to 
500 nM CRF treatment for 5 and 15 min. CAL overexpression resulted in a statistically 
significant reduction in ERK1/2 phosphorylation and siRNA knockdown of endogenously 
expressed CAL increased HA-CRFR1- stimulated ERK1/2 phosphorylation following the 
activation of HA-CRFR1 for 5 and 15 min with 500 nM CRF (Fig. 2.5A). In contrast, 
neither CAL overexpression nor CAL knockdown affected HA-CRFR1-ΔTAV-stimulated 
ERK1/2 phosphorylation (Fig. 2.5B). Taken together, these data suggested that CAL 
negatively regulates CRFR1-mediated ERK1/2 signaling via a PDZ binding motif 
interaction-dependent signaling mechanism. 
2.3.6 Effect of CAL on CRFR1 glycosylation and degradation 
CAL overexpression consistently altered the molecular migration of HA-CRFR1, but not 
HA-CRFR1-ΔTAV by SDS-PAGE (Fig. 2.1 and Fig. 2.5). To further characterize this 
CAL expression-dependent change in the molecular mass of the HA-CRFR1, we co-
transfected HEK 293 cells with either HA-CRFR1 or HA-CRFR1-ΔTAV along with 
increasing cDNA concentrations of CAL and then performed western blotting on HEK 293 
cell lysates for receptor expression (Fig. 2.6A). We found that, even at the lowest levels of 
CAL overexpression, the molecular mass of a substantial proportion of HA-CRFR1 
decreased as evidenced by an increased mobility on the SDS-PAGE gel, suggesting that 
this represented an immature, non-glycosylated form of the receptor (Fig. 2.6A). In 
contrast, CAL overexpression did not alter the mobility of the HA-CRFR1-ΔTAV on an 
SDS PAGE gel (Fig. 2.6A). Densitometric analysis of the gels revealed that there was a 
significant reduction in the higher molecular mass HA-CRFR1 receptor band following 
CAL overexpression, whereas, CAL overexpression did not alter the proportion of the 
higher molecular mass HA-CRFR-ΔTAV band (Fig. 2.6B). To ascertain that the lower  
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Figure 2.5: CAL negatively regulates HA-CRFR1-mediated ERK1/2 
phosphorylation: A) Representative immunoblot showing ERK1/2 phosphorylation in 
response to 500 nM CRF treatment for 0, 5, and 15 min in non-transfected (NT) HEK 293 
cells, and HEK 293 cells transfected with HA-CRFR1 along with either YFP, CAL-YFP, 
scrambled (SCR) siRNA or CAL siRNA. Also shown are corresponding immunoblots for 
total ERK1/2, CAL and HA-CRFR1 protein expression. Shown below is the densitometric 
analysis of ERK1/2 phosphorylation in response to 500 nM CRF treatment for 0, 5, and 15 
min in non-transfected (NT) HEK 293 cell, and HEK 293 cells transfected with HA-
CRFR1 along with either YFP, CAL-YFP, scrambled (SCR) siRNA or CAL siRNA. The 
data represent the mean ± SEM of six independent experiments. * P < 0.05 versus SCR 
siRNA treated cells. B) Representative immunoblot showing ERK1/2 phosphorylation in 
response to 500 nM CRF treatment for 0, 5, and 15 min in non-transfected (NT) HEK 293 
cells, and HEK 293 cells transfected with HA-CRFR1-ΔTAV along with either YFP, CAL-
YFP, scrambled (SCR) siRNA or CAL siRNA. Also shown are corresponding 
immunoblots for total ERK1/2, CAL and HA-CRFR1-ΔTAV protein expression. Shown 
below is the densitometric analysis of ERK1/2 phosphorylation in response to 500 nM CRF 
treatment for 0, 5, and 15 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells 
transfected with HA-CRFR1-ΔTAV along with either YFP, CAL-YFP, scrambled (SCR) 
siRNA or CAL siRNA. The data represent the mean ± SEM of 6 independent experiments. 
* P < 0.05 versus SCR siRNA treated cells.  
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 molecular mass species of the HA-CRFR1 construct was not the consequence of increased 
receptor degradation following CAL overexpression, we stimulated HA-CRFR1 
expressing cells with 100 nM CRF for 0, 2, 4 or 6 h in the presence of scrambled siRNA, 
CAL or CAL siRNA. However, we did not observe any time-dependent change in the 
fraction of the lower molecular mass HA-CRFR1 species in CAL overexpressing cells (Fig. 
2.6C). Consistent with the hypothesis that CAL interactions with HA-CRFR1, but not 
CRFR1-ΔTAV, affected the maturation of the glycosylation state of the receptor, both 
endoglycosidase F (1h) and H (3h) treatment reduced the molecular mass of the lower 
molecular weight HA-CRFR1 species (Fig. 2.6D). Taken together, these results indicated 
that PDZ motif-dependent interactions with the CRFR1 altered CRFR1 glycosylation. The 
amino-terminal domain of CRFR1 has five potential N-linked glycosylation sites at 
positions N38, N45, N78, N90 and N98 (Assil and Abou-Samra, 2001). Therefore, we 
generated point mutations where potentially glycosylated asparagine residues were 
replaced with glutamine, HA-CRFR1-N38Q, HA-CRFR1-N78Q, HA-CRFR1-N90Q and 
HA-CRFR1-N98Q. When expressed with YFP in HEK 293 cells HA-CRFR1-N38Q and 
HA-CRFR1-N78Q exhibited a wild-type pattern of protein expression (Fig. 2.7). However, 
when transfected with YFP, HA-CRFR1-N90Q and HA-CRFR1-N98Q had a mobility 
pattern on SDS-PAGE that was similar to what was observed following CAL-YFP 
overexpression with HA-CRFR1 (Fig. 2.7). However, overexpression of CAL-YFP 
resulted in the appearance of a lower molecular mass species for the wild-type, as well as 
the N38Q and N78Q CRFR1 mutants (Fig. 2.7). CAL-YFP overexpression resulted in 
nearly the complete loss of upper molecular mass protein band for the HA-CRFR1-N90Q 
and HACRFR1-N98Q mutants (Fig. 2.7). Taken together, CRFR1 N90 and N98 appear to 
be the primary residues that undergo receptor glycosylation.  
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Figure 2.6: Effect of CAL on CRFR1 glycosylation and degradation: A) Representative 
immunoblot of 1 μg HA-CRFR1 and HA-CRFR1-ΔTAV cell lysates from transfected 
HEK 293 cells immunoblotted with HA antibody. Cells were co-transfected with 
increasing amounts of plasmid cDNA encoding CAL (0, 0.25, 0.5, 1, and 2 μg plasmid 
cDNA). Shown below are representative immunoblots for CAL and actin expression. B) 
Densitometric analysis of the relative amount of the upper molecular mass CRFR1 
immunoreactive band compared to total receptor immunoreactivity. The data represent the 
mean ± SEM of 5 independent experiments. * P < 0.05 versus cells expressing receptor 
alone. C) Representative immunoblot (n= 3) of 1 μg HA-CRFR1 cell lysates from 
transfected HEK 293 cells immunoblotted with HA-antibody following CRF treatment 0, 
2, 4, 6 h, in cells transfected with scrambled siRNA, CAL, or CAL siRNA. Shown below 
is a representative immunoblot for CAL expression. D) Representative immunoblot (n= 5) 
of 1 μg HA-CRFR1 and HA-CRFR1-ΔTAV cell lysates from transfected HEK 293 cells 
immunoblotted with HA-antibody. Cells were co-transfected with and without plasmid 
cDNA encoding CAL-YFP and treated with and without endoglycosidase (Endo) F and H 
for 60 and 180 min, respectively. Shown below is representative immunoblot for CAL 
expression.  
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Figure 2.7: Glycosylation of HA-CRFR1-N38Q, -N78Q, -N90Q and -N98Q mutants 
in the absence and presence of CAL: Shown is a representative immunoblot of 1 μg HA-
CRFR1, HA-CRFR1-N38Q, HA-CRFR1-N78Q, HA-CRFR1-N90Q and HA-CRFR1-
N98Q cell lysates from HEK 293 cells co-transfected with either YFP or CAL-YFP. Blots 
are representative of four independent experiments.  
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2.3.7 Subcellular localization and signaling of CRFR1 glycosylation 
mutants 
To examine whether the glycosylation status of the CRFR1 was important for cell surface 
expression, we assessed the subcellular localization of both the HA-CRFR1-N78Q mutant 
that exhibited a wild-type glycosylation pattern, and the HA-CRFR1-N90Q mutant that 
exhibited altered glycosylation in the presence and absence of CAL-YFP by 
immunofluorescence microscopy. We found that the HA-CRFR1-N78Q mutant was 
expressed at the cell surface of HEK 293 cells and was not co-localized with TGN-CFP 
Golgi marker in YFP expressing cells (Fig. 2.8A), but was retained in the Golgi following 
CAL-YFP overexpression (Fig. 2.8B). In contrast, the HA-CRFR1-N90Q mutant exhibited 
extensive co-localization with TGN-CFP Golgi marker in both the absence and presence 
of CAL-YFP (Fig. 2.8C and 2.8D). Consistent with this observation, the cell surface 
expression of both the HA-CRFR1-N90Q and HA-CRFR1-N98Q mutants was reduced to 
the same extent as what was observed for the HA-CRFR1 in the presence of CAL-YFP 
while the cell surface expression of the HA-CRFR1-N38Q and HA-CRFR1-N78Q was 
similar to the HA-CRFR1 (presented as the dotted line) (Fig. 2.9A). The reduction in cell 
surface expression was not sufficient to impair G protein coupling but all glycosylation-
deficient mutations decreased the efficacy of CRF treatment for CRFR1-stimulated cAMP 
formation (Fig. 2.9B). Thus, a fully glycosylated CRFR1 was required for appropriate cell 
surface expression of the CRFR1 and mutation of any glycosylation site reduces the 
efficacy for CRF-stimulated cAMP formation. This unique effect on cAMP formation was 
not observed with the over-expression of CAL which suggests that introducing mutations 
and their effect on the structure and folding of the receptor has a more prominent effect 
than CAL interaction with the receptor. In addition to cAMP formation, we have also 
assessed ERK1/2 signaling by the glycosylation-deficient mutants. Our data showed that 
both CRFR1-N90Q and CRFR1-N98Q have altered ERK1/2 signaling illustrated as a 
reduction in phosphorylation that is about 50% less compared to CRF-stimulated ERK1/2 
phosphorylation by CRFR1 (Fig. 2.9C). 
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Figure 2.8: Subcellular localization of HA-CRFR1 glycosylation site mutants in the 
presence and absence of CAL: A) Representative confocal microscopy image of fixed 
HEK 293 cells transfected with TGN-CFP (blue), YFP (green), and HA-CRFR1-N78Q 
(red). B) Representative confocal microscopy image of fixed HEK 293 cells transfected 
with TGN-CFP (blue), CAL-YFP (green), and HA-CRFR1-N78Q (red). C) Representative 
confocal microscopy image of fixed HEK 293 cells transfected with TGN-CFP (blue), YFP 
(green), and HA-CRFR1-N90Q (red). D) Representative confocal microscopy image of 
fixed HEK 293 cells transfected with TGN-CFP (blue), CAL-YFP (green), and HA-
CRFR1-N90Q (red). Scale bar= 10 μM. Images are representative of 12 cells from three 
independent experiments. 
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Figure 2.9: Cell surface expression, cAMP signaling and ERK1/2 signaling of CRFR1 
glycosylation site mutants: A) Cell surface expression in HEK 293 cells expressing either 
HA-CRFR1 along with CAL, HA-CRFR1-N90Q, HA-CRFR1-N98Q, HA-CRFR1-N38Q 
or HA-CRFR1-N78Q expressed as measured by flow cytometry. Data is normalized to 
HA-CRFR1 expression (as illustrated by the dotted line). The data represent the mean ± 
SEM of 5 independent experiments. * P < 0.05 versus HA-CRFR1 cell surface expression. 
B) Dose-response for CRF-mediated cAMP activation in HEK 293 cells expressing either 
HA-CRFR1, HA-CRFR1 along with CAL, HA-CRFR1-N90Q, HA-CRFR1-N98Q, HA-
CRFR1-N38Q or HA-CRFR1-N78Q. The data represent the mean ± SEM of 5 independent 
experiments. C) Densitometric analysis of ERK1/2 phosphorylation in response to 500 nM 
CRF treatment for 0, 5, and 15 min in HEK 293 cells transfected with HA-CRFR1, HA-
CRFR1-N90Q, HA-CRFR1-N98Q, HA-CRFR1-N38Q or HA-CRFR1-N78Q. The data 
represent the mean ± SEM of three independent experiments. * P < 0.05 versus cells 
transfected with HA-CRFR1.  
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On the other hand, ERK1/2 signaling of both CRFR1-N38Q and CRFR1-N78Q was similar 
to that of CRFR1. This data is consistent with the mobility patterns observed in Fig. 2.7 
where both CRFR1-N90Q and CRFR1-N98Q had a similar pattern to CAL overexpression 
with the receptor and CAL overexpression also reduced ERK1/2 phosphorylation. This 
confirms the importance of CRFR1 glycosylation specifically of resides Asn90 and Asn98 
for proper maturation and signaling. It also supports our hypothesis that CAL's interaction 
with CRFR1 and the effects it has on receptor trafficking and signaling is the result of its 
role in mediating glycosylation.  
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2.4 Discussion 
We previously reported that CAL is one of a series of CRFR1- interacting PDZ 
proteins identified in a proteomic screen, but the functional role of this interaction has not 
been characterized (Dunn et al., 2013). In this study, we have identified the role of CAL in 
the regulation of the CRFR1 function as a protein that negatively regulates cell surface 
CRFR1 expression. We propose that CAL can regulate cell surface expression by 
modulating the post-translational modification involving the glycosylation of amino-
terminal Asn residues which is required for proper maturation and folding of GPCRs 
(Wheatley and Hawtin, 1999; Duvernay et al., 2005). This suggests an important role for 
CAL in the anterograde trafficking of transmembrane proteins through the ER-Golgi 
complex. We also demonstrate a negative functional effect of CAL on CRFR1-stimulated 
ERK1/2 signaling in the absence of alterations in CRFR1-mediated cAMP formation. 
Mutagenesis analysis of putative sites of glycosylation revealed active glycosylation at Asn 
residues 90 and 98 and that mutation of these residues reduced cell surface CRFR1 
expression and decreased the efficacy for CRF-stimulated cAMP formation. 
The role of PDZ proteins is generally considered to be limited to scaffolding molecular 
complexes, but these proteins have started to emerge as important regulators of GPCR 
expression and signaling (Magalhaes et al., 2012). CAL has been shown to associate with 
and regulate the activity of a number of other GPCRs including: the β1-AR (He et al., 2004), 
metabotropic glutamate receptor 1 and 5 (mGluR1a and mGluR5) (Zhang et al., 2008; 
Cheng et al., 2010) and the somatostatin receptor subtype 5 (SSTR5) (Wente et al., 2005; 
Bauch et al., 2014). A common finding in both our current study and previous reports 
examining the role of CAL in regulating GPCR function is that the overexpression of CAL 
results in the intracellular retention of the receptors in the ER-Golgi resulting in the 
reduction of receptor expression at the plasma membrane and this has been shown in 
multiple different cell lines. Moreover, CAL appears to play a role in the ER-Golgi 
retention not only of GPCRs, but also of other transmembrane proteins such as the CFTR 
(Cheng et al., 2002) and the voltage-gated potassium channel (KV10.1) (Herrmann et al., 
2013). However, the mechanism for this regulation is still not clear, especially for GPCRs. 
It has been suggested that CAL can reduce cell surface expression of CFTR by enhancing 
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their ubiquitination, thereby targeting them for lysosomal degradation. In contrast, opposite 
conclusions were drawn with regards to the mechanism by which CAL regulates mGluR5. 
In the case of mGluR5 it is suggested that CAL may stabilize the receptor by inhibiting its 
ubiquitination-dependent degradation process. This is not the case for CRFR1 as we have 
found that CAL overexpression does not contribute to increased CRFR1 degradation 
following CRF stimulation for up to 6h. 
We find that CAL overexpression results in the appearance of a lower molecular mass 
HA-immunoreactive protein band that is not prominently observed in the absence of CAL 
expression. We have hypothesized that this band represents an immature partially 
glycosylated form of the CRFR1. Similar conclusions have been previously made 
regarding the effect of CAL overexpression on the glycosylation status of SSTR5 (Wente 
et al., 2005; Bauch et al., 2014). GPCR maturation is associated with post-translational 
modification of the receptors that can result in the glycosylation of Asn residues localized 
on the extracellular surfaces of the receptors. In the present study, we find that the 
introduction of point mutations at Asn90 and Asn98, results in impaired CRFR1 
glycosylation that is indistinguishable from the effect of overexpressing CAL. We show 
that the addition of polysaccharide chains at either of these two residues is important for 
cell surface CRFR1 expression and the efficacy for CRF-stimulated cAMP formation. 
These results are in contradiction with a previous study of CRFR1 and the parathyroid 
hormone receptor (PTH) glycosylation (Assil and Abou-Samra, 2001). In the previous 
study, altered CRFR1 function required the mutation of at least three N-glycosylation sites 
and suggested that the loss of either one or two polysaccharide chains is well-tolerated 
(Assil and Abou-Samra, 2001). It is likely that the observed differences between these 
studies may be attributed to differences in the methodologies used to measure cell surface 
expression and cAMP formation and the cell types used. 
CAL has been shown to interact with Golgi proteins involved in sorting such as 
Syntaxin 6 or Golgin160 (Herrmann et al., 2013). In addition, CAL can associate with 
many transmembrane proteins and retain them in the transgolgi network (Cheng et al., 
2002; Herrmann et al., 2013). This suggests that CAL may play an important role as either 
an ER-Golgi sorting molecule or contribute directly to the ER-Golgi quality control process 
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to ensure that only properly folded terminally glycosylated proteins exit the ER-Golgi 
complex to traffic to the plasma membrane. If the protein is still not ready, CAL retains it 
to allow for other scaffolding proteins to bind and complete the folding process. This can 
also be used to explain CAL's role in mediating glycosylation. There is currently no known 
sorting mechanism for glycosyltransferases which are the key enzymes in the addition of 
glycans to proteins (Moremen et al., 2012). Given the ubiquitous distribution of CAL 
throughout the different Golgi compartments and its potential role as a sorting molecule, 
we can speculate that it is involved in the vesicular transport and sorting of 
glycosyltransferases and hence mediate the glycosylation of transmembrane proteins. 
A very recent paper has demonstrated that CAL interacts with the β1-AR (Koliwer et 
al., 2015). This interaction with the β1-AR appears to play an important role in regulating 
the internalization and recycling of the β1-AR and is proposed that this occurs as the 
consequence of an effect of CAL on the endosomal degradation of the receptor following 
endocytosis (Koliwer et al., 2015). The authors also demonstrate that β1-AR expression 
levels are decreased in the hippocampus of CAL knockout mice. Therefore, based on this 
study and our own data showing that CAL is predominantly localized to the Golgi 
apparatus, we propose that CAL may mediate its effects on GPCR function by serving as 
a GPCR sorting protein via two distinct mechanisms. Specifically, by acting as a regulator 
of post-translational GPCR modifications involved in receptor glycosylation, as well as 
functioning as a regulator of endosomal degradation.  
Our data show that CAL overexpression can block agonist-stimulated endocytosis. We 
are suggesting that CAL can mediate post-translational modifications and we have 
provided evidence for it regulating the glycosylation of CRFR1. We can speculate that it 
can mediate other modifications that might be important for receptor internalization like 
phosphorylation. In addition, other PDZ proteins were shown to regulate the recruitment 
of β-arrestin to GPCRs which is a key step in receptor endocytosis (Dunn and Ferguson, 
2015). It has been shown that NHERF1 can enhance β-arrestin recruitment to the 
chemokine receptor CCR5 (Hammad et al., 2010) while PSD95 blocks β-arrestin 
recruitment to 5-HT2AR (Schmid and Bohn, 2010). Therefore, it is possible that CAL 
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interferes with β-arrestin recruitment to the receptor and further studies are needed to 
investigate those mechanisms. 
In addition to its role in CRFR1 trafficking, we find that CAL overexpression affects 
CRFR1-dependent activation of the ERK1/2 signaling pathway. Specifically, CAL 
expression significantly attenuates CRFR1- mediated ERK1/2 phosphorylation in a 
manner that is dependent upon an intact CRFR1 PDZ-binding motif. Similar results have 
been observed for mGluR1a, where CAL overexpression reduces mGluR1a-stimulated 
ERK1/2 phosphorylation (Zhang et al., 2008). Thus, it will be important in the future to 
examine the role of CAL interactions with CRFR1 and other GPCRs that encode PDZ- 
binding motifs in the central nervous system. PCR analysis of mouse tissue revealed that 
CAL is ubiquitously distributed in many different regions of the brain (cerebellum, cortex, 
hippocampus and hypothalamus) as well as the heart, kidney, lungs, testis and spinal cord 
(Duvernay et al., 2005). CAL-deficient mice are infertile so it has been suggested that CAL 
is important in the early stages of development.  
We have reported previously that other PDZ proteins, SAP97 and PDZK1 are also 
important for the regulation of CRFR-mediated activation of the ERK1/2 signal 
transduction pathway. Unlike CAL, both SAP97 and PDZK1 facilitate CRFR1-mediated 
ERK1/2 phosphorylation and SAP97 contributes to GPCR-mediated ERK1/2 activation in 
the absence of PDZ binding motif interactions (Dunn et al., 2013; Dunn et al., 2014; 
Walther et al., 2015). Thus, CAL functions differently than both SAP97 and PDZK1 to 
antagonize CRFR1-mediated activation of ERK1/2 signaling and CAL siRNA increases 
CRFR1-stimulated ERK1/2 phosphorylation. Thus, it appears that, while a number of PDZ 
proteins contribute to the regulation of CRFR1 ERK1/2 signaling they have opposing 
effects and mediate their actions by distinct mechanisms. The precise mechanism by which 
CAL regulates the activation of the ERK1/2 pathway remains to be determined, but it does 
not appear to involve reduced cell surface expression of CRFR1, as cAMP formation is not 
altered following CAL overexpression. 
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2.5 Conclusion 
In conclusion, we find that CAL regulates N-glycosylation and cell surface 
expression of CRFR1 as well as negatively regulates CRFR1- mediated ERK1/2 
phosphorylation. This adds CRFR1 to a growing list of CAL-interacting GPCRs. The 
effects of CAL on CRFR1 glycosylation, cell surface expression and ERK1/2 signaling are 
all dependent upon an intact PDZ binding motif. Taken together, these observations and 
previous studies examining CAL function suggest that CAL represents another important 
PDZ domain containing protein that contributes to distinct aspects of GPCR trafficking 
and signaling.  
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Chapter 3  
3 Role of MAGI proteins in regulating CRFR1 activity 
A version of this chapter has been accepted for publication in the Journal of Molecular 
Signaling 
Hammad MM, Dunn HA, and Ferguson SS (2016) MAGI proteins regulate the trafficking 
and signaling of corticotropin-releasing factor receptor 1 via a compensatory mechanism 
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3.1 Introduction 
Membrane-associated guanylate kinase (MAGUK) family proteins are synaptic 
scaffolding proteins within a structured protein network responsible for the spatial 
organization of the presynaptic and postsynaptic compartments. They play a crucial role in 
the formation and function of synapses in the central nervous system (CNS) by regulating 
multiple aspects of synapse physiology such as synaptogenesis, receptor trafficking, 
synaptic function, and plasticity (Funke et al., 2005; Feng and Zhang, 2009; Yamagata and 
Sanes, 2010). MAGUKs are well-conserved throughout evolution and are widely-
expressed in the brain and periphery. They include multiple subfamilies including 
membrane palmitoylated proteins (MPPs), zona occludens (ZO), caspase recruitment 
domain-containing MAGUK protein (CARMA), discs large (DLGs) and MAGUK with 
inverted orientation PSD-95/Disc Large/Zona Occludens (PDZ) (MAGIs) proteins (Oliva 
et al., 2012). Generally, these proteins contain multiple domains that control their function 
and facilitate their interactions with their targets. The two common domains among all 
members are PDZ domains and the guanylate kinase (GK) domain. (Oliva et al., 2012). An 
important target for the MAGUKs scaffolding proteins is the G protein-coupled receptors 
(GPCRs) family (Dunn and Ferguson, 2015). Many GPCRs encode a short class I PDZ-
binding motif (S/T-x-ϕ, where ϕ is any aliphatic amino acid residue) at the end of their 
carboxyl-terminal tail that is recognized by the PDZ domain of the MAGUK proteins. This 
protein-protein interaction between the receptor and MAGUKs results in the regulation of 
GPCR function. MAGUK proteins play a key role in mediating the subcellular localization, 
trafficking, cell surface expression and signal transduction of multiple GPCRs and different 
proteins have both overlapping and distinct roles in the regulation of GPCR activity (Harris 
and Lim, 2001; Lee and Zheng, 2010; Romero et al., 2011; Magalhaes et al., 2012). One 
of the important subfamilies of MAGUKs is the membrane-associated guanylate kinase 
with inverted orientation (MAGI) protein subfamily (Dunn and Ferguson, 2015), which 
consists of three members; MAGI-1, MAGI-2 and MAGI-3. All three proteins share a 
similar structure containing one guanylate kinase-like (GK) domain, two tryptophan 
tryptophan (WW) domains and six PDZ domains. MAGI proteins, particularly MAGI-2 
and MAGI-3, have been shown to regulate the trafficking and signaling of multiple GPCRs. 
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MAGI-1, also known as BAP-1 (BAI-1-associated protein 1), has 7 isoforms that 
are widely expressed in different tissues. Isoform 1, isoform 2 and isoform 6 are highly 
expressed in colon, kidney, lung, liver, and pancreas. Isoform 5 is predominantly expressed 
in brain and heart. Isoform 3 and isoform 4 are highly expressed in pancreas and brain 
(Dobrosotskaya et al., 1997; Laura et al., 2002). MAGI-1 interacts with BAI-1 (brain-
specific angiogenesis inhibitor-1), a family B GPCR that functions as an adhesion 
molecule. Therefore, it is suggested that MAGI-1 might play an important role in the 
organization of membrane proteins and cytoskeleton by transmitting signals related to cell- 
cell or cell- matrix interactions through BAI-1 (Shiratsuchi et al., 1998; Stetak et al., 2009; 
Stephenson et al., 2014). MAGI-1 also regulates AMPA receptor activity and modulate 
behavioral plasticity (Emtage et al., 2009). 
MAGI-2, also known as S-SCAM (synaptic scaffolding molecule), is specifically 
expressed in the brain and has 2 isoforms (Wood et al., 1998). A previous study has 
illustrated an association between MAGI-2 and β1-AR that is enhanced upon agonist 
stimulation (Xu et al., 2001). The study also reports an increase in agonist-induced 
internalization of β1-AR when MAGI-2 is co-expressed, but no effect on cAMP generation 
induced by isoproterenol stimulation. In contrast, MAGI-2 has been shown to inhibit both 
vasoactive intestinal polypeptide type 1 (VPAC1) receptor-mediated cAMP production and 
internalization (Gee et al., 2009). 
MAGI-3 is also widely expressed in different tissues. It has been shown to interact 
with β2-AR and reduce signaling via the extracellular signal-regulated kinase 1 and 2 
(ERK1/2) pathway (Yang et al., 2010). MAGI-3 also associates with lysophosphatidic 
acid-activated receptor subtype-2 (LPA2R) and opposite to the effect that is observed for 
the β2-AR, knockdown of MAGI-3 results in a decrease in LPA2R-mediated ERK 1/2 
signaling (Zhang et al., 2007). The study also reports a significant reduction in Rho 
activation upon knockdown of MAGI-3. 
The corticotropin releasing factor receptor 1 (CRFR1) is activated by corticotropin-
releasing factor (CRF), a 41 amino acid neuropeptide secreted from the paraventricular 
nucleus of the hypothalamus in response to stress. Release of CRF can lead to the activation 
of the hypothalamic-pituitary-adrenal axis (HPA axis) (Vale et al., 1981; Arzt and 
Holsboer, 2006). CRF can also bind to and activate CRFR2, however the affinity of CRF 
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for CRFR1 is much higher than that for CRFR2. Both CRF receptors are widely expressed 
in the brain (neocortex and cerebellum) and pituitary (Chalmers et al., 1995; Palchaudhuri 
et al., 1998). A number of studies have elucidated a link between the pathophysiological 
changes in the CRF system and various neuropsychiatric disorders such as major 
depression, panic disorder, anorexia nervosa, and Alzheimer's disease (Behan et al., 1996; 
Lanfumey et al., 2008). CRFRs can primarily couple to Gαs for the activation of adenylyl 
cyclase leading to the formation of cyclic adenosine monophosphate (cAMP) (Chalmers et 
al., 1996) as well as the activation of the mitogen-activated protein kinase (MAPK) 
signaling pathway (Kageyama et al., 2007). CRFR1 encodes a PDZ-binding motif at the 
carboxyl-terminal tail presented by the last three amino acids, threonine - alanine - valine 
(TAV). Our laboratory has reports of the interaction between CRFR1 and multiple PDZ 
domain-containing proteins including SAP97, PSD-95, CAL and PDZK1. These studies 
showed that both SAP97 and CAL function to antagonize the internalization of CRFR1 
(Dunn et al., 2013; Hammad et al., 2015). Interestingly, the two proteins had opposite 
effects on CRF-stimulated ERK1/2 signaling where knockdown of SAP97 suppressed 
ERK activation while knockdown of CAL resulted in a significant enhancement of this 
activation. CAL, a Golgi PDZ protein, seems to regulate CRFR1 function via mediating 
the post-translational modifications since it prevents the glycosylation of the receptor in 
the Golgi. On the other hand, SAP97 regulation of ERK signaling is a general regulatory 
mechanism that is independent from the receptor-PDZ protein interaction. This only further 
confirms the distinct functions of PDZ proteins depending on the particular GPCR with 
which they are associated. PDZK1 had no significant effect on the endocytosis of CRFR1 
but enhanced ERK1/2 signaling (Walther et al., 2015). 
A PDZ overlay assay previously performed utilizing the carboxyl-terminal tail of 
the CRFR1 suggests an interaction between the first PDZ domain of all three MAGI 
proteins with the receptor (Dunn et al., 2013). Therefore, we have further investigated these 
interactions and examined the effects of the MAGI family members on CRFR1 signaling 
and trafficking. We find that all three MAGI proteins as MAGUK proteins can interact 
with CRFR1 via the class I PDZ-binding motif. We find that MAGI proteins can regulate 
the endocytosis of CRFR1 by mediating β-arrestin recruitment upon stimulation with CRF. 
We also demonstrate that siRNA knockdown of MAGI proteins can result in an 
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enhancement in ERK1/2 signaling. Furthermore, we show that knocking down one of the 
MAGI proteins results in the upregulation of the expression levels of the other members of 
the MAGI subfamily suggesting a compensatory mechanism for regulation. Taken 
together, our results indicate that MAGI proteins interactions with CRFR1 play an 
important role in regulating CRFR1 function. 
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3.2 Materials and Methods 
3.2.1 Materials 
Protein G beads were purchased from GE Healthcare (Oakville, ON, Canada). CRF was 
purchased from R&D Systems (Minneapolis, MN). HA peroxidase high affinity antibody 
was purchased from Roche (Mississauga, ON, Canada). Rabbit anti-GFP antibody was 
obtained from Invitrogen/Life Technologies (Burlington, ON, Canada). MAGI-1, MAGI-
2 and MAGI-3 antibodies were purchased from Thermo Fisher (Burlington, ON, Canada). 
ECL Western blotting detection reagents were purchased from Biorad (Mississauga, ON, 
Canada). Mouse anti-HA antibody and all other biochemical reagents were purchased from 
Sigma-Aldrich (Oakville, ON, Canada). 
3.2.2 Plasmids 
HA-CRFR1, CRFR1-YFP and HA-CRFR1-ΔTAV were described previously (Holmes et 
al., 2006; Magalhaes et al., 2010). His-MAGI-1, HA-MAGI-2 and His-MAGI-3 were 
kindly provided by Dr. Randy Hall (Emory University, School of Medicine). MAGI-1 
siRNA, MAGI-2 siRNA and MAGI-3 siRNA were purchased from Thermo Fisher 
(Burlington, ON, Canada). For the negative control, we used Silencer Negative Control #1 
AM4635 AGUACUGCUUACGAUACGGTT from Thermo Fisher (Burlington, ON, 
Canada). The exchange proteins directly activated by cAMP biosensor (EPAC) was a gift 
from Drs. Ali Salahpour (University of Toronto) and Marc Caron (Duke University) (Barak 
et al., 2008). 
3.2.3 Cell Culture and Transfection 
Human embryonic kidney (HEK 293) cells were cultured in Eagle’s minimal essential 
medium supplemented with 10% fetal bovine serum. Cells were plated on 10-cm dishes 
24h prior to transfection. All experiments were performed on 75-80% confluent plates. 
Transfections were performed using calcium phosphate protocol except for siRNA 
transfections which were performed using Lipofectamine 2000 following manufacturer’s 
instructions. Transfections were performed with 1 µg of each construct. Empty pcDNA3.1 
vector was used to equalize the total amount of plasmid cDNA used to transfect cells. 18h 
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post-transfection, cells were washed with phosphate-buffered saline (PBS) and 
resuspended with trypsin, 0.25% EDTA. Experiments were performed approximately 48h 
after transfection except for knockdown experiments which were performed 72h post 
transfection since this protocol resulted in the maximum knockdown of the different MAGI 
proteins. 
3.2.4 Co-immunoprecipitation 
24h after transfection, HEK 293 cells were seeded onto 10-cm dishes. Cells were starved 
with HBSS for 1h at 37°C then stimulated with 100 nM CRF agonist for 30 min. Cells 
were then lysed in 500 µL lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, and 0.1% 
Triton X-100) containing protease inhibitors (1 mM AEBSF, 10 µg/ml leupeptin, and 2.5 
µg/ml aprotinin) for 20 min on a rocking platform at 4°C. Samples were collected into 1.5 
ml Eppendorf tubes and centrifuged at 15,000 g for 15 min at 4°C to pellet insoluble 
material. A Bradford protein assay was performed and 300 µg of protein was incubated 
overnight at 4°C with protein G-Sepharose and mouse anti-HA antibody (1:50). Beads 
were washed three times with cold lysis buffer and incubated overnight at room 
temperature in 3xSDS loading buffer containing 2-mercaptoethanol. Samples were 
separated by SDS-PAGE, transferred to a nitrocellulose membrane, and western blots were 
then performed with the indicated antibodies (rabbit anti-GFP, 1:10000), (HA-POD, 
1:1000), (rabbit anti-MAGI-3, 1:1000), (rabbit anti-V5, 1:1000). 
3.2.5 Bioluminescent Resonance Energy Transfer-based biosensor 
cAMP Assay 
HEK 293 cells were co-transfected with 1 µg HA-CRFR1 (WT or ΔTAV) and either 1µg 
pcDNA3.1, MAGI-1, MAGI-2, MAGI-3, 80 pmoles scrambled (SCR) siRNA or siRNA 
against MAGI-1, MAGI-2 or MAGI-3 as well as 2 µg of an EPAC (exchange proteins 
directly activated by cAMP) construct in 10-cm dishes. 24h post-transfection, cells were 
reseeded into 96-well plate (~10,000 cells/well) and left for another 24h. On the following 
day, cells were serum-starved for 1h in induction buffer (200 μM isobutyl-1-
methylxanthine (IBMX) in HBSS). Coelenterazine was then added to the wells at a final 
concentration of 5 µM. Cells were then stimulated with increasing concentrations of CRF 
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peptide for 10 min. The plate was then read by a Victor Plate Reader (Perkin-Elmer) and 
the BRET signal was determined by calculating the ratio of the light emitted at 505 to 555 
nm to the light emitted at 465 to 505 nm. 
3.2.6 Receptor Endocytosis 
Following transfection, HEK 293 cells were re-seeded into 12-well plates. Cells were 
serum-starved in HBSS for 1h at 37°C then stimulated for 0 or 30 min with 500 nM CRF 
in HBSS at 37 °C. Cells were washed with cold HBSS and incubated with mouse anti-HA 
antibody (1:1000) for 1h on ice. Cells were washed with cold HBSS then labeled with 
Alexa Fluor 647 donkey anti-mouse IgG (1:1000) for 1h on ice in the dark. Cells were 
washed with cold HBSS and treated with 5mM EDTA in PBS for 5 min on ice. Cells were 
collected and transferred to flow cytometry tubes containing 4% formaldehyde in PBS. 
Samples were run on a FACS Calibur cytometer using BD Cell Quest Pro software (BD 
Biosciences, Mississauga, ON) until 10,000 cells were counted. The geometric mean of 
fluorescence was determined using Flow Jo analysis software and was representative of 
the expression levels of the receptor on the plasma membrane (BD Biosciences, 
Mississauga, ON). 
3.2.7 Western Blot Analysis 
75-90 μl of the samples from the different assays which is equivalent to about 50-70 μg of 
protein was diluted in β-mercaptoethanol-containing 3xSDS loading buffer and then 
applied to 10% SDS-PAGE (30% acrylamide mix, 1.5 M tris-HCl, 20% SDS, 10% 
ammonium persulfate and TEMED). Separated proteins were then transferred to 
nitrocellulose membranes and membranes were then blocked in 10% milk in TBS for 1h. 
Membranes were then blotted overnight by incubation with the appropriate antibody at 
4°C. 24h later, membranes were washed at least three times with 1X TBS with 0.05% 
Tween 20, and then incubated with a horseradish peroxidase-conjugated secondary 
antibody (1:10000) for 1h. Membranes were finally washed again with 1X TBS with 0.05% 
Tween 20 three times before being developed using a BioRad chemiluminescence system. 
91 
 
3.2.8 Bioluminescent Resonance Energy Transfer 
Cells were co-transfected with the indicated cDNA using Lipofictamine 2000. β-arrestin 
was tagged with Renilla luciferase (Rluc) and used as the energy donor while CRFR1 was 
tagged with YFP and used as the energy acceptor. 72h after transfection, cells were starved 
with HBSS for 1h at 37°C. The reaction was then started by the addition of Coelenterazine 
at a final concentration of 5 μM followed by increasing concentrations of CRF. Signal was 
collected on a Synergy Neo2 plate reader (Thermo Fisher) using 460/40-nm (luciferase) 
and 540/25-nm (YFP) band pass filters. Whether or not BRET occurred was determined 
by calculating the ratio of the light passed by the 540/25 filter to that passed by the 460/40 
filter. This ratio is referred to as the BRET ratio. 
3.2.9 Statistical Analysis 
All measurements are represented as mean ± SEM. Comparisons were performed using 
one way analysis of variance test (ANOVA) followed by Bonferroni’s or Dunn’s Multiple 
comparisons test to determine significance. * indicate P values less than 0.05 and is 
considered to be significant.  
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3.3 Results 
3.3.1 MAGI proteins interact with CRFR1 via the PDZ-binding motif 
independent of CRF activation 
The different members of the MAGI subfamily of proteins were previously shown to 
interact with different GPCRs. MAGI-2 was shown to interact with β1-AR, mGluR1a and 
VPAC1 while MAGI-3 was shown to interact with β1-AR, β2-AR, BAI-1 and LPA2R. We 
previously identified the first PDZ domains of MAGI-1, MAGI-2 and MAGI-3 as positive 
hits among several PDZ domains that interact with a GST fusion of the CRFR1 carboxyl-
terminal tail (Dunn et al., 2013). To further validate this interaction between MAGI 
proteins and CRFR1, we performed co-immunoprecipitation experiments with His-MAGI-
1 or His-MAGI-3 and either wild-type HA-tagged CRFR1 (HA-CRFR1) or HA-tagged 
CRFR1 mutant that lacked the PDZ-binding motif (HA-CRFR1-TAV) in transiently 
transfected HEK 293 cells. We found that His-MAGI-1 and His-MAGI-3 co-
immunoprecipitated with HA-CRFR1 but not CRFR1-TAV (Fig. 3.1A and 3.1C) and that 
the interaction with HA-CRFR1 was not altered following agonist treatment with 100 nM 
CRF for 30 min (Fig. 3.1B and 3.1D). Similarly, MAGI-2 was previously shown to interact 
with CRFR1 via the carboxyl terminal tail by another group (Bender et al., 2015). 
3.3.2 Effect of MAGI proteins expression on cAMP signaling 
PDZ domain-containing proteins were previously shown to have the potential to regulate 
cAMP signaling of some GPCRs (Magalhaes et al., 2012; Dunn and Ferguson, 2015) and 
MAGI-2 in particular was shown to reduce cAMP formation upon activation of VPAC1 
(Gee et al., 2009). Therefore, we tested whether MAGI proteins contributed to the 
regulation of CRFR1-mediated cAMP formation. In HEK 293 cells transfected with either 
HA-CRFR1 or HA-CRFR1-TAV, with or without MAGI-1, MAGI-2 or MAGI-3, there 
were no significant changes in the maximum efficacy for cAMP signaling in response to 
treatment with increasing concentrations of CRF for 10 min (Fig. 3.2A-C). In addition, we 
examined whether the attenuation of MAGI proteins expression could alter CRFR1-
mediated cAMP signaling. We found that transfection of HEK 293 cells with siRNA 
directed to knockdown MAGI-1, MAGI-2 or MAGI-3 had no effect on either HA-CRFR1- 
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Figure 3.1: MAGI proteins co-immunoprecipitate with HA-CRFR1 in a PDZ-binding 
motif-dependent manner: HEK 293 cells were co-transfected with HA-CRFR1 (WT or 
ΔTAV) and pcDNA or His-MAGI-1-V5. (A) Representative immunoblot of His-MAGI-1-V5 
co-immunoprecipitated (IP) with HA-CRFR1 but not HA-CRFR1-ΔTAV which lacks the 
PDZ-binding motif. SDS-PAGE was used to analyze samples and immunoblots were 
performed with rabbit anti-V5. (B) Effect of CRF treatment was quantified using densitometry 
and had no significant difference on the amount of MAGI-1 co-immunoprecipitated with HA-
CRFR1. HEK 293 cells were co-transfected with HA-CRFR1 (WT or ΔTAV) and pcDNA or 
His-MAGI-3. (C) Representative immunoblot of His-MAGI-3 co-immunoprecipitated (IP) 
with HA-CRFR1 but not HA-CRFR1-ΔTAV which lacks the PDZ-binding motif. SDS-PAGE 
was used to analyze samples and immunoblots were performed with rabbit anti-MAGI-3. (D) 
Effect of CRF treatment was quantified using densitometry and had no significant difference 
on the amount of His-MAGI-3 co-immunoprecipitated with HA-CRFR1. Data are 
representative of three independent experiments. 
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Figure 3.2: MAGI proteins do not regulate CRFR1-mediated cAMP formation: Dose 
response for CRF-stimulated cAMP formation assessed using a BRET-based cAMP biosensor 
assay. CRFR1- and CRFR1-ΔTAV- mediated cAMP formation in either plasmid vector or 
MAGI-1 (A), MAGI-2 (B) or MAGI-3 (C) transfected HEK 293 cells. CRFR1- and CRFR1- 
ΔTAV- mediated cAMP formation in either MAGI-1 siRNA (D), MAGI-2 siRNA (E) or 
MAGI-3 siRNA (F) transfected HEK 293 cells. Shown are representative immunoblots 
showing siRNA knockdown of (G) MAGI-1, (H) MAGI-2, and (I) MAGI-3 with 80 pmol 
siRNA for 72 hours. The data represent the mean ± SEM of at least three independent 
experiments.  
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or HA-CRFR1-TAV- stimulated cAMP signaling in response to treatment with 
increasing concentrations of CRF for 10 min (Fig. 3.2D-F). These results suggested that 
MAGI proteins did not contribute to the regulation of CRFR1 activation of the cAMP 
pathway. We validated the knockdown of MAGI proteins by co-transfecting HEK 293 cells 
with MAGI proteins cDNA (MAGI-1, MAGI-2 or MAGI-3) and 80 pmoles of either SCR 
siRNA or MAGI-siRNA. We observed 90% knockdown with MAGI-1 siRNA (Fig. 3.2G), 
50% knockdown with MAGI-2 siRNA (Fig. 3.2H) and 65% knockdown with MAGI-3 
siRNA (Fig. 3.2I). 
3.3.3 Effect of MAGI proteins on cell surface expression 
A previous study from our laboratory illustrated an effect of CAL, a Golgi PDZ protein, 
on cell surface expression of CRFR1 (Hammad et al., 2015). Therefore, we used flow 
cytometry to measure the plasma membrane expression of CRFR1 upon overexpression as 
well as knockdown of MAGI proteins. While overexpression of MAGI proteins had no 
effect on receptor expression levels (Fig. 3.3A-C), knockdown of certain MAGI proteins 
altered CRFR1 membrane expression. Our data show that knockdown of MAGI-1 resulted 
in an enhancement in CRFR1 expression at the plasma membrane (Fig. 3.3D). Knockdown 
of MAGI-2 and MAGI-3 on the hand had no effect on CRFR1 expression levels (Fig. 3.3E-
F). This illustrated the importance of MAGI proteins in regulating receptor expression and 
reflects distinguished effects among the members of the subfamily. 
3.3.4 Effect of MAGI proteins on CRF-mediated ERK1/2 signaling 
MAGI-3 was previously shown to regulate ERK1/2 signaling of other GPCRs in a 
distinctive manner as it was shown to enhance ERK1/2 activation in the case of LPA2R 
and BAI-1 and inhibit β-AR-stimulated ERK1/2 phosphorylation (He et al., 2006; Zhang 
et al., 2007). Since CRFR1 was shown to have the ability to activate the MAPK cascade, 
we assessed the effects of MAGI proteins overexpression on CRFR1-mediated ERK1/2 
phosphorylation. We found that the overexpression of MAGI-1, MAGI-2 and MAGI-3 did 
not have an effect on ERK1/2 phosphorylation (Fig. 3.4). Interestingly, when we 
knockdown endogenous expression of MAGI-1, MAGI-2 or MAGI-3, we observed a 
significant increase in ERK1/2 phosphorylation in response to stimulation of CRFR1  
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Figure 3.3: Effect of MAGI proteins on cell surface expression: Cell surface expression 
in HEK 293 cells expressing either HA-CRFR1 or HA-CRFR1-ΔTAV along with MAGI-1 
(A), MAGI-2 (B), MAGI-3 (C), MAGI-1 siRNA (D), MAGI-2 siRNA (E) or MAGI-3 siRNA 
(F) expressed as measured by flow cytometry. Data is normalized to HA-CRFR1 expression 
in the control pcDNA or SCR siRNA. The data represent the mean ± SEM of four independent 
experiments. * P < 0.05 versus HA-CRFR1 cell surface expression. 
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Figure 3.4: Effect of MAGI proteins overexpression on CRFR1-mediated ERK1/2 
signaling: (A) Representative immunoblot showing ERK1/2 phosphorylation in response to 
500 nM CRF treatment for 0, 2, 5, and 15 min in non-transfected (NT) HEK 293 cells, and 
HEK 293 cells transfected with HA-CRFR1 along with either pcDNA or His-MAGI-1. Also 
shown are corresponding immunoblots for total ERK1/2, MAGI-1 and HA-CRFR1 protein 
expression. (B) Densitometric analysis of ERK1/2 phosphorylation in response to 500 nM CRF 
treatment for 0, 2, 5, and 15 min. The data represent the mean ± SEM of four independent 
experiments. (C) Representative immunoblot showing ERK1/2 phosphorylation in response to 
500 nM CRF treatment for 0, 2, 5, and 15 min in non-transfected (NT) HEK 293 cells, and 
HEK 293 cells transfected with HA-CRFR1 along with either pcDNA or MAGI-2. Also shown 
are corresponding immunoblots for total ERK1/2, MAGI-2 and HA-CRFR1 protein 
expression. (D) Densitometric analysis of ERK1/2 phosphorylation in response to 500 nM CRF 
treatment for 0, 2, 5, and 15 min. The data represent the mean ± SEM of six independent 
experiments. (E) Representative immunoblot showing ERK1/2 phosphorylation in response to 
500 nM CRF treatment for 0, 2, 5, and 15 min in non-transfected (NT) HEK 293 cells, and 
HEK 293 cells transfected with HA-CRFR1 along with either pcDNA or MAGI-3. Also shown 
are corresponding immunoblots for total ERK1/2, MAGI-3 and HA-CRFR1 protein 
expression. (F) Densitometric analysis of ERK1/2 phosphorylation in response to 500 nM CRF 
treatment for 0, 2, 5, and 15 min. The data represent the mean ± SEM of six independent 
experiments.  
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Figure 3.5: Effect of MAGI proteins knockdown on CRF-mediated ERK1/2 signaling: 
(A) Representative immunoblot showing ERK1/2 phosphorylation in response to 500 nM CRF 
treatment for 0, 5, and 15 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells 
transfected with HA-CRFR1 along with either SCR siRNA or MAGI-1 siRNA. Also shown 
are corresponding immunoblots for total ERK1/2, MAGI-1 and HA-CRFR1 protein 
expression. (B) Densitometric analysis of ERK1/2 phosphorylation in response to 500 nM CRF 
treatment for 0, 5, and 15 min. The data represent the mean ± SEM of four independent 
experiments. (C) Representative immunoblot showing ERK1/2 phosphorylation in response to 
500 nM CRF treatment for 0, 5, and 15 min in non-transfected (NT) HEK 293 cells, and HEK 
293 cells transfected with HA-CRFR1 along with either SCR siRNA or MAGI-2 siRNA. Also 
shown are corresponding immunoblots for total ERK1/2 and HA-CRFR1 protein expression. 
The antibody was not sensitive enough to blot for endogenous MAGI-2. (D) Densitometric 
analysis of ERK1/2 phosphorylation in response to 500 nM CRF treatment for 0, 5, and 15 
min. (E) Representative immunoblot showing ERK1/2 phosphorylation in response to 500 nM 
CRF treatment for 0, 5, and 15 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells 
transfected with HA-CRFR1 along with either SCR siRNA or MAGI-3 siRNA. Also shown 
are corresponding immunoblots for total ERK1/2, MAGI-3 and HA-CRFR1 protein 
expression. (F) Densitometric analysis of ERK1/2 phosphorylation in response to 500 nM CRF 
treatment for 0, 5, and 15 min. The data represent the mean ± SEM of four independent 
experiments. * P < 0.05 versus SCR siRNA control.  
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with 500 nM CRF for 5 or 15 minutes (Fig. 3.5). 
3.3.5 Effect of MAGI proteins expression on agonist-stimulated 
CRFR1 endocytosis 
Our laboratory previously reported that other members of the MAGUK family such as 
SAP97 and PSD-95, as well as the Golgi PDZ protein CAL could regulate CRF-induced 
CRFR1 internalization (Dunn et al., 2013; Hammad et al., 2015; Dunn et al., 2016). To 
determine whether MAGI proteins also contributed to the regulation of CRFR1 
endocytosis, we utilized flow cytometry to assess the loss of cell surface HA-CRFR1 by 
immunofluorescence. We found that the overexpression of MAGI-1, MAGI-2 and MAGI-
3 each attenuated agonist-stimulated HA-CRFR1 internalization following treatment with 
500 nM CRF for 30 min (Fig. 3.6A-C). However, although the internalization of the mutant 
HA-CRFR1-TAV was not altered by either MAGI-2 or MAGI-3, the overexpression of 
MAGI-1 significantly reduced HA-CRFR1-TAV (Fig. 3.6A-C). In addition, we assessed 
the effect of knockdown of endogenous MAGI proteins on agonist-stimulated CRFR1 
internalization. We observe that all MAGI siRNAs attenuated the internalization of CRFR1 
(Fig. 3.6D-F) and that MAGI-1 siRNA had the same effect on CRFR1-TAV 
internalization (Fig. 3.6D). Thus, MAGI proteins could regulate CRFR1 endocytosis. 
3.3.6 MAGI proteins can regulate CRFR1 endocytosis by mediating 
β-arrestin recruitment to the receptor 
The primary pathway contributing to CRFR1 internalization was previously shown to be 
β-arrestin-dependent (Holmes et al., 2006). Because of the effect of MAGI proteins on the 
regulation of CRFR1 endocytosis observed in Fig. 3.6, we decided to study the effect of 
MAGI proteins on β-arrestin recruitment to CRFR1. To do this, we employed a BRET 
assay to investigate this interaction between rLuc-tagged β-arrestin2 and YFP-tagged 
CRFR1. The overexpression of all MAGI proteins resulted in a right-ward shift in the CRF 
dose response curve for -arrestin2 recruitment (Fig. 3.7A). There was also a significant 
reduction in the maximal response for β-arrestin recruitment at 500 nM CRF with time 
(Fig. 3.7B). We also examined the effect of knockdown of MAGI proteins on β-arrestin2 
recruitment and similar results were observed, with a right-ward shift in the does response 
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Figure 3.6: Effect of MAGI proteins expression on agonist-stimulated CRFR1 
endocytosis: Agonist-stimulated internalization of either HA-CRFR1 or HA-CRFR1-
ΔTAV following 500 nM CRF treatment for 30 min in the presence of either MAGI-1 (A), 
MAGI-2 (B), MAGI-3 (C), MAGI-1 siRNA (D), MAGI-2 siRNA (E), or MAGI-3 siRNA 
(F). The data represent the mean ± SEM of at least three independent experiments. * P < 
0.05 versus empty vector or SCR siRNA control. 
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Figure 3.7: Effect of MAGI proteins expression on β-arrestin recruitment to CRFR1: 
BRET assays measured between β-arrestin-rLuc and CRFR1-YFP in the presence of 
MAGI-1, MAGI-2 or MAGI-3 (A, B) or MAGI-1 siRNA, MAGI-2 siRNA or MAGI-3 
siRNA (C, D). A and C show dose responses of the interaction while B and D show the 
interaction as a function of time upon stimulation with 500 nM CRF.   
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curve and significant reduction in the maximal response, with MAGI-3 exhibiting the most 
prominent effect (Fig. 3.7C and 3.7D). Taken together, these data suggested that MAGI 
proteins are regulating CRFR1 endocytosis by mediating β-arrestin recruitment to CRFR1. 
3.3.7 Knockdown of one MAGI proteins can lead to the upregulation 
in the expression level of the others 
The results we obtained from our internalization assays and β-arrestin recruitment assays 
were surprising in terms of having similar effects upon overexpression and knockdown of 
MAGI proteins. Therefore, we hypothesized that the expression levels of different 
members of the MAGI subfamily of proteins might be changing to compensate for the loss 
of another family member. In order to test this, we assessed the expression levels of each 
MAGI protein upon knockdown of the other MAGI proteins. We observed a significant 
up-regulation of MAGI-1 expression levels upon knockdown of MAGI-3 (Fig. 3.8A). 
Similarly, there was a significant up-regulation of MAGI-3 expression levels when MAGI-
1 is knocked down (Fig. 3.8B). This suggested a compensatory effect between MAGI-1 
and MAGI-3 that could explain the similar results observed for CRFR1 internalization and 
-arrestin2 recruitment following either MAGI protein overexpression or knockdown. 
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Figure 3.8: Knockdown of one MAGI protein results in an increase of expression of 
the other MAGI proteins: (A) Representative immunoblot showing the levels of MAGI-
1 in HEK 293 cells transfected with siRNA combinations as labeled. Densitometric 
analysis shows MAGI-1 levels after normalization to actin as a loading control. (B) 
Representative immunoblot showing the levels of MAGI-3 in HEK 293 cells transfected 
with siRNA combinations as labeled. Densitometric analysis shows MAGI-3 levels after 
normalization to actin as a loading control. The data represent the mean ± SEM of at least 
eight independent experiments. * P < 0.05 versus SCR siRNA control.  
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3.4 Discussion 
We have previously identified all three members of the MAGI subfamily as 
CRFR1-interacting PDZ proteins in the PDZ overlay assay (Dunn et al., 2013). Despite 
similarities in their molecular topology, the members of the MAGI subfamily, specifically 
MAGI-2 and MAGI-3, are known to have distinct function with respect to their functional 
regulation of different GPCRs, but their role in regulating CRFR1 activity has not been 
investigated (Xu et al., 2001; Sugi et al., 2007; Zhang et al., 2007; Gee et al., 2009; Yang 
et al., 2010). We find that all three MAGI proteins are co-immunoprecipitated with CRFR1 
in a PDZ motif dependent manner and that either overexpression or knockdown of each of 
the MAGI proteins is able to negatively regulate CRFR1 endocytosis with MAGI-1 
overexpression or knockdown negatively regulating CRFR1 endocytosis in a PDZ motif-
independent manner. This antagonism of CRFR1 endocytosis that is mediated by either 
MAGI protein overexpression or knockdown appears to involve the antagonism of -
arrestin recruitment to the receptor. In the case of siRNA-mediated knockdown of 
individual MAGI proteins there appears to be a compensatory up-regulation of the 
expression of other MAGI protein subtypes. In addition we find that while the 
overexpression of each of the MAGI proteins does not influence CRFR1-stimulated 
ERK1/2 phosphorylation, siRNA knockdown of each of the MAGIs results in a significant 
increase in CRFR1-mediated ERK1/2 phosphorylation. Taken together, our results indicate 
that MAGI protein interactions with CRFR1 play an important role in regulating CRFR1 
function. 
MAGUK proteins comprise a subfamily of scaffolding proteins that are defined by 
having PDZ, SH3 and GK domains with an emerging role in synapse formation and 
function. DLG (discs large) subfamily (mainly SAP97 and PSD-95) have been the focus 
of many studies and are shown to play key roles in synaptogensis, the creation of neural 
circuits, synaptic transmission, memory and learning, as well as glutamate receptor 
clustering and trafficking (Stetak et al., 2009). On the other hand, few studies have looked 
at the MAGI subfamily of MAGUK proteins, although they are abundantly expressed in 
the brain. Current understanding of MAGI protein function in the brain suggests a role on 
memory and learning, but the mechanism is still unknown (Funke et al., 2005; Stetak et al., 
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2009; Oliva et al., 2012). In terms of the MAGUKs role in regulating GPCRs function, 
studies from our laboratory illustrate distinct roles for SAP97 and PSD-95 in regulating 
CRFR1 trafficking and signaling (Dunn et al., 2013; Dunn et al., 2016). This is an 
intriguing observation because of the overlapping sequence and structural similarities of 
SAP97 and PSD-95. This lead to the hypothesis that MAGI proteins would also elicit 
diverse effects on receptor physiology. Although previous studies have looked at the effects 
of MAGI proteins on regulating GPCRs function, none of these previous reports have 
compared the relative function of all three MAGI proteins in regulating the activity of an 
individual GPCR, despite evidence that many GPCRs interact with all three MAGIs (Xu 
et al., 2001; He et al., 2006; Sugi et al., 2007; Zhang et al., 2007; Gee et al., 2009; Yang et 
al., 2010; Dunn and Ferguson, 2015). For example, MAGI-2 interacts with the β1-AR and 
enhances its internalization, whereas it also interacts with VPAC1 to regulate its 
intracellular localization in epithelial cells and inhibit agonist-induced internalization (Xu 
et al., 2001; He et al., 2006; Gee et al., 2009). MAGI-3 on the other hand is found to 
antagonize ERK1/2 activation by both the β1-AR and the β2-AR (Zhang et al., 2007; Yang 
et al., 2010; He et al., 2006). We find here that the overexpression of any of the MAGI 
proteins reduces CRF-stimulated CRFR1 internalization, which is similar to what is 
observed for VPAC1, but opposite to what is observed for the β1-AR. Interestingly, this 
effect is dependent on an intact CRFR1 PDZ-binding motif for MAGI-2 and MAGI-3, but 
not MAGI-1. This suggests that MAGI-1 may associate with CRFR1 via other interactions 
than those mediated by the PDZ domain. An alternative possibility would be that MAGI-1 
is antagonizing the formation of protein complexes required for GPCR endocytosis. 
Further studies on receptors that do not harbor a PDZ-binding motif such as CRFR2 would 
be required to further investigate this role of MAGI-1. It will also be important to study the 
effect of MAGI-1 on the ESCRT complex and its components. 
As is the case for many GPCRs, the primary internalization pathway utilized by the 
CRFR1 involves β-arrestin-dependent endocytosis via clathrin-coated pits (Ferguson et al., 
1998; Ferguson, 2001; Holmes et al., 2006; von Zastrow and Williams, 2012). The 
observation that each of the MAGI proteins antagonize CRFR1 endocytosis suggested the 
possibility that MAGI proteins may play a role in regulating β-arrestin recruitment to the 
receptor. Consistent with this hypothesis, the overexpression of all of the MAGIs resulted 
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in the antagonism of -arrestin2 recruitment to the receptor as measured by BRET assay 
as assessed by a right-ward shift in the CRF dose response curve and a blunting of the 
maximal translocation response. Surprisingly, when the same assay is repeated with siRNA 
against MAGI-1, MAGI-2 or MAGI-3 to knockdown the endogenous proteins, we still 
observe a right-ward shift in the dose response curve and an even more prominent reduction 
in the maximal response. This result is opposite to what we had anticipated. Therefore, we 
investigated whether changes in the expression levels of other MAGI protein subtypes is 
compensating for the loss of expression of the MAGI protein knocked down by siRNA. 
This concept of compensation is not entirely novel to the field of PDZ domain- containing 
proteins, as it is suggested that PSD-95 and PSD-93 can replace one another to regulate 
GPCR function in a similar manner (Sun and Turrigiano, 2011). Interestingly, we observe 
a compensatory up-regulation of MAGI-1 expression upon MAGI-3 knockdown and an 
up-regulation of MAGI-3 expression following MAGI-1 protein knockdown. Thus, 
compensatory MAGI protein expression provides a plausible mechanism by which 
knocking down individual MAGI proteins attenuates CRFR1 endocytosis and impairs -
arrestin2 recruitment. However, this mechanism may not be entirely sufficient to explain 
our results, as although MAGI-2 knockdown resulted in increased MAGI-1 and MAGI-3 
protein expression in the representative blots shown in Fig. 3.8, this result is not reliably 
reproduced when compared to MAGI-1 and MAGI-3 knockdown. Additional work would 
be necessary to further assess this interplay between the MAGI subfamily members. 
We have previously reported the interaction of other PDZ domain- containing 
proteins with CRFR1 and the consequences of that on receptor endocytosis. We have 
shown that the overexpression of SAP97 antagonizes agonist-stimulated CRFR1 
internalization, whereas single hairpin (shRNA) knockdown of endogenous SAP97 in 
HEK 293 cells results in increased agonist-stimulated CRFR1 endocytosis and that PSD-
95 elicits the same effects on CRFR1 endocytosis (Dunn et al., 2015; Dunn et al., 2016). 
Similarly, we also find that CAL negatively regulates CRFR1 endocytosis when 
overexpressed (Hammad et al., 2015). Despite seemingly having similar effects, the 
mechanism of GPCR regulation by these PDZ proteins is vastly different. SAP97 and PSD-
95 are suggested to regulate the internalization by affecting β-arrestin recruitment to 
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CRFR1, while CAL acts as a major sorting protein at different subcellular levels and by 
modifying the post-translational modifications that the receptor undergoes at the Golgi. 
Thus, the MAGI proteins employ a similar “MAGUK-like” mechanism to regulate CRFR1 
endocytosis via the attenuation of β-arrestin recruitment. However, their collective function 
is further complicated by a compensatory mechanism involving changes in protein 
expression of other subtypes. Future studies will examine this potential phenomenon and 
how it may affect other GPCRs function.
In addition to the role that MAGI proteins play in regulating the trafficking of 
CRFR1, we find that they have an important effect on the regulation of CRFR1 signaling, 
specifically via the MAPK pathway, but not G protein-mediated cAMP formation. While 
the overexpression of each of the MAGI proteins has no effect on CRFR1-mediated 
ERK1/2 phosphorylation, siRNA knockdown of all of the MAGIs results in a significant 
increase in the extent of ERK1/2 phosphorylation induced by CRFR1 activation. 
Interestingly, a study on LPA2R showed opposite effects on ERK1/2 activation where 
MAGI-3 knockdown reduced the signal. However, similar to our study, the LPA2R study 
which was performed on SW480 cells reported no difference in ERK activity upon 
overexpression of MAGI-3 suggesting that different tissues and cell lines express 
endogenous MAGI proteins in high levels. Previous experiments examining the regulation 
of CRFR1-mediated ERK1/2 activation by two other MAGUK family members, SAP97 
and PSD-95 yielded different results (Dunn et al., 2013; Dunn et al., 2016). Whereas, 
SAP97 expression significantly enhanced CRFR1-stimulated ERK1/2 phosphorylation, 
PSD-95 overexpression had no effect on ERK1/2 phosphorylation induced by CRFR1 
activation. In contrast, the observed increase in CRFR1-mediated ERK1/2 phosphorylation 
following siRNA knockdown of each of the MAGI proteins is similar to what we have 
previously observed following siRNA knockdown of PDZK1 (Walther et al., 2015). The 
mechanism by which siRNA knockdown of an individual MAGI protein results in 
compensatory changes in the expression levels of other MAGI proteins to attenuate CRFR1 
endocytosis without compensating for CRFR1-mediated ERK1/2 activation is unclear. 
However, these results might suggest that the observed increase in ERK1/2 
phosphorylation is mediated by a -arrestin-independent pathway as CRFR1/-arrestin 
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interactions are predominantly regulated by GRK5 phosphorylation, which is thought to 
preferentially allow activation of ERK1/2 via the -arrestin-mediated pathway (Holmes et 
al., 2006; Zidar et al., 2009). 
Now that we have a better understanding for the role of MAGI proteins in 
regulating CRFR1 function in HEK293 cells, the next step would be to asses these 
interactions in vivo. RT-PCR in mouse tissue showed that the MAGI proteins are expressed 
in different regions of the brain including the cortex, thalamus and cerebellum (Sugnet et 
al., 2006). We would predict that MAGI proteins are expressed in CRF-containing neurons 
and would regulate CRFR1 physiology. Some knockout mouse models of MAGI proteins 
are available (MAGI-1 and MAGI-2) and have exhibited some renal deficits (Ihara et al., 
2014). This reflects the importance of MAGI proteins in periphery. In addition, MAGI-2 
knockout mice show abnormal elongation of dendritic spines indicating a possible role for 
MAGI-2 during morphogenesis of neurons. (Iida et al., 2007). Furthermore, studies on C. 
elegans demonstrate a role for MAGI-1 in regulating the clustering of ionotropic glutamate 
receptors in certain neurons that are associated with learning and memory (Stetak et al., 
2009). Therefore, further characterization of MAGI proteins knockout models is required 
to determine the role of this subfamily in the CNS.
In summary, the current study completes a series of investigations examining the 
role of PDZ proteins in regulating the expression, trafficking and signaling of CRFR1. We 
find that PDZ proteins play an overlapping but distinguishable role in regulating the post-
translation modification, ER-Golgi trafficking, endocytosis and signaling of CRFR1 (Dunn 
et al., 2013; Hammad et al., 2015; Walther et al., 2015; Dunn et al., 2016). Although each 
of these proteins had a similar effect on CRFR1 endocytosis, as they each, with the 
exception of PDZK1, function to antagonize CRFR1 internalization, they exhibit 
pleiotropic effects on the regulation of CRFR1-mediated ERK1/2 activity. These 
observations indicate that there is likely no redundancy of function for PDZ proteins in the 
regulation of GPCR activity in vivo, and suggest that in a cellular context these proteins 
may interchangeably interact with GPCRs to differentially regulate the recruitment of 
signaling complexes required for their activation of mitogenic signaling pathways. 
109 
 
3.5 Conclusion 
In conclusion, our data demonstrate an interaction between all three MAGI 
proteins, MAGI-1, MAGI-2 and MAGI-3 with CRFR1 that leads to the regulation of 
receptor activity. We illustrate that all MAGI proteins can regulate the internalization of 
the receptor by mediating β-arrestin recruitment. We also provide evidence that MAGI 
proteins can regulate CRFR1 signaling via the MAPK pathway but not the G protein-
dependent pathways presented by cAMP formation. We also suggest a compensatory effect 
of regulation among the members of the MAGI subfamily. Taken together, these 
observations along with our previous studies on CRFR1 confirm the distinctive functions 
of PDZ domain-containing proteins in regulating GPCRs function. 
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4.1 Introduction 
The family of serotonin receptors (5-HTRs) consists of 7 receptor types and 15 
subtypes that belong to Class A G protein-coupled receptors (GPCRs), except for 5-HT3Rs 
which are ligand-gated ion channels (Gray and Roth, 2001; Lanfumey et al., 2008). 5-HTRs 
contribute to the modulation of various biological processes including sleep-wake cycles, 
appetite, mood, memory, breathing, cognition and sexual behavior (McCorvy and Roth, 
2015). Serotonin has been the focus of many pharmacological studies for the treatment of 
neuropsychiatric disorders with drugs that target either the serotonin receptors or serotonin 
uptake (Kroeze and Roth, 1998; Roth et al., 2004). Examples include SSRIs (serotonin-
selective reuptake inhibitors), SNRIs (dual serotonin-norepinephrine reuptake inhibitors) 
and partial agonists or antagonists for the 5-HTRs. Among the different serotonin receptor 
subtypes, the most ubiquitous and extensively studied 5-HTRs in the human brain are the 
5-HT1AR and 5-HT2AR. These receptors have been shown to have potential roles in 
different neuropsychiatric diseases such as Alzheimer’s disease, schizophrenia, depression 
and suicide (Burnet et al., 1995; Roth et al., 2004). 
The 5-HT2R subfamily consists of three subtypes: 5-HT2A, 5-HT2B and 5-HT2C. The 
family is primarily coupled to Gq leading to the activation of phospholipase Cβ (PLCβ) 
which hydrolyzes the phosphatidylinositol diphosphate (PIP2) to release diacylglycerol 
(DAG) and inositol triphosphate (IP3) (Gray and Roth, 2001; Roth et al., 2004). 5-HT2R 
coupling to Gq ultimately culminates in the release of Ca2+ from intracellular stores and 
the subsequent activation of protein kinase C. In addition to activating Gq-dependent cell 
signaling, 5-HTRs can activate the MAPK pathway resulting in the extracellular signal-
regulated kinase 1 and 2 (ERK1/2) phosphorylation. 5-HT2AR also encodes a class I PDZ-
binding motif at the distal end of its carboxyl-terminal tail that consists of three amino 
acids; serine, cysteine and valine (SCV). It was shown to be regulated by multiple PSD-
95/Disc Large/Zona Occludens (PDZ) domain-containing proteins such as SAP97, PSD-
95, PDZK1 and MUPP1 (Xia et al., 2003; Jones et al., 2009; Jones et al., 2009; Dunn et 
al., 2014; Walther et al., 2015). SAP97 and PSD-95 belong to the membrane associated 
guanylate kinase (MAGUK) subfamily of PDZ proteins (Funke et al., 2005; te Velthuis et 
al., 2007; Oliva et al., 2012). 
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The MAGUK family of proteins are synaptic scaffolding proteins that belong to a 
protein network responsible for the spatial organization of the presynaptic and postsynaptic 
compartments. One of their primary functions is to regulate the formation of synapses in 
the central nervous system (Funke et al., 2005; Zhang et al., 2009; Yamagata and Sanes, 
2010). MAGUKs are widely-expressed in the brain and periphery and they consist of 
multiple subfamilies including membrane palmitoylated proteins (MPPs), zona occludens 
(ZO), caspase recruitment domain containing MAGUK protein (CARMA), discs larges 
(DLGs) and MAGUK with inverted orientation PDZ proteins (MAGIs) (Oliva et al., 2012). 
As scaffolding proteins, they contain multiple domains to control their function and 
facilitate their interactions with their targets. The two common domains among all 
members are PDZ domains and guanylate kinase (GK) domains (Oliva et al., 2012). One 
of the important targets for MAGUKs are GPCRs (Dunn and Ferguson, 2015). The protein-
protein interaction between GPCRs and MAGUKs have crucial effects on the regulation 
of GPCR activity (reviewed by Dunn and Ferguson, 2015). MAGUK proteins play a central 
role in mediating the subcellular localization, trafficking, cell surface expression and signal 
transduction of multiple GPCRs and different proteins have both overlapping and distinct 
roles in the regulation of GPCR activity (Harris and Lim, 2001; Lee and Zheng, 2010; 
Romero et al., 2011; Magalhaes et al., 2012). MAGI protein represent an important 
subfamily of MAGUK proteins and is comprised of three members: MAGI-1, MAGI-2 and 
MAGI-3. All three proteins share a similar structure containing one guanylate kinase-like 
(GK) domain, two tryptophan tryptophan (WW) domains and six PDZ domains (te 
Velthuis et al., 2007; Oliva et al., 2012; Dunn and Ferguson, 2015). 
MAGI-1 is also called BAP-1 (BAI-1-associated protein 1) and has 7 different 
splice variants that exhibit distinct but overlapping tissue distributions (Dobrosotskaya et 
al., 1997; Laura et al., 2002). MAGI-2 or S-SCAM (synaptic scaffolding molecule) has 
two alternative splice variants and is brain-specific, whereas MAGI-3 exhibits a 
widespread expression pattern. MAGI-1 through its interaction with the brain-specific 
angiogenesis inhibitor-1 (BAI-1) is proposed to contribute to regulating the cytoskeletal 
organization and membrane protein distribution, likely by relaying signals via BAI-1 that 
control both cell- cell and cell- matrix interactions (Shiratsuchi et al., 1998; Stetak et al., 
2009; Stephenson et al., 2013). MAGI-2 interacts with β1-AR in an agonist-dependent 
117 
 
manner to facilitate β1-AR endocytosis without altering cAMP responses (Xu et al., 2001) 
In contrast, MAGI-2 negatively regulates the internalization and Gs-coupling of the 
vasoactive intestinal polypeptide type 1 receptor (VPAC1R) (Gee et al., 2009). MAGI-3 
overexpression inhibits β2-AR-mediated signaling via the extracellular signal-regulated 
kinase 1 and 2 (ERK1/2) pathway, whereas a loss of MAGI-3 expression antagonizes 
lysophosphatidic acid-activated receptor subtype-2 (LPA2R)-stimulated ERK1/2 
phosphorylation (Yang et al., 2010). We previously identified all three MAGI protein 
subtypes as 5-HT2AR-interacting proteins using a 96 well PDZ protein array. In the present 
study we confirm the interaction of each of the MAGI proteins with 5-HT2AR and 
investigate their role in regulating 5-HT2AR cell surface expression, trafficking and 
signaling. 
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4.2 Materials and Methods 
4.2.1 Materials 
MAGI-1, MAGI-2 and MAGI-3 antibodies were purchased from Thermo Fisher 
(Burlington, ON, Canada). Rabbit anti-phospho-p44/42 MAPK (Thr-202/Tyr-402) and 
rabbit anti-p44/42 MAPK antibodies were obtained from Cell Signaling Technology 
(Pickering, ON, Canada). Rabbit anti-PLCβ3 was purchased from abcam (Toronto, ON, 
Canada). ECL Western blotting detection reagents were purchased from Biorad 
(Mississauga, ON, Canada). Rabbit anti-Flag antibody and all other biochemical reagents 
were purchased from Sigma-Aldrich (Oakville, ON, Canada). 
4.2.2 Plasmids 
FLAG-tagged 5-HT2AR and 5-HT2AR-ΔSCV constructs were described previously 
(Magalhaes et al., 2010). His-MAGI-1, HA-MAGI-2 and His-MAGI-3 were kindly 
provided by Dr. Randy Hall (Emory University, School of Medicine). PLCβ3 was kindly 
provided by Dr. Alan Smrcka (University of Rochester Medical Center). MAGI-1 siRNA, 
MAGI-2 siRNA and MAGI-3 siRNA were purchased from Thermo Fisher (Burlington, 
ON, Canada). For the negative controls, we used Silencer Negative Control #1 AM4635 
AGUACUGCUUACGAUACGGTT from Invitrogen (Burlington, ON, Canada). 
4.2.3 Cell Culture and Transfection 
Human embryonic kidney (HEK 293) cells were grown in Eagle’s minimal essential 
medium supplemented with 10% fetal bovine serum.  Cells were plated on 10-cm dishes 
24h prior to transfection. All experiments were performed on 75-80% confluent plates. 
Transfections were performed using calcium phosphate protocol except for siRNA 
transfections which were performed using Lipofictamine 2000 following manufacturer’s 
instructions. Transfections were performed with 2 g of each construct. Empty pcDNA3.1 
vector was used to equalize the total amount of plasmid cDNA used to transfect cells. 18h 
post-transfection, cells were washed with phosphate-buffered saline (PBS) and 
resuspended with trypsin, 0.25% EDTA. Experiments were performed approximately 48h 
after transfection except for knockdown experiments which were performed 72h post 
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transfection since this protocol resulted in the maximum knockdown of the different MAGI 
proteins. 
4.2.4 Co-immunoprecipitation 
24h after transfection, HEK 293 cells were seeded onto 10-cm dishes. Cells were starved 
in HBSS lacking serum for 1h at 37°C then stimulated with 10 µM 5-HT for 30 mins. Cells 
were then lysed in 500 L lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, and 0.1% 
Triton X-100) containing protease inhibitors (1 mM AEBSF, 10 g/ml leupeptin, and 2.5 
g/ml aprotinin) for 20 min on a rocking platform at 4°C. Samples were collected into 1.5 
ml Eppendorf tubes and centrifuged at 15,000 g for 15 min at 4°C to pellet insoluble 
material. A Bradford protein assay was performed and 300 µg of protein was incubated 
overnight at 4°C with 40 µl Flag-immunoprecipitation beads. Beads were washed three 
times with cold lysis buffer and incubated overnight at room temperature in 3xSDS loading 
buffer containing 2-mercaptoethanol. Samples were separated by SDS-PAGE, transferred 
to a nitrocellulose membrane, and western blots were then performed with the indicated 
antibodies (rabbit anti- Flag, 1:1000), (rabbit anti-MAGI-2, 1:1000), (rabbit anti-MAGI-3, 
1:1000), (rabbit anti- V5, 1:1000), (rabbit anti-PLCβ3, 1:1000). 
4.2.5 Measurement of Inositol Phosphate Formation 
HEK 293 cells were transiently co-transfected with 2 μg Flag-5-HT2AR or Flag-5-HT2AR-
ΔSCV with 2 µg of MAGI-1, MAGI-2 or MAGI-3. 48h post-transfection cells were 
incubated overnight in inositol-free Dulbecco’s modified Eagle’s medium with 1 μCi/ml 
myo-[3H]-Inositol. For all experiments cells were incubated for 1h in warm HBSS and were 
then incubated with 10 mM LiCl alone for 10 minutes followed by increasing doses of 5-
HT in LiCl for 30 minutes. Cells were placed on ice and the reaction was stopped with 500 
μl of perchloric acid and was neutralized with 400 μl of 0.72 M KOH, 0.6 M KHCO3. Total 
cellular [3H] inositol incorporation was determined in 50 μl of cell lysate. Total inositol 
phosphate was purified by anion exchange chromatography using Dowex 1-X8 (formate 
form) 200–400 mesh anion exchange resin and [3H] inositol phosphate formation was 
determined by liquid scintillation using a Beckman LS 6500 scintillation system. 
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Alternatively for siRNA experiments, HEK 293 cells were transiently transfected with 2 
μg Flag-5-HT2AR or Flag-5-HT2AR-ΔSCV with either MAGI-1, MAGI-2 or MAGI-3 
siRNA as described in the figure legends. 24h post-transfection, cells were reseeded into 
96-well poly-lysine coated plates. Cells were left to recover for another 24h and were then 
incubated overnight in inositol-free Dulbecco’s modified Eagle’s medium with 1 μCi/well 
myo-[3H]-Inositol. On the next day, cells were incubated for 1h in HBSS and were then 
incubated with 15 mM LiCl for 15 minutes followed by increasing doses of 5-HT in LiCl 
for 30 minutes. Cells were then lysed with 50 mM formic acid. 30 μl of cell lysates were 
mixed with 75 μl of 2.67 mg/ml of SPA beads diluted in water (RNA binding YSi beads, 
GE Healthcare) in a 96-well/plate and agitated at 4°C for 3h. The radioactivity was counted 
with a Wallac MicroBeta luminescence counter (PerkinElmer). 
4.2.6 Receptor Endocytosis 
Following transfection, HEK 293 cells were re-seeded into 12-well plates. Cells were 
serum-starved in HBSS lacking serum for 1h at 37°C then stimulated for 0 or 30 min with 
10 µM 5-HT in HBSS at 37 °C. Cells were washed with cold HBSS and incubated with 
mouse anti-Flag antibody (1:1000) for 1h on ice. Cells were washed with cold HBSS then 
labeled with Alexa Fluor 647 donkey anti-mouse IgG (1:1000) for 1h on ice in the dark. 
Cells were washed with cold HBSS and treated with 5 mM EDTA in PBS for 5 min on ice. 
Cells were collected and transferred to flow cytometry tubes containing 4% formaldehyde 
in PBS. Samples were run on a FACS Calibur cytometer using BD Cell Quest Pro software 
(BD Biosciences, Mississauga, ON) until 10,000 cells were counted. The geometric mean 
of fluorescence was determined using Flow Jo analysis software and was representative of 
the expression levels of the receptor on the plasma membrane (BD Biosciences, 
Mississauga, ON). 
4.2.7 Western Blot Analysis 
75-90 μl of the samples from the different assays which is equivalent to about 50-70 μg of 
protein was diluted in β-mercaptoethanol-containing 3xSDS loading buffer and then 
applied to 10% SDS-PAGE (30% acrylamide mix, 1.5 M tris-HCl, 20% SDS, 10% 
ammonium persulfate and TEMED). Separated proteins were then transferred to 
121 
 
nitrocellulose membranes and membranes were then blocked in 10% milk in TBS for 1h. 
Membranes were then blotted overnight by incubation with the appropriate antibody at 
4°C. 24h later membranes were washed at least three times with 1X TBS with 0.05% 
Tween 20, and then incubated with a horseradish peroxidase- conjugated secondary 
antibody (1:10,000) for 1h. Membranes were finally washed again with 1X TBS with 
0.05% Tween 20 three times before being developed using a BioRad chemiluminescence 
system. 
4.2.8 ERK Phosphorylation 
Following 48h of transfection, HEK 293 cells were re-seeded into 6-well plates. Cells were 
serum starved overnight in DMEM. On the day of the experiment, cells were starved for 
1h at 37°C in HBSS and then stimulated with 10 µM 5-HT agonist for 0, 5 and 10 min. 
Cells were lysed with lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, and 1% Triton X-
100) containing protease inhibitors (1 mM AEBSF, 10 μg/ml leupeptin, and 2.5 μg/ml 
aprotinin) and phosphatase inhibitors (10 mM NaF and 500 μM Na3VO₄) for 20 min on a 
rocking platform at 4°C. Samples were collected into 1.5 ml Eppendorf tubes and 
centrifuged at 15,000 g for 15 min at 4°C to pellet insoluble material. A Bradford protein 
assay was performed, and 30–50 μg of protein was incubated overnight at room 
temperature in 3xSDS loading buffer containing 2-mercaptoethanol. Samples were 
separated by SDS-PAGE, transferred to a nitrocellulose membrane, and western blot 
analysis was performed for ERK1/2 (rabbit anti-p44/42 MAPK, 1:1000), phospho-ERK1/2 
(rabbit anti-phospho-p44/42 MAPK, 1:1000), MAGI antibodies (1:1000), Flag-5-HT2AR 
(rabbit anti-Flag, 1:1000). 
4.2.9 Statistical Analysis 
All measurements are represented as mean ± SEM. Comparisons were performed using 
one way analysis of variance test (ANOVA) followed by Bonferroni’s or Dunn’s Multiple 
comparisons test to determine significance. * indicate P values less than 0.05 and is 
considered to be significant.  
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4.3 Results 
4.3.1 MAGI proteins co-immunoprecipitate with Flag-5-HT2AR 
All the MAGI subfamily proteins (MAGI-1, 2 and 3) were identified using a PDZ domain 
proteomic array as potential 5-HT2AR-interacting proteins (unpublished data). To validate 
this interaction we assessed whether V5-His-MAGI-1, HA-MAGI-2 and V5-His-MAGI-3 
were co-immunoprecipitated with either Flag-tagged 5-HT2AR (Flag-5-HT2AR) or a Flag-
5-HT2AR construct lacking the PDZ binding motif (Flag-5-HT2AR-ΔSCV). We found that 
all of the MAGI proteins were effectively co-immunopreciptated with Flag-5-HT2AR, but 
not Flag-5-HT2AR-ΔSCV (Fig. 4.1A-C). However, the interaction between Flag-5-HT2AR 
and each of the MAGI proteins was not altered by agonist activation of the receptor (Fig. 
4.1D). 
4.3.2 Effect of MAGI proteins on agonist-stimulated 5-HT2AR 
endocytosis 
MAGI proteins were previously shown to regulate the endocytosis of other GPCRs, such 
as VPAC1 and β1-AR (Xu et al., 2001; Gee et al., 2009). In addition, the internalization of 
both CRFR1 and 5-HT2AR was shown to be mediated by the MAGUK protein SAP97 
(Dunn et al., 2013; Dunn et al., 2014). Therefore, we assessed the effects of MAGI protein 
overexpression and knockdown on both Flag-5-HT2AR and Flag-5-HT2AR-ΔSCV 
internalization by flow cytometry. We found that the overexpression of each of the MAGI 
proteins had no effect on either Flag-5-HT2AR or Flag-5-HT2AR-ΔSCV internalization 
following agonist treatment with 10 µM 5-HT for 30 min (Fig. 4.2A-C). In contrast, while 
MAGI-2 siRNA knockdown did not alter either Flag-5-HT2AR or Flag-5-HT2AR-ΔSCV 
endocytosis, MAGI-3 knockdown significantly decreased Flag-5-HT2AR internalization 
(Fig 4.2D and 4.2E). Thus, MAGI protein expression could differentially regulate 5-HT2AR 
endocytosis. 
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Figure 4.1: MAGI proteins co-immunoprecipitate with Flag-5-HT2AR in a PDZ-
binding motif-dependent manner and an agonist-independent manner: HEK 293 
cells were co-transfected with Flag-5-HT2AR (WT or ΔSCV) and pcDNA3.1 along with 
MAGI-1, MAGI-2 or MAGI-3. Shown are representative immunoblots for the co-
immunoprecipitation (IP) of (A) MAGI-1, (B) MAGI-2, and (C) MAGI-3 with Flag-5-
HT2AR, but not Flag-5-HT2AR-ΔSCV which lacks the PDZ-binding motif. (D) 
Densitometric quantification of changes in agonist-stimulated (10 M 5-HT) co-
immunoprecipitation of MAGI-1, MAGI-2 or MAGI-3 with Flag-5-HT2AR. Data are 
representative of 3-4 independent experiments. NT: non-transfected. 
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Figure 4.2: Effect of MAGI proteins on 5-HT2AR endocytosis: Agonist-stimulated 
internalization of Flag-5-HT2AR and Flag-5-HT2AR-SCV in response to 10 M 5-HT 
for 30 min in HEK 293 cells upon overexpression of either (A) MAGI-1, (B) MAGI-2 
or (C) MAGI-3. Agonist-stimulated internalization of Flag-5-HT2AR and Flag-5-
HT2AR-SCV in response to 10 M 5-HT for 30 min in HEK 293 cells upon siRNA 
knockdown of either (D) MAGI-2 or (E) MAGI-3. SCV, Flag-5-HT2AR-SCV. * P < 
0.05 versus pcDNA or scrambled siRNA peptide (SCR) control. 
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4.3.3 MAGI proteins modulate 5-HT2AR-stimulated IP formation 
5-HT2AR can couple to Gαq/11 protein resulting in the activation of PLC and the formation 
of DAG and IP3. Both SAP97 and PSD-95 regulate 5-HT-mediated IP formation where 
knockdown of SAP97 reduces IP signaling and overexpression of PSD-95 enhances it (Xia 
et al., 2003; Dunn et al., 2014). Therefore, we examined whether either the overexpression 
or knockdown of MAGI proteins can alter 5-HT-stimulated IP formation in either Flag-5-
HT2AR or Flag-5-HT2AR-SCV expressing HEK 293 cells. We found that the 
overexpression of each of the MAGI proteins significantly increased the maximum 
response for 5-HT-stimulated IP formation mediated by both Flag-5-HT2AR and Flag-5-
HT2AR-SCV, compared with cells transfected with receptor alone (Fig. 4.3A-C). In 
contrast, we found that whereas siRNA knockdown of endogenous MAGI-1 or -3 had no 
effect upon Flag-5-HT2AR-stimulated IP formation, knockdown of MAGI-2 resulted in a 
reduction of Flag-5-HT2AR-induced IP formation significantly (Fig. 4.3D). The siRNA 
knockdown of either MAGI-2, or -3 resulted in a significant reduction of Flag-5-HT2AR-
ΔSCV-mediated IP formation (Fig. 4.3E). This suggested that this effect does not require 
a direct interaction between the receptor and the MAGI proteins, because each of the MAGI 
proteins did not immunoprecipitate with the truncated receptor mutant. 
4.3.4 MAGI proteins can enhance cell surface trafficking of 5-HT2AR 
to the plasma membrane 
MAGUK proteins were previously shown to regulate the cell surface expression of the 
CRFR1 (Dunn et al., 2013; Dunn et al., 2016). Therefore, we examined whether either the 
overexpression or the siRNA knockdown of MAGI-1, -2 or -3 altered the cell surface 
expression of 5-HT2AR. We found that the overexpression of MAGI-1 did not alter cell 
surface expression of either Flag-5-HT2AR or Flag-5-HT2AR-ΔSCV (Fig. 4.4A). In 
contrast, the overexpression of both MAGI-2 and MAGI-3 increased the cell surface 
expression of Flag-5-HT2AR, whereas MAGI-3 also increased the plasma membrane 
expression of Flag-5-HT2AR-ΔSCV (Fig. 4.4B and 4.4C). The siRNA-mediated 
knockdown of both MAGI-2 and MAGI-3 did not alter the relative cell surface expression 
of either Flag-5-HT2AR or Flag-5-HT2AR-ΔSCV (Fig. 4.4D and 4.4E). 
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Figure 4.3: MAGI proteins regulate 5-HT2AR-stimulated IP formation in PDZ motif-
independent manner: Dose response curves for 5-HT-stimulated (30 min) inositol 
phosphate (IP) formation in HEK 293 cells co-transfected with either Flag-5-HT2AR or 
Flag-5-HT2AR-SCV along with either (A) MAGI-1, (B) MAGI-2 or (C) MAGI-3. Inositol 
phosphate formation in cells expressing either (D) Flag-5-HT2AR or (E) Flag-5-HT2AR-
SCV along with MAGI-1 siRNA, MAGI-2 siRNA or MAGI-3 siRNA and treated with 
10 M 5-HT for 30 min. * P < 0.05 versus scramble (SCR) peptide treated control. SCV, 
Flag-5-HT2AR-SCV.  
127 
 
 
 
Figure 4.4: Effect of MAGI proteins on the trafficking of 5-HT2AR to the plasma 
membrane: Cell surface expression of Flag-5-HT2AR and Flag-5-HT2AR-ΔSCV at basal 
level following the overexpression of MAGI-1 (A) or MAGI-2 (B) or MAGI-3 (C) or the 
knockdown of MAGI-2 (D) or MAGI-3 (E). SCV, Flag-5-HT2AR-ΔSCV. * P < 0.05 
versus pcDNA or scrambled peptide (SCR) control.  
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4.3.5 MAGI-3 can enhance the recruitment of PLCβ3 to 5-HT2AR 
Overexpression of MAGI proteins appeared to significantly enhance 5-HT2AR signaling 
via Gαq/11 pathway for which the key effector enzyme is PLC. It was previously reported 
that MAGI-3 could interact directly with PLCβ3 to alter LPA2 receptor-stimulated IP 
formation (Lee et al., 2011). Therefore, we assessed by co-immunoprecipitation whether 
PLC could be co-immumoprecipitated with both Flag-5-HT2AR and Flag-5-HT2AR-
SCV and whether this was influenced either by agonist treatment or by MAGI-3 
overexpression. We found that PLC3 could be co-immunoprecipitated with Flag-5-
HT2AR and that 5-HT treatment (10 M) for 30 min increased the association with the 
receptor (Fig. 4.5A and 4.5B). In contrast, PLC3 co-immunoprecipitation with Flag-5-
HT2AR-SCV was enhanced when compared to Flag-5-HT2AR but did not exhibit agonist 
regulation. Interestingly, we observe a stronger interaction between the Flag-5-HT2AR and 
PLCβ3 in the presence of MAGI-3, but not Flag-5-HT2AR-SCV. This could provide 
another possible mechanism to explain the enhancement in 5-HT-stimulated IP formation. 
4.3.6 Effect of MAGI proteins on regulating 5-HT-mediated ERK1/2 
phosphorylation 
MAGI proteins were previously shown to have distinct effects on ERK1/2 signaling since 
it has been reported that MAGI-3 can enhance BAI-1- and LPA2R- mediated ERK1/2 
phosphorylation and attenuate the same pathway if the β1- and β2- adrenergic receptors are 
stimulated (He et al., 2006; Zhang et al., 2007; Yang et al., 2010; Stephenson et al., 2013). 
Therefore, we assessed whether MAGI overexpression or siRNA-mediated knockdown of 
endogenous MAGI proteins would alter Flag-5-HT2AR-mediated ERK1/2 phosphorylation 
in response to 10 µM 5-HT treatment for 5, 10 and 30 min. We found that the 
overexpression of MAGI-1, MAGI-2 or MAGI-3 had no effect on ERK1/2 signaling (Fig. 
4.6A-F). However, when siRNA was used to silence the expression of endogenous MAGI 
proteins, we found a significant increase in the signal following stimulation with 10 µM 5-
HT for 5, 10 and 30 min for MAGI-1 (Fig. 4.6A and 4.6B), 5 and 10 min for MAGI-2 (Fig 
4.6C and 4.6D), but only 5 min for MAGI-3 (Fig. 4.6E and 4.6F). When ERK1/2 
phosphorylation was tested in response to Flag-5-HT2AR-SCV activation in the presence 
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Figure 4.5: MAGI-3 can enhance the association of PLCβ3 with 5-HT2AR: A) HEK 
293 cells were co-transfected with Flag-5-HT2AR (WT or ΔSCV) and PLCβ3 or MAGI-3 
+ PLCβ3. Representative immunoblot of PLCβ3 co-immunoprecipitated (IP) with both 
Flag-5-HT2AR and Flag-5-HT2AR-ΔSCV. SDS-PAGE was used to analyze samples and 
immunoblots were performed with rabbit anti-PLCβ3. B) Densitometric analysis of the 
effect of MAGI-3 co-transfection. Data are representative of four independent experiments. 
* P < 0.05 versus 5-HT2AR + PLC.  
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of overexpressed MAGI proteins no change in phosphorylation was observed (Fig.4.7A-
F). In contrast, siRNA knockdown of MAGI-1 increased Flag-5-HT2AR-SCV-stimulated 
ERK1/2 phosphorylation following 5 and 10 min 5-HT treatment (Fig. 4.7A and 4.7B) and 
MAGI-2 knockdown increased ERK1/2 phosphorylation in response to 10 min 5-HT 
treatment (Fig. 4.7C and 4.7D). MAGI-3 knockdown had no effect on Flag-5-HT2AR-
SCV activated ERK1/2 phosphorylation (Fig. 4.7E and 4.7F).  
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Figure 4.6: Effect of MAGI proteins on 5-HT2AR-mediated ERK1/2 signaling: (A) 
Representative immunoblot showing ERK1/2 phosphorylation in response to 10 µM treatment for 
0, 5, 10, and 30 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells transfected with 
Flag-5-HT2AR along with either pcDNA, MAGI-1, SCR siRNA or MAGI-1 siRNA. Also shown 
are corresponding immunoblots for total ERK1/2, MAGI-1 and Flag-5-HT2AR protein expression. 
(B) Densitometric analysis of ERK1/2 phosphorylation in response to 10 µM treatment for 0, 5, 10, 
and 30 min. The data represent the mean ± SEM of four independent experiments. (C) 
Representative immunoblot showing ERK1/2 phosphorylation in response to 10 µM treatment for 
0, 5, and 10 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells transfected with Flag-
5-HT2AR along with either pcDNA, MAGI-2, SCR siRNA or MAGI-2 siRNA. Also shown are 
corresponding immunoblots for total ERK1/2, MAGI-2 and Flag-5-HT2AR protein expression. (D) 
Densitometric analysis of ERK1/2 phosphorylation in response to 10 µM treatment for 0, 5, and 10 
min. The data represent the mean ± SEM of four independent experiments. E) Representative 
immunoblot showing ERK1/2 phosphorylation in response to 10 µM treatment for 0, 5, 10, and 30 
min in non-transfected (NT) HEK 293 cells, and HEK 293 cells transfected with Flag-5-HT2AR 
along with either pcDNA, MAGI-3, SCR siRNA or MAGI-3 siRNA. Also shown are 
corresponding immunoblots for total ERK1/2, MAGI-3 and Flag-5-HT2AR protein expression. (F) 
Densitometric analysis of ERK1/2 phosphorylation in response to 10 µM treatment for 0, 5, 10, 
and 30 min. The data represent the mean ± SEM of four independent experiments. * P < 0.05 versus 
pcDNA or scramble peptide (SCR) control. 
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Figure 4.7: Effect of MAGI proteins on 5-HT2AR-SCV-mediated ERK1/2 signaling: (A) 
Representative immunoblot showing ERK1/2 phosphorylation in response to 10 µM treatment for 
0, 5, and 10 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells transfected with Flag-
5-HT2AR-SCV along with either pcDNA, MAGI-1, SCR siRNA or MAGI-1 siRNA. Also shown 
are corresponding immunoblots for total ERK1/2, MAGI-1 and Flag-5-HT2AR-SCV protein 
expression. (B) Densitometric analysis of ERK1/2 phosphorylation in response to 10 µM treatment 
for 0, 5, and 10 min. The data represent the mean ± SEM of four independent experiments. (C) 
Representative immunoblot showing ERK1/2 phosphorylation in response to 10 µM treatment for 
0, 5, and 10 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells transfected with Flag-
5-HT2AR-SCV along with either pcDNA, MAGI-2, SCR siRNA or MAGI-2 siRNA. Also shown 
are corresponding immunoblots for total ERK1/2, MAGI-2 and Flag-5-HT2AR-SCV protein 
expression. (D) Densitometric analysis of ERK1/2 phosphorylation in response to 10 µM treatment 
for 0, 5, and 10 min. The data represent the mean ± SEM of four independent experiments. E) 
Representative immunoblot showing ERK1/2 phosphorylation in response to 10 µM treatment for 
0, 5, and 10 min in non-transfected (NT) HEK 293 cells, and HEK 293 cells transfected with Flag-
5-HT2AR-SCV along with either pcDNA, MAGI-3, SCR siRNA or MAGI-3 siRNA. Also shown 
are corresponding immunoblots for total ERK1/2, MAGI-3 and Flag-5-HT2AR-SCV protein 
expression. (F) Densitometric analysis of ERK1/2 phosphorylation in response to 10 µM treatment 
for 0, 5, and 10 min. The data represent the mean ± SEM of four independent experiments. * P < 
0.05 versus pcDNA or scramble peptide (SCR) control.  
133 
 
4.4 Discussion 
Recent studies have illustrated the importance of PDZ domain-containing proteins 
in the regulation of GPCR activity (Dunn and Ferguson, 2015). Furthermore, studies on 
the 5-HT2AR demonstrated the roles of MAGUKs such as PSD-95 (Xia et al., 2003) and 
SAP97 (Dunn et al., 2014) and other PDZ proteins including MUPP1 (Jones et al., 2009) 
and PDZK1 (Walther et al., 2015) in mediating the trafficking and signaling of the receptor. 
In a PDZ overlay assay performed in our laboratory, we found that all three MAGI proteins 
can associate with the carboxyl-terminal tail of 5-HT2AR (unpublished data). Therefore, we 
decided to further characterize this interaction and determine its functional consequences 
on the signaling and trafficking of 5-HT2AR. Despite the similarity in sequence and domain 
structure of these proteins, we hypothesized that they would exhibit distinct functions. We 
find that MAGI proteins regulate both IP3 and ERK1/2 signaling downstream of the 
activation of the 5-HT2AR. We propose that the observed increase in 5-HT-mediated IP3 
signaling is mediated at least in part by the regulated recruitment of PLCβ to the receptor. 
We also show that silencing the expression of endogenous MAGI proteins using siRNA 
can enhance 5-HT-mediated ERK1/2 signaling. 
MAGI-2 has been shown to play an important role in regulating the trafficking and 
signaling of multiple receptors including β1-AR and VPAC1 (Xu et al., 2001; Gee et al., 
2009). In the current study, we were able to show an effect of MAGI-2 knockdown on 
regulating ERK1/2 activation. This is the first report to implicate MAGI-2 with the MAPK 
pathway. Our data also showed that MAGI-2 can regulate IP formation where 
overexpression resulted in an enhancement of the signal and knockdown reduced it. This 
is the first report of MAGI-2 regulation of a Gαq-dependent pathway as well, however 
MAGI-2 was previously shown to regulate Gαs-mediated cAMP formation by VPAC1 (Gee 
et al., 2009). Despite previous reports indicating an effect of MAGI-2 overexpression on 
GPCR internalization where it had a positive effect on β1-AR (Xu et al., 2001) and a 
negative effect on VPAC1 (Gee et al., 2009), our observations indicated that MAGI-2 did 
not affect the endocytosis of 5-HT2AR. However, we observed a significant increase in 
receptor expression levels upon MAGI-2 overexpression. Therefore, it seems that MAGI-
2 is involved in regulating both the signaling and trafficking of 5-HT2AR. 
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MAGI-3 has also been shown to regulate the signaling of a number of GPCRs 
including LPA2R and β-adrenergic receptors (Zhang et al., 2007; Yang et al., 2010; Lee et 
al., 2011). Our current study showed that MAGI-3 can regulate both G protein-dependent 
as well as G protein- independent signaling pathways. Our data demonstrated that MAGI-
3 can regulate IP formation in a PDZ motif-independent manner. This is illustrated by the 
enhancement in IP formation mediated by both 5-HT2AR and 5-HT2AR-ΔSCV upon 
overexpression of MAGI-3 and the reduction in this effect upon MAGI-3 knockdown. The 
effect of MAGI-3 knockdown was statistically different only for the 5-HT2AR-ΔSCV-
tranfected cells despite a trend for reduction with the 5-HT2AR-transfected cells suggesting 
that the assay needs to be repeated for more conclusive statistical data. Interestingly, 
opposite effects were previously observed when LPA-induced IP formation was studied 
where MAGI-3 overexpression resulted in a decrease in IP formation and MAGI-3 
knockdown led to an enhancement in this signaling pathway (Lee et al., 2011). We showed 
that MAGI-3 could also mediate the MAPK cascade. While overexpression of MAGI-3 
did not have an effect on ERK1/2 activation, knockdown led to an enhancement in ERK1/2 
signaling. Interestingly, this effect is opposite to what was reported with LPA2R where 
MAGI-3 knockdown reduced ERK activity (Zhang et al., 2007). However, similar to our 
study, the LPA2R study which was performed on SW480 cells reported no difference in 
ERK activity upon overexpression of MAGI-3 suggesting that different tissues and cell 
lines express endogenous MAGI-3 in high levels (Zhang et al., 2007). Nonetheless, studies 
on both β1-AR and β2-AR showed that MAGI-3 overexpression could lead to a decrease in 
ERK1/2 signaling (He et al., 2006; Yang et al., 2010). It is noteworthy to mention that 
MAGI-3 was also shown to regulate Gα12/13-mediated RhoA activation by LPA2R (Zhang 
et al., 2007). Taken together, our data and previous studies confirmed the importance of 
MAGI-3 in regulating GPCR signaling via multiple pathways and the distinct effects it 
elicits based on the receptor being investigated. In addition to its role on signaling, we also 
illustrated a role for MAGI-3 on 5-HT2AR internalization where MAGI-3 knockdown 
resulted in a significant reduction in the internalization of the receptor. This is the first 
report of a role for MAGI-3 in receptor endocytosis and as mentioned previously, MAGI-
2 was usually the MAGI protein responsible for this regulation for other receptors (Xu et 
al., 2001; Gee et al., 2009). This emphasized the importance of investigating all PDZ 
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proteins that interact with a receptor to gain complete understanding of how they regulate 
its function. 
To our knowledge, no previous reports studied the functional role of MAGI-
1/GPCR interactions. MAGI-1 was first characterized as a BAI-1 (Brain-specific 
angiogenesis inhibitor 1) interacting protein and has been shown to co-immunoprecipitate 
with VPAC1, but more studies are required to investigate the role it plays in regulating 
GPCRs. Data from our current study suggest that MAGI-1 seems to be more important for 
regulation of 5-HT2AR signaling as opposed to its trafficking. We demonstrate that MAGI-
1 overexpression can increase IP formation, while its knockdown can enhance ERK1/2 
activation. 
We proposed two mechanisms of regulation for 5-HT2AR signaling by MAGI 
proteins. First, the increase in receptor expression level at the plasma membrane could 
partly explain the enhancement in IP formation upon overexpression. However, this would 
not apply to MAGI-1 which despite enhancing IP signaling had no effect on cell surface 
levels. It also does not completely explain the fact that this effect on IP formation did not 
require an intact PDZ motif, while the effect on receptor expression level was PDZ-
dependent for MAGI-2 and PDZ-independent for MAGI-3. Second, the other mechanism 
we presented here involved the effect of MAGIs on PLCβ3 recruitment to the receptor. We 
specifically tested MAGI-3, since it has been shown to interact with PLCβ3 (Lee et al., 
2011). We found that MAGI-3 overexpression can increase the association between 5-
HT2AR and PLCβ3. However, although the representative blot in Fig. 4.5A shows this 
enhancement with 5-HT2AR-ΔSCV, it was not a reproducible effect and therefore, we could 
not conclude that it was PDZ-independent. These mechanisms might also provide a general 
MAGUK regulation of IP signaling since both SAP97 and PSD-95 were shown previously 
to mediate IP formation (Xia et al., 2003; Dunn et al., 2014). Another possibility that can 
be explored is to examine whether MAGI proteins can affect the coupling of Gαq to 5-
HT2AR in a PDZ motif-independent manner. This is particularly important because MAGI-
3 has been shown to associate with different G proteins and has been suggested to bias the 
coupling of different G proteins to LPA2R (Lee et al., 2011). 
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The mechanism of regulation of the MAPK cascade remains unknown and further 
studies are required to understand it. However, one speculation would be an effect of the 
MAGI proteins on the recruitment of β-arrestin to the receptor. The activation of MAP 
kinase pathway by GPCRs can be mediated by both arrestin- dependent and independent 
pathways and previous studies showed a role for multiple PDZ proteins in mediating β-
arrestin recruitment either by enhancing it or by interfering with it (Hu et al., 2002; 
Hammad et al., 2010). 
Now that we have demonstrated the distinct roles of MAGI proteins in regulating 
the function of the 5-HT2AR in HEK 293 cells, it would be important to further examine 
this association and its physiological consequences in vivo. RT-PCR in mouse tissue 
revealed that MAGI proteins are expressed in different regions of the brain including the 
cortex, thalamus and cerebellum (Sugnet et al., 2006). We would predict that MAGI 
proteins are expressed in serotonergic neurons where they co-localize with 5-HT2AR but 
their effects need to be explored. In light of the involvement of 5-HT2AR in multiple mental 
disorders such as schizophrenia and anxiety, it will also be important to study how 5-
HT2AR- MAGIs interactions contribute to using the receptor as a pharmacological target 
(Gray and Roth, 2001; Roth et al., 2004). In fact, a study showed that PSD-95, another 
MAGUK protein, is essential for the actions of atypical antipsychotics on 5-HT2Rs. 
Therefore, a better understanding of PDZ protein regulation of 5-HT2AR function in vivo 
is vital. 
In conclusion, in this study, we compare the function of three PDZ proteins in 
regulating 5-HT2AR activity. This is unique because previous studies have focused on one 
MAGI protein based on the strength of interaction or tissue distribution despite reporting 
the interaction with at least two of the MAGI proteins (Xu et al., 2001; Zhang et al., 2007; 
Gee et al., 2009). It will be important to further investigate the dynamics between the three 
MAGI proteins to determine if they have synergistic or competitive effects with one 
another and one way to do so could be simultaneous overexpression and knockdown of the 
MAGI proteins followed by an assessment of the receptor function. 
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Chapter 5  
5 Discussion 
5.1 Summary 
Previous research from our laboratory illustrated a crosstalk between CRFR1 and 
5-HT2AR (Magalhaes et al., 2010). Magalhaes et. al showed that the activation of CRFR1 
mediates the signaling of 5-HT2AR since pretreatment with CRF enhances 5-HT2AR- 
mediated inositol phosphate formation. This effect was abolished when mutant forms of 
the receptors that lack the PDZ motif are used indicating that intact PDZ motifs are required 
for the crosstalk to occur and suggested a role for PDZ proteins in regulating the process. 
They also reported that this effect was dependent on receptor internalization and recycling 
by showing that using dominant negative forms of Rab4, Rab5 or dynamin could lead to 
blockade of the crosstalk. Moreover, infusion of CRF peptide (1.5 μg) into the medial 
prefrontal cortex of mice followed by the intraperitoneal administration of the 5-HT2R-
selective agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) (0.15 mg/kg) results in 
enhanced 5-HT2 receptor-stimulated anxiety-related behaviors. Our hypothesis was that a 
PDZ-binding protein was recruited for the CRFR1-mediated sensitization of 5-HT2AR 
signaling and it could enhance the expression of both receptors by regulating the 
internalization and recycling of CRFR1/5-HT2AR complexes. To better understand the 
molecular mechanism behind this crosstalk between receptors and to be able to use this 
phenomenon in the development of therapeutic agents, the overall objective of this study 
was to determine the PDZ protein responsible for CRFR1-mediated sensitization of 5-HT2A 
receptor signaling. 
In order to find PDZ domain-containing proteins that would be good candidates for 
this regulation, a screen of 96 PDZ domains with the carboxyl-terminal tails of 5-HT2AR 
and CRFR1 was performed (Dunn et al., 2013). This resulted in a sub-group of common 
PDZ proteins that interacts with both receptors. These were SAP97, PDS-95, MAGI-1 
MAGI-2, MAGI-3, CAL, PDZK1, MUPP1 and PTPN13. The proteins I chose to work 
with for my thesis projects were CAL, MAGI-1, MAGI-2 and MAGI-3. These proteins 
have been previously shown to regulate the trafficking and signaling of some members of 
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the GPCRs family (Dunn and Ferguson, 2015).  However, their role in regulating CRFR1 
and 5-HT2AR was yet to be determined. It was essential to characterize the functional roles 
of the interaction between the PDZ proteins and the two receptors separately before we 
could assess the effects on the crosstalk regulation. Therefore, the three specific objectives 
of this thesis were: 
1. To determine the role of CAL in regulating the trafficking and 
signaling of CRFR1 and the mechanism for this regulation 
 
2. To determine the role of MAGI proteins in regulating the trafficking 
and signaling of CRFR1 and the mechanism for this regulation 
 
3. To determine the role of MAGI proteins in regulating the trafficking 
and signaling of 5-HT2AR and the mechanism for this regulation 
In the second chapter of this thesis, the interaction of CAL with CRFR1 is 
characterized and shown to be dependent on the PDZ-binding motif of the receptor. CAL 
is shown to localize with CRFR1 at the Golgi and is demonstrated to have a role in 
inhibiting CRFR1 endocytosis, cell surface expression, and CRF-mediated ERK1/2 
signaling via the CRFR1 PDZ-binding motif (Hammad et al., 2015). CAL does not have 
an effect on CRF-mediated cAMP formation. Interestingly and contrary to studies where 
the mechanism of CAL regulation of receptor expression is attributed to an effect of CAL 
on degradation (Cheng et al., 2010; Koliwer et al., 2015), our work demonstrates that CAL 
can elicit its effects on CRFR1 by mediating the post-translational glycosylation of the 
nascent receptor at the Golgi. By characterizing glycosylation-deficient mutants of CRFR1 
with a point mutation on the asparagine residues, we find that the effects that CAL has on 
CRFR1 expression are comparable to the receptor expression levels of CRFR1 mutants. In 
addition, the cellular distribution of the glycosylation-deficient mutants reveals that they 
are mainly expressed in the Golgi. Similar localization of CRFR1 is observed upon 
overexpression with CAL since a big portion of the receptor is retained intracellularly in 
the Golgi. We also find that the signaling of the mutants via the MAPK pathway is similar 
to that of CRFR1 in the presence of CAL. Although multiple PDZ proteins were shown to 
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regulate GPCRs, mediating post-translational modifications seems to be exclusive to CAL 
(Hammad et al., 2015; Dunn and Ferguson, 2015). It is also unique to show an effect for a 
PDZ- binding protein during the early biosynthesis pathway as opposed to the later stages 
during the life cycle of a GPCR. 
Data presented in the third and fourth chapters illustrate distinct functions for the 
MAGI subfamily of proteins in regulating the trafficking and signaling of CRFR1 
compared to that of 5-HT2AR. Furthermore, we present different mechanisms by which 
MAGI proteins can elicit their effects. In terms of their effect on trafficking and 
internalization, we show that MAGI proteins can regulate CRFR1 endocytosis, but have 
no effect on 5-HT2AR internalization.  We also show that MAGI proteins can mediate their 
effect on CRFR1 internalization by interfering with β-arrestin2 recruitment to the receptor, 
a key step in the endocytic pathway. We also show that while no effect is observed on the 
basal plasma membrane expression of CRFR1 in response to overexpression or knockdown 
of MAGI proteins, there is a trend for an increase in expression levels of 5-HT2AR when 
MAGI proteins are overexpressed. The results from investigating the trafficking and 
internalization reflect the specificity and distinct functions of the proteins in regulating the 
receptors. Our findings from studying the effects on the signaling pathways are also very 
intriguing. CRFR1 and 5-HT2AR differ in the G protein subtypes that they couple to, but 
they both have the ability to activate the ERK1/2 signaling pathway. There is no effect of 
MAGI proteins on Gαs-mediated cAMP upon activation of CRFR1. On the other hand, 5-
HT-stimulated IP accumulation via Gαq coupling appears to be enhanced by MAGI 
proteins. There are two possible mechanisms for this regulation of IP3 formation. It could 
be in part due to the increase in receptor expression levels at the plasma membrane but the 
more appealing mechanism is the enhancement of PLCβ3 association with the receptor 
when MAGI proteins are overexpressed. Studying signaling via the MAPK pathway, we 
find that knockdown of the endogenous MAGI proteins results in an enhancement in both 
CRF-mediated and 5-HT-mediated activation of ERK1/2 signaling. Taken together, the 
data from the third and fourth chapters suggest that MAGI proteins play important roles in 
regulating the trafficking of CRFR1 and the signaling of 5-HT2AR. 
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5.2 Regulation of GPCRs Trafficking by MAGI and CAL 
Proteins 
Data presented in this thesis illustrate an important role for PDZ domain-containing 
MAGI and CAL proteins in regulating the trafficking of CRFR1 and 5-HT2AR (Fig. 5.1). 
The effect on CRFR1 is prominent upon studying agonist-induced internalization of the 
receptor. The main effect that is reported here is a decrease in CRFR1 internalization when 
CAL is overexpressed and when levels of MAGI proteins are altered either by 
overexpression or siRNA-mediated knockdown. An effect on 5-HT2AR plasma membrane 
expression levels is observed following altered MAGI protein expression. Although not 
significant for all the MAGI transfection conditions, there is a trend towards an enhanced 
surface receptor levels. The reason for the big variation in the flow measurement of 5-HT-
mediated endocytosis, as well as surface receptor levels could be attributed to the nature of 
the receptor which exhibits constitutive internalization activity and exhibits poor 
dependence on β-arrestins for internalization (Albert and Tiberi, 2001; Bhatnagar et al., 
2001; Gray et al., 2001; Bhattacharyya et al., 2002). Therefore, it might be worth repeating 
the assays with a more sensitive approach to arrive at more conclusive results. Interestingly, 
previous work from our laboratory demonstrates an effect of other PDZ proteins on the 
trafficking of CRFR1 and 5-HT2AR. These include SAP97, PSD-95 and PDZK1. SAP97 
and PSD-95 function to reduce the internalization of both CRFR1 and 5-HT2AR (Dunn et 
al., 2013; Dunn et al., 2014; Dunn et al., 2016). PDZK1 also reduces 5-HT2AR 
internalization, but has no effect on CRFR1 internalization (Walther et al., 2015). Other 
groups show a role for MAGI-2 in regulating GPCR trafficking, where it reduces VPAC1 
internalization (Gee et al., 2009), enhances β1-AR internalization (Xu et al., 2001) and 
facilitates localization of mGluR1 to the Golgi (Sugi et al., 2007). MAGI-1 and MAGI-3 
have not been shown to affect GPCRs trafficking prior to the studies presented in this 
thesis. 
Another aspect of GPCRs trafficking is the regulation of CRFR1 surface expression by 
CAL. We show that overexpression of CAL results in the retention of CRFR1 
intracellularly in the Golgi. Previous studies show a similar effect of CAL on other GPCRs 
such as mGluRs, SSTR5 and β1-AR, as well as other transmembrane proteins including  
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Figure 5.1: A schematic representation of the processes in GPCRs endocytosis and 
biosynthesis summarizing the findings of this thesis in terms of the role of MAGI 
and CAL proteins in regulating these functions. 
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CFTR and the voltage-gated potassium channel KV10.1 (Cheng et al., 2002; Wente et al., 
2005; Zhang et al., 2008; Cheng et al., 2010; Herrmann et al., 2013; Koliwer et al., 2015). 
It has been previously suggested that CAL might be playing a role as a sorting molecule, 
but the mechanism was believed to be via ubiquitination and degradation (Cheng et al., 
2010; Koliwer et al., 2015). However, we show here that at least for the regulation of 
CRFR1, CAL contributes to the regulation of post-translational glycosylation and to the 
assessment of the maturation state of the receptor and whether it has achieved proper 
folding to be transported from the Golgi and expressed at the plasma membrane. 
5.3 Regulation of GPCRs Signaling by MAGI and CAL 
Proteins 
Data presented in the previous chapters demonstrate distinct roles for MAGI and 
CAL proteins in regulating both G protein-dependent as well as G protein-independent 
signaling pathways (Fig. 5.2). Although MAGI-2 has previously been shown to reduce 
cAMP signaling mediated by VPAC1, it does not seem to affect Gαs-mediated signaling by 
CRFR1 and neither did MAGI-1, MAGI-3 nor CAL. However, the MAGI proteins do have 
a significant effect on Gαq-mediated IP3 formation as a result of 5-HT2AR activation. It is 
of interest to observe an effect of the MAGI proteins on one G protein sub-type, but not 
another and confirms the selectivity of their effect on G protein signaling pathways. 
Previous studies from our laboratory have shown an effect of SAP97 and PDZK1 on 5-
HT-induced IP3 formation where knockdown of endogenous expression of the PDZ 
proteins results in a reduction in Gαq-mediated signaling by 5-HT2AR (Dunn et al., 2014; 
Walther et al., 2015). However, a noticeable difference among the previous studies with 
SAP97 and PDZK1 and the data reported here is that the effects shown here with MAGI 
proteins were observed with both 5-HT2AR and 5-HT2AR-ΔSCV, while SAP97 and PDZK1 
could only elicit their functional effects on 5-HT2AR. This most likely suggests that the 
effects of SAP97 and PDZK1 on 5-HT2AR signaling are PDZ motif-dependent and the 
effects of MAGIs on 5-HT2AR signaling are PDZ motif-independent. Other examples of 
PDZ domain-containing proteins that are known to regulate Gαq signaling include 
NHERF1, which was demonstrated to increase coupling and activation of Gαq by 
parathyroid 1 receptor (PTH1R), and NHERF2 which increases secondary messenger IP3  
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Figure 5.2: A schematic representation of the signaling pathways activated by CRFR1 
and 5-HT2AR and the involvement of MAGI and CAL proteins in regulating these 
pathways as reported in this thesis. 
147 
 
accumulation via LPA2R (Oh et al., 2004; Wang et al., 2010). 
It is also essential to study the effects of our PDZ proteins of interest on the MAPK 
pathway, which represents a signaling pathway shared by both CRFR1 and 5-HT2AR. 
Interestingly, our data show that MAGI proteins can regulate ERK1/2 activation by both 
CRFR1 and 5-HT2AR in a similar manner. We find that the overexpression of MAGI 
proteins do not alter the extent of ERK1/2 phosphorylation stimulated by the activation of 
either the CRFR1 or the 5-HT2AR. On the other hand, siRNA-mediated knockdown of 
endogenous MAGI proteins in HEK 293 cells results in a significant enhancement in 
MAPK activation by the CRFR1 and the 5-HT2AR. The only other MAGI protein to exhibit 
an effect on ERK1/2 signaling is MAGI-3. MAGI-3 has been reported to show distinctive 
effects on the MAPK pathway depending on the receptor being investigated (He et al., 
2006; Zhang et al., 2007; Yang et al., 2010; Stephenson et al., 2013). MAGI-3 expression 
results in an enhancement in signaling for BAI-1 and LPA2R and a reduction in signaling 
for the adrenergic receptors. Our laboratory has previously investigated the role of SAP97 
in regulating GPCR-mediated ERK1/2 signaling (Dunn et al., 2013). This work 
demonstrates a general role for SAP97 in regulating the MAPK signaling pathway 
independently from the PDZ motif, since the effects are observed with CRFR1-ΔTAV as 
well as CRFR2. Interestingly, SAP97 has an opposite effect to MAGI proteins in regulating 
ERK1/2 phosphorylation by both CRFR1 and 5-HT2AR, as the knockdown of endogenous 
SAP97 results in a reduction in ERK1/2 activation. 
In this thesis, we also study the effects of CAL on CRFR1-mediated ERK1/2 
signaling and demonstrate that CAL can negatively regulate this pathway. Our data indicate 
that CAL overexpression results in a significant attenuation of ERK1/2 activation, while 
CAL siRNA knockdown of endogenous levels of the CAL protein results in enhanced 
CRFR1-mediated ERK1/2 signaling (Hammad et al., 2015). Similarly, CAL 
overexpression reduces ERK1/2 activation by mGluR1 (He et al., 2004; Zhang et al., 2008) 
and β1-AR (He et al., 2004). The effect of CAL on regulating 5-HT-mediated ERK1/2 
signaling remains to be determined. 
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5.4 Mechanisms of GPCRs Regulation by MAGI and CAL 
Proteins 
The various mechanisms underlying the functional regulation of PDZ motif 
expressing GPCRs examined in the present thesis highlight the specificity and uniqueness 
of this group of scaffolding proteins. While CAL mediates its effects via regulation of post-
translational glycosylation, MAGI proteins perform their functions by regulating receptor 
interactions with key elements such as β-arrestin and PLCβ. This confirms the importance 
of PDZ domain-containing proteins in regulating GPCRs functions and given that more 
than 50% of pharmaceutical drugs directly or indirectly act on GPCRs, proper 
characterization of PDZ protein-receptor interactions is essential. 
Despite some differences in the extent of their effects on different aspects of 
CRFR1 and 5-HT2AR activity, it is fair to say that MAGIs 1, 2 and 3 share some similar 
effects on the trafficking and signaling of CRFR1 and 5-HT2AR. Therefore, we further 
investigated their ability to compensate for one another and provided evidence for a 
possible compensatory protein expression mechanism of up-regulation between MAGI-1 
and MAGI-3 based on their similar functional roles, when the expression of either protein 
is altered by siRNA knockdown. This is not the first report to suggest either compensatory 
or complimentary effects of PDZ proteins. It has been previously documented that PSD-
93 and PSD-95 can compensate for one another (Sun and Turrigiano, 2011) and regulate 
GPCRs function similarly. 
5.5 MAGI and CAL Proteins in Disease 
CAL-deficient mice are infertile and it has been suggested that they can present a 
unique model for human globozoospermia, an inherited infertility syndrome in humans 
where the acrosome is lost. The acrosome is a unique organelle that plays an important role 
at the site of sperm-zona pellucida binding during the fertilization process and has been 
reported to be completely lost in CAL knockout mouse models (Yao et al., 2002). It is 
therefore suggested that CAL plays a role in the fusion of transport vesicles to the 
acrosome. PCR analysis of mouse tissue reveals that CAL is ubiquitously distributed in 
many different regions of the brain (cerebellum, cortex, hippocampus and hypothalamus) 
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as well as the heart, kidney, lungs, testis and spinal cord (Charest et al., 2001; Cheng et al., 
2002; Herrmann et al., 2013). However, other than spermatogenesis, no overt abnormalities 
are noted in CAL knockout mice (Yao et al., 2002). A study shows that β1-AR expression 
levels are decreased in the hippocampus of CAL knockout mice (Koliwer et al., 2015). 
Given its wide distribution in multiple areas of the brain as well as its confirmed role as an 
essential sorting protein, further examination is required to understand the role of CAL and 
whether it has any implications for mental illnesses. 
MAGI proteins are important scaffolding proteins and have been implicated in 
various physiological functions (Funke et al., 2005; Oliva et al., 2012). MAGI proteins are 
suggested to be involved in learning and memory. All MAGI proteins are also believed to 
be involved in cancer cell signaling via their interaction with PTEN, a tumor suppressor 
gene (Zaric et al., 2012; Matsuda et al., 2013). MAGIs expression level is correlated with 
the cancer cell invasion where their levels were shown to be reduced in different cancer 
types (Matsuda et al., 2013). PCR results performed in our laboratory indicate that MAGIs 
1, 2 and 3 are expressed in the human brain. RT-PCR in mouse tissues show that MAGI-1 
is expressed in the colon, kidney, lung, liver, and pancreas and different areas of the brain 
including the cerebellum, cortex and thalamus. MAGI-2 is expressed in the cortex and 
thalamus as well as the kidneys and testis. MAGI-3 is very widely distributed in the 
cerebellum, cortex and thalamus as well as heart, kidney, colon and lung (Wu et al., 2000; 
Sugnet et al., 2006). 
MAGI-1 expression is decreased in cancers and this correlates with poor prognosis, 
suggesting MAGI-1 as a novel prognostic marker for cancer (Zaric et al., 2012). On the 
other hand, overexpression of MAGI-1 induces stabilization of E-cadherin and β-catenin 
localization at cell-cell junctions, enhances actin stress fiber and focal adhesion formation, 
increases cell adhesion to matrix proteins and suppresses anchoragein dependent growth 
and migration. In fact, MAGI-1 overexpression suppresses subcutaneous primary tumor 
growth and attenuates spontaneous lung metastasis in experimental colon cancer 
(Pleasance et al., 2010). MAGI-1 deficient mice are suggested to have renal problems but 
further characterization of this model is required. 
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MAGI-2 has been found to localize to the postsynaptic density area of the spine 
and bind to N-methyl-D-aspartate receptor (Hirao et al., 1998; Iida et al., 2007; Sumita et 
al., 2007). Furthermore, MAGI-2 has been shown to be localized to both excitatory and 
inhibitory synapses. Taken together, this data suggest a neuronal role for MAGI-2. In fact, 
MAGI-2 knockout mice models show abnormal elongation of dendritic spines, indicating 
a possible role for MAGI-2 during morphogenesis of neurons (Iida et al., 2007). MAGI-2 
has also been shown to be expressed in the kidneys and was recently found to play a critical 
role in the formation and maintenance of the glomerular filtration barrier (Ihara et al., 
2014). It is reported that the renal function of excretion of waste matter was entirely lost in 
MAGI-2 knockout mice and this caused neonatal lethality. MAGI- 2 gene has been shown 
to undergo rearrangement in the genome of a melanoma cell line and prostate cancer 
(Berger et al., 2011). 
MAGI-3 has been shown to interact with Lysophosphatidic Acid (LPA) receptor 
type 2 and regulate its signaling pathways. LPA is a potent inducer of colon cancer and 
LPA receptor type 2 is overexpressed in colon tumors (Zhang et al., 2007). No reports are 
published about a knockout model of MAGI-3. 
5.6 Future Directions 
Now that we have a better understanding for the role of MAGI proteins in 
regulating both CRFR1 and 5-HT2AR, the next step would be to assess whether MAGI 
proteins are involved in regulating the crosstalk between the receptors. The best way to test 
this is by performing IP3 assays in cells transfected with 5-HT2AR and CRFR1 and either 
overexpressed MAGI proteins or siRNA against the MAGI proteins. We could then 
pretreat cells with CRF and measure IP3 formation to examine the effects of MAGI 
proteins on the enhancement of signaling that was observed in Magalhaes et al. (2010). We 
would expect that overexpression of MAGI proteins will result in further enhancement in 
IP3 formation, because it had this effect even without CRF pretreatment. Given the similar 
function of the three MAGI proteins and the apparent compensation mechanism governing 
that function, one should also consider the possibility that a certain combination of 
overexpression or knockdown might be involved and therefore, these conditions would 
have to be tested as well. 
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The effect of CAL on the signaling and trafficking of 5-HT2AR remains unknown. 
CAL is one of the PDZ proteins that was detected as an interacting protein in the PDZ blot 
overlay assay performed with the carboxyl-terminal tail of 5-HT2AR to screen 96 PDZ 
domains. Despite containing one PDZ domain, it is still a candidate regulator of the 
crosstalk between CRFR1 and 5-HT2AR because of its ability to self-dimerize via the coiled 
coil motif. Given that CAL overexpression results in the reduction of expression of CRFR1 
at the cell surface, it would be unlikely for CAL to be required for CRFR1-mediated 5-
HT2AR sensitization. In fact, we could speculate that maybe a knockdown of CAL would 
facilitate this crosstalk since CAL seems to be retaining receptors in the intracellular 
compartments as reported by us for CRFR1 and by others for mGluRs, β1-AR and SSTR5. 
This would suggest that it is indeed a group of PDZ proteins that collectively work in 
regulating the crosstalk as opposed to one PDZ protein. 
Our studies confirm the importance of the family of PDZ domain-containing 
proteins in regulating GPCRs activity. We illustrated the distinct function of the MAGI 
subfamily of proteins in regulating the trafficking and signaling of CRF1 and 5-HT2A 
receptors. We also showed a unique mechanism of regulation for CAL in mediating post-
translational modifications of the receptors. Considering the fact that more than 40% of 
currently available pharmaceuticals act directly or indirectly on GPCRs, it is essential to 
fully characterize their interacting partners and the consequences such interactions have on 
receptor function. Multi-domain-containing proteins such as PDZ proteins present exciting 
models since it would be possible to target either their interaction with the receptor, their 
PDZ domains, the PDZ motifs of the receptor or allosteric sites on the proteins to change 
their conformation. Therefore, the findings from these studies can be utilized in the design 
of new pharmacological tools for the treatment of diseases including mental disorders. 
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